Research activity information

• Jun. 2017 日本ビフィズス菌センター/腸内細菌学会, 第21回腸内細菌学会 最優秀発表賞, Anti-tumor immune responses induced by oral cancer vaccine using recombinant Bifidobacterium displaying Wilms’ tumor 1 protein

  辰巳 真帆, KITAGAWA KOICHI, 五ノ井 玲菜, 斉藤 大樹, 橋井 佳子, 片山 高嶺, SHIRAKAWA TOSHIRO

  Japan society


• Jun. 2008 日本遺伝子治療学会, 第13回JSGT学会賞, 学会発表演題

  白川 利朗


• Aug. 2006 (財)クリタ水･環境科学振興財団, クリタ水・環境科学振興財団 研究助成金, 命にかかわる下痢性感染症予防のための水質汚染モニタリング法の開発

  SHIRAKAWA TOSHIRO


• 2004 前立腺研究財団, 前立腺研究財団優秀研究課題受賞, 腫瘍特異的増殖型アデノウイルスおよびキャリアー細胞を用いた前立腺癌に対する遺伝子治療法の開発

  SHIRAKAWA Toshiro

• Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.

  Junya Furukawa, Yasumasa Kakei, Sae Murakami, Hiroshi Kita, Hideto Ueki, Takuto Hara, Jun Teishima, Nobuyuki Hinata, Hideaki Miyake, Masato Fujisawa, Toshiro Shirakawa

  BACKGROUND: This is a multicenter, open-label, single-arm clinical trial to evaluate the safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer. METHODS: The trial will be performed at three university hospitals in Japan. The target number of patients will be 12. The patients will be treated orally with B440 once daily for 5 days followed by 2 days for four consecutive courses (4 weeks, 20 treatments). The low-dose group will receive 800 mg (4 capsules) per dose and the high-dose group will receive 1,600 mg (8 capsules) per dose. The primary outcome will be the number and incidence of DLT cases the start of treatment and Day 28. Secondary outcomes are the presence or absence of a response, the best overall response and PFS. DISCUSSION: If this trial shows B440 to be safe and effective, it may lead to a late phase randomized controlled trial in advanced urothelial cancer. Ultimately, we hope to provide a new treatment option for such patients. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) identifier: jRCT2051220143. Registered on December 27, 2022.

  Feb. 2025, BMC cancer, 25(1) (1), 195 - 195, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine.

  Yuri Fujioka, Hideto Ueki, Ruhan A, Akari Sasajima, Takumi Tomono, Masami Ukawa, Haruya Yagi, Shinji Sakuma, Koichi Kitagawa, Toshiro Shirakawa

  Cancer immunotherapy using antigen-pulsed dendritic cells can induce strong cellular immune responses by priming cytotoxic T lymphocytes. In this study, we pulsed tumor cell lysates with VP-R8, a cell-penetrating D-octaarginine-linked co-polymer of N-vinylacetamide and acrylic acid (PNVA-co-AA), into the DC2.4 murine dendritic cell line to improve antigen uptake and then determined the anti-tumor effect in tumor-bearing mice. DC2.4 cells were pulsed with the cell lysate of EL4, a murine lymphoma cell line, and VP-R8 to generate the DC2.4 vaccine. For the in vivo study, DC2.4 cells pulsed with EL4 lysate and VP-R8 were subcutaneously injected into the inguinal lymph node to investigate the anti-tumor effect against EL4 and EL4-specific T cell immune responses. VP-R8 significantly improved antigen uptake into DC2.4 compared to conventional keyhole limpet hemocyanin (p < 0.05). The expression of MHC class I, MHC class II, and CD86 in DC2.4 cells significantly increased after pulsing tumor lysates with VP-R8 compared to other treatments (p < 0.05). The intra-lymph node injection of DC2.4 pulsed with both VP-R8 and EL4 lysate significantly decreased tumor growth compared to DC2.4 pulsed with KLH and lysates (p < 0.05) and induced tumor-infiltrating CD8T cells. The DC2.4 vaccine also remarkably increased the population of IFN-gamma-producing T cells and CTL activity against EL4 cells. In conclusion, we demonstrated that VP-R8 markedly enhances the efficiency of dendritic cell-based vaccines in priming robust anti-tumor immunity, suggesting its potential as a beneficial additive for dendritic cell-based immunotherapy.

  May 2024, International journal of molecular sciences, 25(11) (11), English, International magazine

  [Refereed]

  Scientific journal


• Metagenome and Resistome Analysis of Beta-Lactam-Resistant Bacteria Isolated from River Waters in Surabaya, Indonesia.

  Ryohei Nomoto, Kayo Osawa, Shohiro Kinoshita, Koichi Kitagawa, Noriko Nakanishi, Rosantia Sarassari, Dadik Raharjo, Masato Fujisawa, Kuntaman Kuntaman, Toshiro Shirakawa

  Antimicrobial agents are administered to humans and livestock, and bacterial antimicrobial resistance (AMR) and antimicrobial agents are released into the environment. In this study, to investigate the trend of AMR in humans, livestock, and the environment, we performed a metagenomic analysis of multidrug-resistant bacteria with CHROMagar ESBL in environmental river water samples, which were collected using syringe filter units from waters near hospitals, downtown areas, residential areas, and water treatment plants in Surabaya, Indonesia. Our results showed that Acinetobacter, Pseudomonas, Aeromonas, Enterobacter, Escherichia, and Klebsiella grew in CHROMagar ESBL; they were most frequently detected in water samples from rivers surrounding hospitals contaminated with various AMR genes (ARGs) in high levels. These results identified bacteria as ARG reservoirs and revealed that hospitals could be sources for various ARGs disseminated into the environment. In conclusion, this study details a novel metagenomic analysis of collected bacteria in environmental water samples using a syringe filter unit for an AMR epidemiological study based on the One Health approach.

  Jan. 2024, Microorganisms, 12(1) (1), English, International magazine

  [Refereed]

  Scientific journal


• An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.

  Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Toshiro Shirakawa

  Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60-70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 antibodies compared to the mice treated by the antibodies alone. This result suggests that B. longum 420 oral cancer vaccine as an adjunct to ICIs could provide a novel treatment option for RCC patients. Our microbiome analysis revealed that the proportion of Lactobacilli was significantly increased by B. longum 420. Although the detailed mechanism of action is unknown, it is possible that microbiome alteration by B. longum 420 enhances the efficacy of the ICIs.

  Jun. 2023, Scientific reports, 13(1) (1), 9994 - 9994, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.

  Hikaru Minagawa, Yoshiko Hashii, Hiroko Nakajima, Fumihiro Fujiki, Soyoko Morimoto, Jun Nakata, Toshiro Shirakawa, Takane Katayama, Akihiro Tsuboi, Keiichi Ozono

  BACKGROUND: A Wilms' tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and other immunocompetent cells (e.g., helper T cells). We developed a novel, oral, helper epitope-containing WT1 protein vaccine (B. longum 2656) to examine whether or not B. longum 420/2656 combination further accelerates the CD4+ T cell help-enhanced antitumor activity in a model of murine leukemia. METHODS: C1498-murine WT1-a genetically-engineered, murine leukemia cell line to express murine WT1-was used as tumor cell. Female C57BL/6 J mice were allocated to the B. longum 420, 2656, and 420/2656 combination groups. The day of subcutaneous inoculation of tumor cells was considered as day 0, and successful engraftment was verified on day 7. The oral administration of the vaccine by gavage was initiated on day 8. Tumor volume, the frequency and phenotypes of WT1-specific CTLs in CD8+ T cells in peripheral blood (PB) and tumor-infiltrating lymphocytes (TILs), as well as the proportion of interferon-gamma (INF-γ)-producing CD3+CD4+ T cells pulsed with WT135-52 peptide in splenocytes and TILs were determined. RESULTS: Tumor volume was significantly smaller (p < 0.01) in the B. longum 420/2656 combination group than in the B. longum 420 group on day 24. WT1-specific CTL frequency in CD8+ T cells in PB was significantly greater in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 (p < 0.05) and 6 (p < 0.01). The proportion of WT1-specific, effector memory CTLs in PB increased significantly in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 and 6 (p < 0.05 each). WT1-specific CTL frequency in intratumoral CD8+ T cells and the proportion of IFN-γ-producing CD3+CD4+ T cells in intratumoral CD4+ T cells increased significantly (p < 0.05 each) in the B. longum 420/2656 combination group than in the 420 group. CONCLUSIONS: B. longum 420/2656 combination further accelerated antitumor activity that relies on WT1-specific CTLs in the tumor compared with B. longum 420.

  Feb. 2023, BMC cancer, 23(1) (1), 167 - 167, English, International magazine

  [Refereed]

  Scientific journal


• A recombinant adenovirus vector containing the synNotch receptor gene for the treatment of triple-negative breast cancer.

  Ruhan A, Naoto Kunimura, Shoko Tominaga, Erika Hirata, Shunya Nishioka, Misato Uesugi, Rion Yamazaki, Hideto Ueki, Koichi Kitagawa, Masato Fujisawa, Toshiro Shirakawa

  Triple-negative breast cancer (TNBC) is known as the most difficult molecular subtype of breast cancer to treat. Recent studies revealed that cancer stem cells (CSCs) play a critical role in TNBC recurrence and metastasis. In this study, we developed a recombinant replication-deficient adenoviral vector (Ad-CD44-N-HIF-3α4), which contains a gene encoding a synthetic Notch (synNotch) receptor composed of the extracellular domain of CD44 (CD44-ECD) and the hypoxia-inducible factor (HIF)-3α4 connected by the Notch core regulatory region. CD44 is a transmembrane glycoprotein and known as a CSC marker in breast cancer and other malignancies. HIF-3α4 is a dominant-negative regulator of HIF-1α and HIF-2α and inhibits hypoxia-inducing effect. Both CD44 and HIF signals contribute cancer stemness and maintaining CSCs in breast cancer. The CD44-ECD in the synNotch receptor acts as the CD44 decoy receptor, and after a ligand such as a hyaluronic acid binds to the CD44-ECD, HIF-3α4 is released from the Notch core domain. We performed an in vivo study using a mouse xenograft model of MDA-MB-231, a highly invasive TNBC cell, and confirmed the significant antitumor activity of the intratumoral injections of Ad-CD44-N-HIF3α4. Our findings in this study warrant the further development of Ad-CD44-N-HIF3α4 for the treatment of patients with TNBC.

  2023, Frontiers in oncology, 13, 1147668 - 1147668, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Editorial: Targeting tumor vasculature to enhance cancer immunotherapy.

  Jieying Yang, Li Fu, Toshiro Shirakawa, Tong Xiang

  2023, Frontiers in oncology, 13, 1199811 - 1199811, English, International magazine


• An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia.

  Natsuki Nakagawa, Yoshiko Hashii, Hisako Kayama, Ryu Okumura, Hiroko Nakajima, Hikaru Minagawa, Soyoko Morimoto, Fumihiro Fujiki, Jun Nakata, Toshiro Shirakawa, Takane Katayama, Kiyoshi Takeda, Akihiro Tsuboi, Keiichi Ozono

  Wilms' tumor 1 (WT1) is a promising tumor-associated antigen for cancer immunotherapy. We developed an oral protein vaccine platform composed of WT1-anchored, genetically engineered Bifidobacterium longum (B. longum) and conducted an in vivo study in mice to examine its anticancer activity. Mice were orally treated with phosphate-buffered saline, wild-type B. longum105-A, B. longum 2012 displaying only galacto-N-biose/lacto-N-biose I-binding protein (GLBP), and WT1 protein- and GLBP-expressing B. longum 420. Tumor size reduced significantly in the B. longum 420 group than in the B. longum 105-A and 2012 groups (P < 0.00 l each), indicating B. longum 420's antitumor activity via WT1-specific immune responses. CD8+ T cells played a major role in the antitumor activity of B. longum 420. The proportion of CD103+CD11b+CD11c+ dendritic cells (DCs) increased in the Peyer's patches (PPs) from mice in the B. longum 420 group, indicating the definite activation of DCs. In the PPs, the number and proportion of CD8+ T cells capable of producing interferon-gamma were significantly greater in the B. longum 420 group than in the B. longum 2012 group (P < 0.05 or < 0.01). The production of WT1-specific IgG antibody was significantly higher in the B. longum 420 group than in the 2012 group (P < 0.05). The B. longum 420 group showed the most intense intratumoral infiltration of CD4+ and CD8+ T cells primed by activated DCs in the PPs of mice in the B. longum 420 group. Our findings provide insights into a novel, intestinal bacterium-based, cancer immunotherapy through intestinal immunity.

  Jun. 2022, Cancer immunology, immunotherapy : CII, English, International magazine

  [Refereed]

  Scientific journal


• Antibiotic Resistance in Non-Typhoidal Salmonella enterica Strains Isolated from Chicken Meat in Indonesia.

  Minori Takaichi, Kayo Osawa, Ryohei Nomoto, Noriko Nakanishi, Masanori Kameoka, Makiko Miura, Katsumi Shigemura, Shohiro Kinoshita, Koichi Kitagawa, Atsushi Uda, Takayuki Miyara, Ni Made Mertaniasih, Usman Hadi, Dadik Raharjo, Ratna Yulistiani, Masato Fujisawa, Kuntaman Kuntaman, Toshiro Shirakawa

  The increase in antibiotic resistance in non-typhoidal Salmonella enterica (NTS) has been confirmed in Indonesia by this study. We confirmed the virulence genes and antimicrobial susceptibilities of clinical NTS (n = 50) isolated from chicken meat in Indonesia and also detected antimicrobial resistance genes. Of 50 strains, 30 (60%) were non-susceptible to nalidixic acid (NA) and all of them had amino acid mutations in gyrA. Among 27 tetracycline (TC) non-susceptible strains, 22 (81.5%) had tetA and/or tetB. The non-susceptibility rates to ampicillin, gentamicin or kanamycin were lower than that of NA or TC, but the prevalence of blaTEM or aadA was high. Non-susceptible strains showed a high prevalence of virulence genes compared with the susceptible strains (tcfA, p = 0.014; cdtB, p < 0.001; sfbA, p < 0.001; fimA, p = 0.002). S. Schwarzengrund was the most prevalent serotype (23 strains, 46%) and the most frequently detected as multi-antimicrobial resistant. The prevalence of virulence genes in S. Schwarzengrund was significantly higher than other serotypes in hlyE (p = 0.011) and phoP/Q (p = 0.011) in addition to the genes above. In conclusion, NTS strains isolated from Indonesian chicken had a high resistance to antibiotics and many virulence factors. In particular, S. Schwarzengrund strains were most frequently detected as multi-antimicrobial resistant and had a high prevalence of virulence genes.

  May 2022, Pathogens (Basel, Switzerland), 11(5) (5), English, International magazine

  Scientific journal


• Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.

  H Ueki, N Hinata, K Kitagawa, T Hara, T Terakawa, J Furukawa, K Harada, Y Nakano, M Komatsu, M Fujisawa, T Shirakawa

  OBJECTIVES: Recently, the standard of care for advanced urothelial cancer (UC) has been changed by developing immune-checkpoint inhibitors (ICIs). However, its response rate is limited to 20-30%. The identification of biomarkers to predict the therapeutic effects of ICIs is urgently needed. The present study explored the association between immunohistochemical biomarkers and clinical outcomes in UC patients treated with pembrolizumab. PATIENTS AND METHODS: A total of 85 patients with UC who received pembrolizumab after chemotherapy from January 2018 to May 2020 were retrospectively reviewed. Tumor tissues were obtained for immunohistochemical study from 47 out of 85 patients. The protein expressions of PD-L1, WT1, Nectin-4, CD4, CD8, Foxp3, and CD68 in tumor cells and/or tumor infiltrating lymphocytes were immunohistochemically examined. The associations between protein expressions and overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) were statistically analyzed. RESULTS: Patients with positive PD-L1 in tumor cells showed significantly worse OS (Log-rank test: HR 5.146, p = 0.001, Cox regression analysis: HR 4.331, p = 0.014) and PFS (Log-rank test: HR 3.31. p = 0.022), along with significantly lower DCR (14.3%) compared to the PD-L1 negative patients (67.5%). In addition, patients with strong expression of Nectin-4 in tumor cells showed significantly higher DCR (100%) than the other patients (50%). CONCLUSION: PD-L1 expression in tumor cells was associated with poor prognosis (OS and PFS) and low DCR. Interestingly, the strong expression of Nectin-4 was correlated with high DCR. PD-L1 and Nectin-4 expression in tumor cells could be prognostic biomarkers useful for pembrolizumab in patients with advanced UC.

  Oct. 2021, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, English, International magazine

  Scientific journal


• Analysis of the upstream genetic structures of the ISEcp1-blaCTX-M transposition units in Escherichia coli isolates carrying blaCTX-M obtained from the Indonesian and Vietnamese communities.

  Fikri S Widyatama, Nobuyoshi Yagi, Rosantia Sarassari, Toshiro Shirakawa, Danh Tuyen Le, Mai Huong Thi Bui, Kuntaman Kuntaman, Itaru Hirai

  Extended spectrum β-lactamase (ESBL)-producing Escherichia coli have been found in healthy individuals in Indonesia and Vietnam. The ISEcp1-blaCTX-M transposition unit of ESBL-producing bacterial isolates has been considered responsible for the production of CTX-M type ESBL and it is important for the dissemination of blaCTX-M . This study aimed to characterize the upstream genetic structure (UGS) of E. coli isolates possessing blaCTX-M-1 group and/or blaCTX-M-9 group genes obtained from healthy individuals in Indonesia and Vietnam. A total of 501 CTX-M type ESBL-producing E. coli isolates possessing blaCTX-M-1 group and/or blaCTX-M-9 group genes were obtained from healthy individuals of the two countries in 2018. The UGSs of the ISEcp1-blaCTX-M transposition unit of the 501 ESBL-producing E. coli isolates were amplified by barcode-adaptor-ligation-mediated PCR and analyzed using the Nanopore sequencer. The obtained sequence information was used to classify the UGSs of the ISEcp1-blaCTX-M transposition unit. From the 501 ESBL-producing E. coli isolates, 502 UGSs were obtained, which were classified into 85 UGS types based on the sequence. ISEcp1 of 359 (71.5%) of the 502 UGSs was disrupted by gene insertion, and ISEcp1-blaCTX-M transposition unit of most (87.1%) of the determined UGSs was confirmed as plasmidic. Only 6 (7.1%) of the 85 UGS types were common to both countries. Our results indicated that many different UGSs of ISEcp1-blaCTX-M transposition units were detected in Indonesia and Vietnam; hence, we suggest that structurally different kinds of plasmids harboring blaCTX-M were separately distributed in the two countries.

  Sep. 2021, Microbiology and immunology, 65(12) (12), 542 - 550, English, International magazine

  Scientific journal


• An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model.

  Koichi Kitagawa, Maho Tatsumi, Mako Kato, Shota Komai, Hazuki Doi, Yoshiko Hashii, Takane Katayama, Masato Fujisawa, Toshiro Shirakawa

  Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors has been well established for various types of cancer. Monotherapy with ICIs, however, can achieve a durable response in only a subset of patients. There is a great unmet need for the ICI-resistant-tumors. Since patients who respond to ICIs should have preexisting antitumor T cell response, combining ICIs with cancer vaccines that forcibly induce an antitumor T cell response is a reasonable strategy. However, the preferred administration sequence of the combination of ICIs and cancer vaccines is unknown. In this study, we demonstrated that combining an oral WT1 cancer vaccine using a Bifidobacterium vector and following anti-PD-1 antibody treatment eliminated tumor growth in a syngeneic mouse model of bladder cancer. This vaccine induced T cell responses specific to multiple WT1 epitopes through the gut immune system. Moreover, in a tumor model poorly responsive to an initial anti-PD-1 antibody, this vaccine alone significantly inhibited the tumor growth, whereas combination with continuous anti-PD-1 antibody could not inhibit the tumor growth. These results suggest that this oral cancer vaccine alone or as an adjunct to anti-PD-1 antibody could provide a novel treatment option for patients with advanced urothelial cancer including bladder cancer.

  Sep. 2021, Molecular therapy oncolytics, 22, 592 - 603, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Occurrence of Carriage of Multidrug Resistant Enterobacteriaceae among Pregnant Women in the Primary Health Center and Hospital Setting in Surabaya, Indonesia.

  Siti Rochmanah Oktaviani Sulikah, Miratul Hasanah, Wahyu Setyarini, Hari Parathon, Koichi Kitagawa, Noriko Nakanishi, Ryohei Nomoto, Kayo Osawa, Shohiro Kinoshita, Itaru Hirai, Toshiro Shirakawa, Kuntaman Kuntaman

  Objectives: The incidence of healthy individuals carrying multidrug resistant Enterobacteriaceae, including extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E), especially extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) and extended-spectrum β-lactamase producing Klebsiella pneumoniae (ESBL-KP), is increasing worldwide. Although ESBL-E causes early or late onset of neonatal sepsis, the prevalence of ESBL-E carriage among pregnant women in Indonesia is not clear. In the present study, we compared the occurrence of carriage of ESBL-E among pregnant women in a primary health center (PHC) versus two hospitals. Materials and Methods: We collected rectal swab samples from 200 pregnant women who visited a PHC or were admitted to two hospitals in Surabaya, Indonesia from July to October 2018. The ESBL-E strains were isolated from the samples and phenotypically and genotypically analyzed. Results: ESBL-E strains were isolated from 25 (24.8%) pregnant women who visited the PHC and 49 (49.5%) pregnant women who were admitted to the hospitals. The rate of ESBL-E carriage of pregnant women in the hospitals was significantly higher than that in the PHC. Among the 74 isolated ESBL-E strains, ESBL-EC was most frequently isolated (62 strains), followed by ESBL-KP (12 strains). In addition, blaCTX-M-15 was the most frequent ESBL gene type of the isolated ESBL-E strains. Conclusions: Our results revealed the high occurrence of ESBL-E carriage in pregnant women, especially those who were admitted to the hospitals.

  Aug. 2021, Microbial drug resistance (Larchmont, N.Y.), 28(1) (1), 48 - 55, English, International magazine

  Scientific journal


• Pembrolizumab投与後7ヵ月目にirAEとして一型糖尿病、消化管壊死を来たした転移性膀胱癌の1例

  松山 直幹, 大西 篤史, 原 琢人, 千葉 公嗣, 松下 経, 古川 順也, 原田 健一, 石村 武志, 重村 克巳, 日向 信之, 中野 雄造, 白川 利朗, 藤澤 正人

  泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 259 - 259, Japanese


• Differential effects of chromosome and plasmid blaCTX-M-15 genes on antibiotic susceptibilities in extended-spectrum beta-lactamase-producing Escherichia coli isolates from patients with urinary tract infection.

  Young-Min Yang, Kayo Osawa, Koichi Kitagawa, Samiko Hosoya, Reo Onishi, Aya Ishii, Toshiro Shirakawa, Itaru Hirai, Kuntaman Kuntaman, Hiroshi Tanimoto, Katsumi Shigemura, Masato Fujisawa

  OBJECTIVES: To compare antibiotic susceptibilities between chromosomal and plasmid blaCTX-M-15 locations in urinary tract infection-causing extended-spectrum β-lactamases-producing Escherichia coli blaCTX-M-15 isolated in Indonesia. METHODS: A total of 84 strains identified as extended-spectrum β-lactamases-producing E. coli were isolated from patients with urinary tract infection in Indonesia in 2015. Antimicrobial susceptibility tests were performed on these strains using 18 antibiotics, and extended-spectrum β-lactamase bla genes were detected by polymerase chain reaction. Gene localization of blaCTX-M-15 -positive strains was confirmed by Southern blot hybridization, and epidemiological typing was conducted using multilocus sequence typing. RESULTS: Of 54 strains harboring the blaCTX-M-15 gene, 27 showed localization on chromosome, 20 on plasmid, and seven on chromosome and plasmid. Most multilocus sequence typing sequence types of the 27 strains with chromosomal blaCTX-M-15 were ST405 (25.9%) and ST131 (22.2%) strains, whereas the 20 strains with plasmid-blaCTX-M-15 were mostly ST410 (55.0%). CONCLUSIONS: Extended-spectrum β-lactamases-producing E. coli blaCTX-M-15 with plasmid genes show significantly higher resistant rates against piperacillin-tazobactam but lower resistant rates against chloramphenicol compared to chromosomal strains in Indonesian patients with urinary tract infection. Mechanistic investigations will be necessary to advance our knowledge of antimicrobial resistance in urinary tract infection.

  Jun. 2021, International journal of urology : official journal of the Japanese Urological Association, 28(6) (6), 623 - 628, English, International magazine

  Scientific journal


• Cross-Resistance and the Mechanisms of Cephalosporin-Resistant Bacteria in Urinary Tract Infections Isolated in Indonesia.

  Aya Ishii, Katsumi Shigemura, Koichi Kitagawa, Mizuki Harada, Yuki Kan, Fuka Hayashi, Kayo Osawa, K Kuntaman, Toshiro Shirakawa, Masato Fujisawa

  Urinary tract infection (UTI) by antibiotic-resistant strains has become increasingly problematic, with trends that differ from country to country. This study examined cross-resistance and the mechanisms of cephalosporin resistance in UTI-causative bacteria isolated in Indonesia. Antibiotic susceptibility tests based on Clinical Laboratory Standards Institute (CLSI) standards were done for UTI-causative strains (n = 50) isolated from patients in Indonesia in 2015-2016 and showed resistance against the third-generation cephalosporin. Mechanistic studies were carried out to confirm the presence of extended-spectrum β-lactamase (ESBL) genes, carbapenemase-related genes, the fosA3 gene related to fosfomycin resistance, and mutations of quinolone-resistance-related genes. Isolated UTI-causative bacteria included Escherichia coli (64.0%), Pseudomonas aeruginosa (16.0%), Klebsiella pneumoniae (10.0%), and others (10.0%). These strains showed 96.0% susceptibility to amikacin, 76.0% to fosfomycin, 90.0% to imipenem, 28.0% to levofloxacin, 92.0% to meropenem, and 74.0% to tazobactam/piperacillin. ESBL was produced by 68.0% of these strains. Mechanistic studies found no strains with carbapenemase genes but 6.0% of strains had the fosA3 gene. Seventy-two % of the strains had mutations in the gyrA gene and 74.0% in the parC gene. Most E. coli strains (87.5%) had Ser-83 → Leu and Asp-87 → Asn in gyrA and 93.8% of E. coli had Ser-80 → Ile in parC. There were significant correlations among mutations in gyrA and parC, and fosA3 gene detection (P < 0.05), respectively. To our knowledge, this is the first mechanistic study of antibiotic-cross-resistant UTI-causative bacteria in Indonesia. Further studies with a longer period of observation are necessary, especially for changes in carbapenem resistance without carbapenemase-related genes.

  May 2021, Current microbiology, 78(5) (5), 1771 - 1777, English, International magazine

  Scientific journal


• インドネシアにおける鶏肉由来のキノロン耐性non-typhoidal Salmonella entericaの遺伝子解析

  高市 果希, 大澤 佳代, 重村 克巳, 北川 孝一, 木下 承晧, 亀岡 正典, 楠木 まり, 宮良 高維, 藤沢 正人, 白川 利朗

  (一社)日本感染症学会, Apr. 2021, 感染症学雑誌, 95(臨増) (臨増), 197 - 197, Japanese


• インドネシアにおけるヒト及び環境由来のESBL産生Escherichia coliの分布調査

  坂本 夏那, 大澤 佳代, 重村 克巳, 北川 孝一, 木下 承晧, 亀岡 正典, 楠木 まり, 宮良 高維, 藤沢 正人, 白川 利朗

  (一社)日本感染症学会, Apr. 2021, 感染症学雑誌, 95(臨増) (臨増), 241 - 241, Japanese


• Genetic analysis of ESBL-producing Klebsiella pneumoniae isolated from UTI patients in Indonesia.

  Saya Yamasaki, Katsumi Shigemura, Kayo Osawa, Koichi Kitagawa, Aya Ishii, K Kuntaman, Toshiro Shirakawa, Takayuki Miyara, Masato Fujisawa

  INTRODUCTION: Extended spectrum beta-lactamase (ESBL)-producing Klebsiellapneumoniae is a serious concern for nosocomial infection and the emergence rate in Indonesia is higher than that in developed countries. The purpose of this study was to investigate the genetic characteristics of ESBL-producing K. pneumoniae isolated from UTI patients in Indonesia. MATERIALS AND METHODS: We collected K. pneumoniae resistant to ceftazidime or cefotaxime isolated from UTI patients in Dr. Soetomo's Academic Hospital in Surabaya, Indonesia in 2015. Ninety-four strains were identified as ESBL-producing bacteria by confirmation tests. The isolates were investigated by antimicrobial susceptibility testing with 20 drugs and ESBL gene detection, plasmid replicon typing and virulence genes as hypermucoviscous (HMV) strains were tested by the string test. RESULTS: High rates of resistance to ciprofloxacin (86.2%), tetracycline (80.9%) and nalidixic acid (78.7%) were observed. CTX-M-15 was the most common ESBL gene (89.4%), 33 of which also carried SHV-type ESBL. IncF was the most prevalent plasmid replicon typing (47.6%). Sixteen (17.0%) strains were judged as HMV, all of which had rmpA and more than half of which had fimH, uge, and wab. IncL/M was the most common replicon plasmid in the HMV strains, and the difference in the positive rate was statistically significant (p = 0.0024). CONCLUSION: This study showed the high prevalence of multiple-drug resistant and predominately CTX-M-15-positive ESBL-producing K. pneumoniae in Indonesia. There was a correlation between IncL/M and the HMV phenotype in this study. As such hypervirulent strains continue to emerge, studying their dissemination with resistance determinants is an urgent priority.

  Jan. 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 27(1) (1), 55 - 61, English, International magazine

  Scientific journal


• インドネシアの食肉から分離された薬剤耐性Salmonella entericaの遺伝子解析

  高市 果希, 大澤 佳代, 重村 克巳, 北川 孝一, 木下 承晧, 楠木 まり, 宮良 高維, Dadik Raharjo, Kuntaman Kuntaman, 亀岡 正典, 藤澤 正人, 白川 利朗

  (一社)日本臨床微生物学会, Dec. 2020, 日本臨床微生物学会雑誌, 31(Suppl.1) (Suppl.1), 201 - 201, Japanese


• Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models.

  Naoto Kunimura, Koichi Kitagawa, Ryota Sako, Keita Narikiyo, Shoko Tominaga, Diosdado S Bautista, Wei Xu, Masato Fujisawa, Toshiro Shirakawa

  In this study we undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor (ICI) anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate cancer derived from C57BL/6 mice), MBT-2 (bladder cancer derived from C3H mice) and Renca (kidney cancer derived from BALB/c mice) were used in this study. The highest coxsackie and adenovirus receptor (CAR) mRNA expression was observed in TRAMP-C2 cells, followed by Renca and then MBT-2 cells. Consistent with the CAR expressions, rAd-p53 at 160 multiplicity of infection (MOI) significantly inhibited the cell proliferation of TRAMP-C2 and Renca cells, but not MBT-2 cells. In in vivo experiments, the combination of intratumoral injections of rAd-p53 (1 × 109 plaque-forming units) every other day and intraperitoneal injections of anti-mouse PD-1 antibody (200 μg) twice a week suppressed tumor growth and prolonged survival compared to rAd-p53 or anti-PD-1 antibody monotherapy in both the TRAMP-C2 and Renca models. Our results encourage the clinical development of combination therapy comprised of in situ gene therapy with rAd-p53 and immunotherapy with an ICI anti-PD-1 antibody for urogenital cancers.

  Oct. 2020, Scientific reports, 10(1) (1), 17464 - 17464, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• インドネシア尿路感染症患者より検出されたCTX-M-15型ESBL産生E.coliの染色体性もしくはプラスミド性における薬剤感受性の比較

  細谷 砂美子, 重村 克巳, 宮良 高維, 北川 孝一, 中西 典子, 木下 承晧, 大澤 佳代, Kuntaman Kuntaman, 白川 利朗, 藤澤 正人

  (公社)日本化学療法学会, Sep. 2020, 日本化学療法学会雑誌, 68(Suppl.A) (Suppl.A), 346 - 346, Japanese


• Can ultrasound irradiation be a therapeutic option for prostate cancer?

  Noriaki Maeshige, Koichi Kitagawa, Saya Yamasaki, Aya Ishii, Toshiro Shirakawa, Yong-Ming Yang, Shian-Ying Sung, Kuan-Chou Chen, Zhi-Min Yuan, Katsumi Shigemura, Masato Fujisawa

  BACKGROUND: Focal therapies for prostate cancer (PC) can reduce adverse events and do not lead to androgen-independent progression. Ultrasound could be used for cancer treatments if the repetition frequency is fitted to the purpose. We investigated the possible therapeutic effect of ultrasound irradiation on PC cells. MATERIALS AND METHODS: We irradiated two PC cell lines, androgen-dependent LNCaP and -independent PC-3 with ultrasound (3.0 W/cm2 , 3 MHz, irradiation time rate: 20%) for 2 minutes for 1 day or 3 consecutive days at a repetition frequency of 1, 10, or 100 Hz in vitro. Cell proliferation and apoptosis were determined after irradiation. RESULTS: Cell proliferation of PC-3 was significantly inhibited after 1 day (P < .0001) and 3 days (P < .0001) of 10 Hz ultrasound irradiation, and that of LNCaP after 1 day (P < .0001) and 3 days (P < .0001) of irradiation. LNCaP was more sensitive to ultrasound at both lower and higher cell density but PC-3 was only sensitive at a lower cell density (P < .01). Irradiation with 10 Hz ultrasound-induced significantly more PC-3 apoptotic cells than control (1 day, P = .0137; 3 days, P = .0386) rather than irradiation with 1 Hz. Apoptosis via caspase-3 was induced at 10 Hz in 1-day (P < .05) irradiation in both cell lines. CONCLUSIONS: Ultrasound irradiation with even 1 day of 10 Hz significantly inhibited cell proliferation in both LNCaP and PC-3, especially by the remarkable induction of apoptosis in vitro. Our study indicated that ultrasound irradiation can be a therapeutic option for PC and further studies in vivo will be undertaken.

  Sep. 2020, The Prostate, 80(12) (12), 986 - 992, English, International magazine

  Scientific journal


• Molecular detection of a new pathotype enteroaggregative haemorrhagic Escherichia coli (EAHEC) in Indonesia, 2015.

  Wahyu Setyarini, Dadik Raharjo, Radita Yuniar Arizandy, Zakaria Pamoengkas, Subijanto Marto Sudarmo, Alpha Fardah Athiyyah, Toshiro Shirakawa

  Enteroaggregative haemorrhagic Escherichia coli (E. Coli, EAHEC) has been identified as the agent responsible for one of the largest outbreaks of gastroenteritis and Haemolytic-uremic syndrome (HUS) that is transmitted through food in Germany in 2011. The hypervirulent pathotype has a unique combination of two pathogens namely enterohemorrhagic E.coli strain (EHEC) which produces shiga/verotoxin and enteroaggregative E.coli toxins (EAEC) which produces toxins similar to ST and hemolysin. The toxin produced by the EAHEC strain is a hybrid pathotype that combines the virulence potential of the EAEC and EHEC strains that will damage the microcirculation, cause vasculitis and other toxic effects. The purpose of this study was to determine the percentage of samples infected with enteroaggregative hemorrhagic E. coli bacteria (EAHEC) in pediatric diarrhea patients at DR. Soetomo Hospital, Surabaya, Indonesia, 2015. This study used PCR (Polymerase Chain Reaction) method to detect enteroaggregative E. coli strains (CVD432 and aaic genes) and enterohemorrhagic E.coli (eae gene).The results showed that 33 out of 40 (82,5%) stool samples examined were detected enteroaggregative E. coli (EAEC), 4 out of 40 (10%) enterohemorrhagic E. coli (EHEC) and 3 out of 40 (7,5%) enteroaggregative haemorrhagic E. coli bacteria (EAHEC), which caused diarrhea in pediatric diarrhea patients at Dr. Soetomo General Hospital. The unique combination of genomic features of the Surabaya outbreak strain, containing characteristics from pathotypes EAEC and EHEC, suggested that it represents a new pathotype enteroaggregative haemorrhagic E. coli (EAHEC). It is expected that development of specific primer design and sequencing are needed to continue in this research.

  Jul. 2020, Infectious disease reports, 12(Suppl 1) (Suppl 1), 8745 - 8745, English, International magazine

  Scientific journal


• Characterization of CTX-M-type-extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae isolated from Indonesian undergraduate medical students of a university in Surabaya, Indonesia.

  Sarassari Rosantia, Takuya Higa, Nobuyoshi Yagi, Toshiro Tokunaga, Seina Higa, Yasuaki Yakabi, Toshiro Shirakawa, Kuntaman Kuntaman, Itaru Hirai

  Enterobacteriaceae isolates producing CTX-M-type extended-spectrum β-lactamase (ESBL) has been found in hospitalized patients and healthy individuals in communities of the Southeast Asian countries. Medical students might have more risk of ESBL-producing Enterobacteriaceae contagion, because medical students who belong to communities have direct and indirect contacts with workers and patients in healthcare facilities. The aim of this study was to collect information for evaluation of the potential risk of ESBL-producing Enterobacteriaceae contagion in Indonesian undergraduate medical students by characterizing genotypic properties of Escherichia coli isolates-producing CTX-M-type ESBL. A total 141 fecal samples collected from 207 medical students of a university in Surabaya, Indonesia were subjected to PCR, XbaI and S1 nuclease-pulsed-field gel electrophoresis (PFGE), Southern blotting, and sequencing analysis. Eighty-two ESBL-producing Enterobacteriaceae, including 75 E. coli and 7 Klebsiella pneumoniae were isolated from 79 (56.0%) students. Among 75 ESBL-producing E. coli, blaCTX-M-15 was the most prevalent type (44.0%). Although XbaI-PFGE results showed genetic background of the E. coli isolates producing CTX-M-type ESBL were diverse, five clonal spread cases of certain E. coli producing CTX-M-type ESBL isolates were observed among the medical students. Our results suggested that ESBL-producing Enterobacteriaceae might be circulating among the medical students through contaminated environment such as in a university or communities they belonged.

  Jun. 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 26(6) (6), 575 - 581, English, International magazine

  [Refereed]

  Scientific journal


• Difference of Phenotype and Genotype Between Human and Environmental: Isolated Vibrio cholerae in Surabaya, Indonesia.

  Kayo Osawa, Katsumi Shigemura, Koichi Kitagawa, K Kuntaman, Ni Made Mertaniasih, Wahyu Setyarini, Dita Arizandy, Dadik Rahadjo, Ro Osawa, Toshiro Shirakawa, Masato Fujisawa

  Cholera due to Vibrio cholerae has been spreading worldwide, although the reports focusing on Indonesian V. cholerae are few. In this study, in order to investigate how V. cholerae transmitted to human from environment. We extended an epidemiological report that had investigated the genotype of V. cholerae isolated from human pediatric samples and environmental samples. We examined 44 strains of V. cholerae isolated from pediatric diarrhea patients and the environment such as shrimps or oysters collected in three adjacent towns in Surabaya, Indonesia. Susceptibilities were examined for 11 antibiotics. Serotype O1 or O139 genes and pathogenic genes including cholera toxin were detected. Multi-locus sequence typing (MLST) and enterobacterial repetitive intergenic consensus (ERIC)-PCR were also performed to determine genetic diversity of those isolates. Serotype O1 was seen in 17 strains (38.6%) with all pathogenic genes among 44 isolates. Other isolates were non-O1/non-O139 V. cholerae. Regarding antibiotic susceptibilities, those isolates from environmental samples showed resistance to ampicillin (11.4%), streptomycin (9.1%) and nalidixic acid (2.3%) but those isolates from pediatric stools showed no resistance to those 3 kinds of antibiotics. MLST revealed sequence type (ST) 69 in 17 strains (38.6%), ST198 in 3 strains (6.8%) and non-types in 24 strains (54.5%). All the ST69 strains were classified to O1 type with more than 95% similarity by ERIC-PCR, including all 6 (13.6%) isolates from environmental samples with resistance to streptomycin. In conclusion, V. cholerae O1 ST69 strains has been clonally spreading in Surabaya, exhibiting pathogenic factors and antibiotic resistance to streptomycin, especially in the isolates from environment.

  Jun. 2020, Indian journal of microbiology, 60(2) (2), 230 - 238, English, International magazine

  [Refereed]

  Scientific journal


• Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891

  Natsumi Uehara, Naoki Otsuki, Mie Kubo, Junko Kitamoto, Yasutaka Kojima, Masanori Teshima, Hirotaka Shinomiya, Toshiro Shirakawa, Ken-ichi Nibu

  Feb. 2020, Cancer Reports

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo.

  Tomomi Yoneda, Naoto Kunimura, Koichi Kitagawa, Yuka Fukui, Hiroki Saito, Keita Narikiyo, Motoki Ishiko, Naoki Otsuki, Ken-Ichi Nibu, Masato Fujisawa, Satoshi Serada, Tetsuji Naka, Toshiro Shirakawa

  Prostate cancer is one of the most common cancers in men. The overactivation of IL-6/JAK/STAT3 signaling and silencing of SOCS3 are frequently observed in prostate cancer. In the present study we undertook to develop Ad-SOCS3 gene therapy for the treatment of prostate cancer and also investigated whether Ad-SOCS3 increased sensitivity to NK cells. We demonstrated that Ad-SOCS3 could significantly inhibit growth of castration-resistant prostate cancer (CRPC) cell lines expressing pSTAT3, DU-145 (at 10, 20, and 40 MOI), and TRAMP-C2 (at 40 MOI), but not the PC-3 CRPC cell line with the STAT3 gene deleted. Ad-SOCS3 (40 MOI) could suppress IL-6 production in DU-145 cells and PD-L1 expression induced by IFN-γ in TRAMP-C2 cells, and increased the NK cell sensitivity of both TRAMP-C2 and DU-145 cells. In the DU-145 mouse xenograft tumor model, intratumoral injections (twice/week for 3 weeks) of 1 × 108 pfu of Ad-SOCS3 significantly inhibited tumor growth and combining the Ad-SOCS3 treatment with intratumoral injections (once/week for 2 weeks) of 1 × 107 human NK cells showed the highest tumor growth inhibitory effect. These results suggested that a combination of Ad-SOCS3 gene therapy and NK cell immunotherapy could be a powerful treatment option for advanced CRPC overexpressing pSTAT3.

  Nov. 2019, Cancer gene therapy, 26(11-12) (11-12), 388 - 399, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Prevalence of Quinolone Resistance of Extended-Spectrum β-Lactamase-Producing Escherichia coli with ST131-fimH30 in a City Hospital in Hyogo, Japan.

  Masazumi Teramae, Kayo Osawa, Katsumi Shigemura, Koichi Kitagawa, Toshiro Shirakawa, Masato Fujisawa, Takayuki Miyara

  Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates are known to tolerate superior quinolone antimicrobials compared with other antibacterial agents. Among the clones belonging to sequence type (ST) 131 by multilocus sequence typing, the involvement of the H30-Rx subclone has been reported worldwide with various fimH genes encoding type 1 pili. We investigated 83 isolates of ESBL-producing E. coli and performed antimicrobial susceptibility test, CH (fumC/fimH) ST131 by typing the specific PCR. Moreover, mutation analysis of genes involved in quinolone antibiotic resistance (gyrA and parC) and ESBL genotypes were determined. As a result, 54 of 83 isolates (65.1%) of CH40-30 clones corresponding to ST131-fimH30 were detected, and all were resistant to levofloxacin. Mutations associated with this resistance were common, and included S83L and D87N of gyrA and S80I and E84V of parC. Subclone analysis revealed a high proportion of fimH30-non-Rx (40 isolates, 74.1%). Each subclone was characterized by ESBL genotype, and the CTX-M-15 type was mainly seen for fimH30-Rx, with the CTX-M-14 type or CTX-M-27 type seen for fimH30-non-Rx. This study suggests that an increase in ESBL-producing quinolone-resistant E. coli in a city hospital in Hyogo, Japan, was caused by the spread of subclones belonging to fimH30-non-Rx of ST131.

  Oct. 2019, International journal of molecular sciences, 20(20) (20), English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Possible correlation of sonic hedgehog signaling with epithelial-mesenchymal transition in muscle-invasive bladder cancer progression.

  Koichi Kitagawa, Katsumi Shigemura, Shian-Ying Sung, Kuan-Chou Chen, Chao-Ching Huang, Yi-Te Chiang, Ming-Che Liu, Tzu-Wen Huang, Fukashi Yamamichi, Toshiro Shirakawa, Masato Fujisawa

  PURPOSE: To investigate the role of sonic hedgehog (Shh) signaling and epithelial-mesenchymal transition (EMT) in bladder cancer progression and invasion. METHODS: We cultured three bladder cancer cell lines, muscle-invasive T24 and 5637, and non-muscle-invasive KK47, in the presence of a recombinant-Shh (r-Shh) protein or cyclopamine, a Shh signaling inhibitor, to investigate proliferation and expression of EMT markers. Wound-healing assays and transwell assay were performed to evaluate cell invasion and migration. Mice were then inoculated with bladder cancer cells and treated with cyclopamine. Mouse tumor samples were stained for Shh signaling and EMT markers. RESULTS: R-Shh protein enhanced cell proliferation, whereas cyclopamine significantly suppressed cell proliferation, especially in invasive cancer (5637 and T24) (p < 0.05). R-Shh protein promoted EMT, suppressed E-cadherin and enhanced N-cadherin and vimentin and Gli1, an Shh downstream molecule, while cyclopamine blocked EMT, especially in 5637 and T24. Cyclopamine also inhibited cell invasion and migration in vitro. In the animal study, intraperitoneal injection of cyclopamine significantly suppressed tumor growth in 5637 and T24 in mice (p = 0.01 and p = 0.004, respectively) and slightly suppressing KK47 tumor growth (p = 0.298). Significant cyclopamine-induced suppression of Gli1 in 5637 and T24 mouse tumors (both p = 0.03) was seen, suggesting that muscle-invasive bladder cancer may be more dependent on Shh signaling than non-muscle-invasive bladder cancer. CONCLUSIONS: Shh signaling and EMT were especially enhanced in muscle-invasive bladder cancer progression and invasion, and suppressed by the inhibition of Shh signaling.

  Sep. 2019, Journal of cancer research and clinical oncology, 145(9) (9), 2261 - 2271, English, International magazine

  [Refereed]


• Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer.

  Koichi Kitagawa, Reina Gonoi, Maho Tatsumi, Masahide Kadowaki, Takane Katayama, Yoshiko Hashii, Masato Fujisawa, Toshiro Shirakawa

  Previously, we constructed a recombinant Bifidobacterium longum displaying a partial mouse Wilms' tumor 1 (WT1) protein (B. longum 420) as an oral cancer vaccine using a bacterial vector and demonstrated that oral administration of B. longum 420 significantly inhibited tumor growth compared with the Db126 WT1 peptide vaccine in the TRAMP-C2, mouse castration-resistant prostate cancer (CRPC) syngeneic tumor model. The present study demonstrated that oral administration of 1.0×109 colony-forming units of B. longum 420 induced significantly higher cytotoxicity against TRAMP-C2 cells than intraperitoneal injection of 100 μg of Db126, and the in vivo antitumor activity of B. longum 420 in the TRAMP-C2 tumor model could be augmented by intraperitoneal injections of 250 μg of anti-PD-1 antibody. For the clinical development, we produced the B440 pharmaceutical formulation, which is lyophilized powder of inactivated B. longum 440 displaying the partially modified human WT1 protein. We confirmed that B. longum 440 could induce cellular immunity specific to multiple WT1 epitopes. In a preclinical dosage study, B440 significantly inhibited growth of the TRAMP-C2 tumors compared with that of the control groups (PBS and B. longum not expressing WT1) at all dosages (1, 5, and 10 mg/body of B440). These mouse doses were considered to correspond with practical oral administration doses of 0.2, 1, and 2 g/body for humans. Taken together, these results suggest that the B440 WT1 oral cancer vaccine can be developed as a novel oral immuno-oncology drug to treat CRPC as a monotherapy or as an adjunct to immune checkpoint inhibitors.

  May 2019, Molecular cancer therapeutics, 18(5) (5), 980 - 990, English, International magazine

  [Refereed]


• Stenotrophomonas maltophilia菌血症による死亡の危険因子

  西本 健人, 重村 克巳, 大澤 佳代, 北川 孝一, 白川 利朗, 宮良 高維, 中野 雄造

  (一社)日本感染症学会, Mar. 2019, 感染症学雑誌, 93(臨増) (臨増), 343 - 343, Japanese


• Bacteremia complicating urinary tract infection by Pseudomonas aeruginosa: Mortality risk factors.

  Koichi Kitagawa, Katsumi Shigemura, Fukashi Yamamichi, Kayo Osawa, Atsushi Uda, Chihiro Koike, Issei Tokimatsu, Toshiro Shirakawa, Takayuki Miyara, Masato Fujisawa

  OBJECTIVES: To examine the clinical risk factors for death within 30 days of diagnosis of Pseudomonas aeruginosa-causing bacteremia after a urinary tract infection. METHODS: A total of 62 patients with Pseudomonas aeruginosa isolated from both urine and blood at the same episode from January 2009 to December 2016 were enrolled in the present study. We retrospectively investigated clinical risk factors for death by comparison between surviving patients and those who died within 30 days after diagnosis of P. aeruginosa bacteremia. The comparison for risk factors for bacteremia-related death included 31 categories, such as age, laboratory data, underlying diseases, clinical history, history of surgery, care in the intensive care unit, P. aeruginosa susceptibility to the antibiotics used at the time of bacteremia diagnosis and consultation with urological department. RESULTS: The study included 48 men and 14 women aged 71.3 ± 10.4 years. Nine patients (14.5%) died of P. aeruginosa bacteremia. Statistical analysis showed that non-survivors had significantly lower albumin levels than survivors (2.07 ± 0.62 vs 2.62 ± 0.65; P = 0.023). The non-survivors had significantly higher rates of ventilator use, history of heart disease, septic shock and lower rates of consultation with urological departments after diagnosis (P < 0.05). CONCLUSIONS: Patients with bacteremia complicating urinary infection by P. aeruginosa have a low death rate. Earlier intervention by urologists might improve patients' outcome. Lower albumin levels, ventilator use, history of heart disease and septic shock are factors associated with higher mortality rate.

  Mar. 2019, International journal of urology : official journal of the Japanese Urological Association, 26(3) (3), 358 - 362, English, International magazine

  [Refereed]


• Acquisition of antimicrobial-resistant variants in repeated infections caused by Pseudomonas aeruginosa revealed by whole genome sequencing.

  Noriko Nakanishi, Ryohei Nomoto, Kanako Sato, Chihiro Koike, Mari Kusuki, Tatsuya Nakamura, Katsumi Shigemura, Toshiro Shirakawa, Masato Fujisawa, Issei Tokimatsu, Kayo Osawa

  Pseudomonas aeruginosa, responsible for serious nosocomial-acquired infections, possesses intrinsic antibiotic resistance mechanisms and commonly exhibits multidrug resistance. Here, we report the evolving resistance profiles of strains isolated from the sputum of a patient being treated for repeated P. aeruginosa infections following cancer resection. Whole genome sequencing of six isolates obtained over a 2-month period revealed two key single nucleotide polymorphisms in the mexR and gyrB genes that affected efflux pump expression and antimicrobial resistance.

  Feb. 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 25(2) (2), 154 - 156, English, International magazine

  [Refereed]


• Clinical manifestation of norovirus infection in children aged less than five years old admitted with acute diarrhea in Surabaya, Indonesia: a cross-sectional study.

  Alpha Fardah Athiyyah, Katsumi Shigemura, Koichi Kitagawa, Nazara Agustina, Andy Darma, Reza Ranuh, Dadik Raharjo, Toshiro Shirakawa, Masato Fujisawa, Subijanto Marto Sudarmo

  Background: The objective of this study was to investigate the clinical manifestation of norovirus infection between norovirus genogroup and severity of acute diarrhea in pediatric patients at the Dr. Soetomo Hospital, Surabaya, Indonesia. Methods: This cross-sectional study involved 31 participants aged 1-60 months admitted to the hospital with acute diarrhea from April 2012 to March 2013. Norovirus genogroups (GI and II) were identified from patient stool using reverse transcription polymerase chain reaction (RT-PCR). Severity was measured using the Ruuska and Vesikari scoring system. Results: In total, 94 stool samples were obtained, of which 31 (19%) were norovirus positive. Norovirus GI was found in one sample with mild diarrhea. Norovirus GII was found in 30 samples (96.8%); one sample with mild diarrhea (3.3%), 20 samples with moderate diarrhea (66.7%), and nine samples with severe diarrhea (30%). Conclusion: Norovirus GII was the most prevalent cause of acute diarrhea and 30% of the cases manifested as severe diarrhea.

  2019, F1000Research, 8, 2130 - 2130, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Molecular characteristics of carbapenem-resistant Pseudomonas aeruginosa isolated from urine in Hyogo, Japan.

  Kayo Osawa, Katsumi Shigemura, Koichi Kitagawa, Teruo Fukuda, Ayaka Takasaka, Sakie Wakabayashi, Kanako Sato, Fukashi Yamamichi, Toshiro Shirakawa, Masato Fujisawa

  OBJECTIVES: To investigate the molecular characteristics and epidemiology of metallo-β-lactamase-producing Pseudomonas aeruginosa from urine of urinary tract infection patients in Hyogo Prefecture, Japan. METHODS: Carbapenem-resistant P. aeruginosa isolated from the urine of 21 urinary tract infection patients in three general hospitals in Hyogo Prefecture (Japan) were collected between 2007 and 2014. Their antibiotic susceptibilities, metallo-β-lactamase screening test, metallo-β-lactamase gene sequencing, multilocus sequence typing and repetitive-sequence-based polymerase chain reaction were determined for epidemiological analyses to investigate the genetic characteristics. RESULTS: Out of 21 isolates, 13 (61.9%) were positive for metallo-β-lactamase. There were 11 (52.4%) isolates with IMP-1 in them, one (4.5%) isolate with IMP-7 and one (4.5%) isolate with VIM-1. Metallo-β-lactamase-positive isolates were mainly identified as ST235, and metallo-β-lactamase-negative isolates were STs 357, 277, 234, 439 and 639. Repetitive-sequence-based polymerase chain reaction showed metallo-β-lactamase-positive isolates were grouped in eight clusters, and ST235 isolates with IMP-1 from three hospitals belonging to the identical group I, the other ST235 isolates with IMP-7 and VIM-1 were from two hospitals belonging to group II. CONCLUSIONS: Metallo-β-lactamase-positive P. aeruginosa of ST235 isolates with IPM-1 were mainly identified from the urine of urinary tract infection patients in Hyogo, Japan. A ST235 isolate with VIM-1 was found for the first time. Further investigation is necessary to follow the spread of metallo-β-lactamase-positive isolates.

  Jan. 2019, International journal of urology : official journal of the Japanese Urological Association, 26(1) (1), 127 - 133, English, International magazine

  [Refereed]


• Clinical Risk Factors for Death Caused by Extended-Spectrum Beta-Lactamase: Producing Bacteria.

  Yoshie Mita, Katsumi Shigemura, Kayo Osawa, Koichi Kitagawa, Tomohiro Kotaki, Toshiro Shirakawa, Takayuki Miyara, Masato Fujisawa

  OBJECTIVES: Extended-spectrum beta-lactamase (ESBL)-producing bacteria often causes bacteremia, leading serious outcomes. In this study, we conducted a retrospective analysis to identify the risk factors associated with death by bacteremia of ESBL-producing bacteria. METHODS: Patients with bacteremia by ESBL-producing bacteria were retrospectively collected in Kobe University Hospital, Japan, between January 2011 and December 2015. Potential risk factors for death caused by ESBL-bacteremia were analyzed for patients' outcome (recovery or death) by univariate and multivariate analysis. RESULTS: A total of 101 patients (64 male and 37 female) were recruited. The most frequently detected ESBL-producing bacteria were Escherichia coli (91 cases; 90.1%), followed by Klebsiella pneumoniae (8 cases; 7.9%). Most frequently used antibiotics after the detection of bacteremia was meropenem (66.3%; 67/101) followed by cefmetazole (51.5%; 52/101). Univariate analysis showed a significantly positive correlation with mortality in ICU admission (p < 0.001), circulatory diseases (p = 0.022), shock (p = 0.044), and respirator requirement (p = 0.002). Multivariate analysis showed ICU admission remained significant risk factor for mortality (p = 0.0192). CONCLUSIONS: We showed ICU admission was significantly correlated with death from bacteremia by ESBL-producing bacteria. These factors should be monitored to estimate severity of ESBL causing-bacteremia for better patients' outcomes.

  2019, Urologia internationalis, 102(2) (2), 205 - 211, English, International magazine

  [Refereed]


• Molecular characteristics of carbapenem-resistant Pseudomonas aeruginosa isolated from urine in Hyogo, Japan.

  Kayo Osawa, Katsumi Shigemura, Koichi Kitagawa, Teruo Fukuda, Ayaka Takasaka, Sakie Wakabayashi, Kanako Sato, Fukashi Yamamichi, Toshiro Shirakawa, Masato Fujisawa

  OBJECTIVES: To investigate the molecular characteristics and epidemiology of metallo-β-lactamase-producing Pseudomonas aeruginosa from urine of urinary tract infection patients in Hyogo Prefecture, Japan. METHODS: Carbapenem-resistant P. aeruginosa isolated from the urine of 21 urinary tract infection patients in three general hospitals in Hyogo Prefecture (Japan) were collected between 2007 and 2014. Their antibiotic susceptibilities, metallo-β-lactamase screening test, metallo-β-lactamase gene sequencing, multilocus sequence typing and repetitive-sequence-based polymerase chain reaction were determined for epidemiological analyses to investigate the genetic characteristics. RESULTS: Out of 21 isolates, 13 (61.9%) were positive for metallo-β-lactamase. There were 11 (52.4%) isolates with IMP-1 in them, one (4.5%) isolate with IMP-7 and one (4.5%) isolate with VIM-1. Metallo-β-lactamase-positive isolates were mainly identified as ST235, and metallo-β-lactamase-negative isolates were STs 357, 277, 234, 439 and 639. Repetitive-sequence-based polymerase chain reaction showed metallo-β-lactamase-positive isolates were grouped in eight clusters, and ST235 isolates with IMP-1 from three hospitals belonging to the identical group I, the other ST235 isolates with IMP-7 and VIM-1 were from two hospitals belonging to group II. CONCLUSIONS: Metallo-β-lactamase-positive P. aeruginosa of ST235 isolates with IPM-1 were mainly identified from the urine of urinary tract infection patients in Hyogo, Japan. A ST235 isolate with VIM-1 was found for the first time. Further investigation is necessary to follow the spread of metallo-β-lactamase-positive isolates.

  Jan. 2019, International journal of urology : official journal of the Japanese Urological Association, 26(1) (1), 127 - 133, English, International magazine

  [Refereed]

  Scientific journal


• Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan.

  Kuntaman Kuntaman, Katsumi Shigemura, Kayo Osawa, Koichi Kitagawa, Koharu Sato, Naoki Yamada, Kento Nishimoto, Fukashi Yamamichi, Dadik Rahardjo, Usman Hadi, Ni Made Mertaniasih, Shohiro Kinoshita, Masato Fujisawa, Toshiro Shirakawa

  OBJECTIVES: To explore the occurrence and characterization of carbapenemase-producing pathogens among carbapenem-resistant Gram-negative bacilli isolated from hospitalized patients with urinary tract infection in Indonesia. METHODS: This was a study promoted by the Japanese-Indonesian collaborative research program in the Japan Initiative for Global Research Network on Infectious Diseases. Bacterial pathogens were prospectively isolated from urine specimens of hospitalized urinary tract infection patients at Dr. Soetomo Hospital (Surabaya, Indonesia). All Gram-negative bacteria resistant to third-generation cephalosporin or carbapenem were included in this study. Carbapenemase genes were investigated for phenotype and genotype. RESULTS: In total, 1082 Gram-negative bacilli were isolated, of which 116 strains were resistant to imipenem or meropenem (carbapenem-resistant Gram-negative bacilli), and 22 strains were carbapenemase-producing Gram-negative bacilli. Carbapenemase-producing Gram-negative bacilli consisted of Acinetobacter baumannii (n = 4), Pseudomonas aeruginosa (n = 4), Klebsiella pneumoniae (n = 5), Providencia rettgeri (n = 4) and five others. The carbapenemase-producing Gram-negative bacilli included NDM-1 (n = 18, 81.8%, in Enterobacteriaceae and Acinetobacter spp.) and IMP-7 (n = 4, 18.2%, all in P. aeruginosa). Among carbapenem-resistant Gram-negative bacilli, all four P. aeruginosa were sensitive to colistin, and all six Acinetobacter spp. were sensitive to minocycline, colistin and tigecycline. Of those patients harboring carbapenemase-producing Gram-negative bacilli, 12 (54.5%) were seriously ill at the time of admission, with longer hospital stays and three deaths (13.6% mortality rate). CONCLUSIONS: Urinary tract infection-causing carbapenem-resistant Gram-negative bacilli are widely disseminated in Indonesia. The NDM-1 phenotype seems to be dominant, and it can be treated with colistin and tigecycline in most cases. Most patients harboring carbapenemase-producing Gram-negative bacilli are seriously ill, have a bad prognosis, with a longer hospital stay and a significant mortality rate.

  Nov. 2018, International journal of urology : official journal of the Japanese Urological Association, 25(11) (11), 966 - 972, English, International magazine

  [Refereed]

  Scientific journal


• Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells.

  Yasutaka Kojima, Naoki Otsuki, Mie Kubo, Junko Kitamoto, Eri Takata, Hiroki Saito, Kyoko Kosaka, Naoya Morishita, Natsumi Uehara, Toshiro Shirakawa, Ken-Ich Nibu

  Human papillomavirus (HPV) infection has been identified as an etiologic factor of head and neck cancers (HNCs). We explored the potential use of antisense HPV RNA transcripts for gene therapy and its effect in combination with cisplatin (CDDP) for HPV-positive HNCs. We introduced the antisense RNA transcripts of the E6 and E7 genes of HPV type 16 into UM-SCC-47 cells harboring HPV 16 and YCU-T892 cells that were HPV-negative using a recombinant adenoviral vector, Ad-E6/E7-AS. We then analyzed the effects of the introduction of Ad-E7-AS on cell and tumor growth and the synergistic effect with CDDP in vitro and in vivo. After infection of Ad-E6/E7-AS, the cellular growth of UM-SCC-47 cells were suppressed, but not that of YCU-T892 cells. E7 protein expression was suppressed, and p53 and pRb protein expression increased after infection of Ad-E7-AS. Cell growth and tumorigenicity were greatly suppressed in combination with CDDP compared with Ad-E7-AS or CDDP treatment alone in vitro. Ad-E7-AS combined with CDDP treatment significantly reduced the volumes of established subcutaneous tumors. Transfection with HPV 16 E7 antisense RNA combined with CDDP treatment might be a potentially useful approach to the therapy of HPV 16-positive HNC.

  Oct. 2018, Cancer gene therapy, 25(9-10) (9-10), 274 - 283, English, International magazine

  [Refereed]


• Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis.

  Mari Kusuki, Kayo Osawa, Kentaro Arikawa, Miho Tamura, Katsumi Shigemura, Toshiro Shirakawa, Tatsuya Nakamura, Yuji Nakamachi, Masato Fujisawa, Jun Saegusa, Issei Tokimatsu

  Mycobacterium abscessus complex, including three subspecies-M. abscessus, M. massiliense, and M. bolletii-is resistant to a variety of antibiotics so limited treatment options are available. The susceptibility of these subspecies to antimicrobial agents depends in particular on the erm(41) sequevar and rrl mutations in the 23S rRNA, which are potentially related to clarithromycin (CLR) resistance. The purpose of this study was to carry out identification and molecular characterization of these subspecies based on variable number of tandem repeats (VNTR) analysis. Twenty-four M. abscessus complex strains were identified as M. abscessus and M. massiliense and these subspecies could be discriminated between based on their resistance to CLR, as determined by truncation or mutation of erm(41) or mutation of rrl, as illustrated by their VNTR patterns. In conclusion, we confirmed that the CLR susceptibility profiles could be differentiated according to the subspecies of M. abscessus complex strains by their VNTR patterns.

  Jul. 2018, Diagnostic microbiology and infectious disease, 91(3) (3), 256 - 259, English, International magazine

  [Refereed]

  Scientific journal


• Improved bacterial identification directly from urine samples with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

  Koichi Kitagawa, Katsumi Shigemura, Ken-Ichiro Onuma, Masako Nishida, Mayu Fujiwara, Saori Kobayashi, Mika Yamasaki, Tatsuya Nakamura, Fukashi Yamamichi, Toshiro Shirakawa, Issei Tokimatsu, Masato Fujisawa

  John Wiley and Sons Inc., Mar. 2018, Journal of Clinical Laboratory Analysis, 32(3) (3), English

  [Refereed]

  Scientific journal


• Pseudomonas aeruginosaの連続感染における抗菌耐性機序の分析(Analysis of antimicrobial resistance mechanism in successive infections of Pseudomonas aeruginosa)

  中西 典子, 野本 竜平, 佐藤 加奈子, 小池 千裕, 楠木 まり, 中村 竜也, 重村 克巳, 白川 利朗, 時松 一成, 大澤 佳代

  日本細菌学会, Feb. 2018, 日本細菌学雑誌, 73(1) (1), 141 - 141, English


• Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine

  Toshiro Shirakawa, Koichi Kitagawa

  Taylor and Francis Inc., Jan. 2018, Human Vaccines and Immunotherapeutics, 14(1) (1), 159 - 162, English

  [Refereed]

  Scientific journal


• International comparison of causative bacteria and antimicrobial susceptibilities of urinary tract infections between Kobe, Japan, and Surabaya, Indonesia

  Koichi Kitagawa, Katsumi Shigemura, Fukashi Yamamichi, Lindawati Alimsardjono, Dadik Rahardjo, Kuntaman Kuntaman, Toshiro Shirakawa, Masato Fujisawa

  National Institute of Health, 2018, Japanese Journal of Infectious Diseases, 71(1) (1), 8 - 13, English

  [Refereed]

  Scientific journal


• Wilms'tumor 1抗原発現ビフィズス菌を用いた経口癌ワクチンのマウス前立腺癌に対する抗腫瘍効果の検討

  五ノ井 玲菜, 北川 孝一, 古田 拓也, 辰巳 真帆, 橋井 佳子, 片山 高嶺, 白川 利朗

  生命科学系学会合同年次大会運営事務局, Dec. 2017, 生命科学系学会合同年次大会, 2017年度, [2P - 0893], Japanese


• penA, ponA, porB1, and mtrR Mutations and Molecular Epidemiological Typing of Neisseria gonorrhoeae with Decreased Susceptibility to Cephalosporins

  Kayo Osawa, Katsumi Shigemura, Yukie Nukata, Koichi Kitagawa, Fukashi Yamamichi, Hiroyuki Yoshida, Toshiro Shirakawa, Soichi Arakawa, Masato Fujisawa

  Aug. 2017, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(8) (8), pii: e01174 - 17., English

  [Refereed]

  Scientific journal


• Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro

  H. Saito, K. Kitagawa, T. Yoneda, Y. Fukui, M. Fujsawa, D. Bautista, T. Shirakawa

  Jul. 2017, CANCER GENE THERAPY, 24(7) (7), 289 - 296, English

  [Refereed]

  Scientific journal


• Antibiotic Susceptibilities and Genetic Characteristics of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Stools of Pediatric Diarrhea Patients in Surabaya, Indonesia

  Eddy Bagus Wasitou, Katsumi Shigemura, Kayo Osawa, Alpha Fardah, Akiho Kanaida, Dadik Raharjo, K. Kuntaman, Usman Hadi, Sugeng Harijono, Subijanto Marto Sudarmo, Tatsuya Nakamura, Keigo Shibayama, Masato Fujisawa, Toshiro Shirakawa

  Jul. 2017, JAPANESE JOURNAL OF INFECTIOUS DISEASES, 70(4) (4), 378 - 382, English

  [Refereed]

  Scientific journal


• Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein

  Koichi Kitagawa, Tsugumi Oda, Hiroki Saito, Ayame Araki, Reina Gonoi, Katsumi Shigemura, Yoshiko Hashii, Takane Katayama, Masato Fujisawa, Toshiro Shirakawa

  Jun. 2017, CANCER IMMUNOLOGY IMMUNOTHERAPY, 66(6) (6), 787 - 798, English

  [Refereed]

  Scientific journal


• Prevalence of Antibiotic-resistance Enterobacteriaceae strains Isolated from Chicken Meat at Traditional Markets in Surabaya, Indonesia

  R. Yulistiani, D. Praseptiangga, Supyani, Sudibya, D. Raharjo, T. Shirakawa

  Institute of Physics Publishing, May 2017, IOP Conference Series: Materials Science and Engineering, 193(1) (1), English

  [Refereed]

  International conference proceedings


• Wilms' tumor 1タンパク質発現ビフィズス菌を用いた経口癌ワクチンの抗腫瘍免疫誘導効果に関する検討

  北川 孝一, 辰巳 真帆, 五ノ井 玲菜, 斉藤 大樹, 橋井 佳子, 片山 高嶺, 白川 利朗

  (公財)腸内細菌学会, Apr. 2017, 腸内細菌学雑誌, 31(2) (2), 112 - 112, Japanese


• Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-alpha, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice

  Koichi Kitagawa, Chika Omoto, Tsugumi Oda, Ayame Araki, Hiroki Saito, Katsumi Shigemura, Takane Katayama, Hak Hotta, Toshiro Shirakawa

  Apr. 2017, VIRAL IMMUNOLOGY, 30(3) (3), 196 - 203, English

  [Refereed]

  Scientific journal


• High Prevalence of Diarrheagenic Escherichia coli among Children with Diarrhea in Kenya

  Yoshio Iijimal, Joseph O. Oundo, Takumi Hibino, Suleiman M. Saidi, Atsushi Hinenoya, Kayo Osawa, Toshiro Shirakawa, Ro Osawa, Shinji Yamasaki

  Jan. 2017, JAPANESE JOURNAL OF INFECTIOUS DISEASES, 70(1) (1), 80 - 83, English

  [Refereed]

  Scientific journal


• セフェム系抗菌薬低感受性淋菌の遺伝学的解析

  額田雪絵, 大澤佳代, Shigemura Katsumi, 吉田弘之, 藤澤正人, 荒川創一, 白川利朗

  May 2016, 日本化学療法学会雑誌, 64(Suppl.A) (Suppl.A), 164, Japanese

  Research society


• カルバペネム耐性腸内細菌科細菌の分離状況

  朝比奈桃花, 大澤佳代, Shigemura Katsumi, 吉田弘之, 高羽桂, 時松一成, 藤澤正人, 荒川創一, 白川利朗

  May 2016, 日本化学療法学会雑誌, 64(Suppl.A) (Suppl.A), 178, Japanese

  Research society


• 兵庫県内で分離されたメタロβラクタマーゼ産生緑膿菌の解析

  高坂綾香, 大澤佳代, Shigemura Katsumi, 山道深, 吉田弘之, 中村竜也, 藤澤正人, 荒川創一, 白川利朗

  Mar. 2016, 感染症学雑誌, 90(2号) (2号), 183 - 184, Japanese

  Research society


• MRSA疫学手法としてもPOT法とrep-PCR法の比較

  大澤佳代, Shigemura Katsumi, 吉田弘之, 白川利朗, 藤澤正人, 荒川創一

  Mar. 2016, 感染症学雑誌, 90(臨増) (臨増), 345, Japanese

  Research society


• Association of overexpression of efflux pump genes with antibiotic resistance in Pseudomonas aeruginosa strains clinically isolated from urinary tract infection patients

  Katsumi Shigemura, Kayo Osawa, Ayaka Kato, Issei Tokimatsu, Soichi Arakawa, Toshiro Shirakawa, Masato Fujisawa

  Sep. 2015, JOURNAL OF ANTIBIOTICS, 68(9) (9), 568 - 572, English

  [Refereed]

  Scientific journal


• BACTERIAL IDENTIFICATION USING ssRA ENCODING TRANSFER-MESSENGER RNA

  Kayo Osawa, Katsumi Shigemura, Hiroki Shirai, Ayaka Kato, Yuma Okuya, Takumi Jikimoto, Soichi Arakawa, Masato Fujisawa, Toshiro Shirakawa

  Jul. 2015, SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 46(4) (4), 720 - 727, English

  [Refereed]

  Scientific journal


• A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene

  Yuji Tada, Kenzo Hiroshima, Hideaki Shimada, Naoya Morishita, Toshiro Shirakawa, Kunio Matsumoto, Masato Shingyoji, Ikuo Sekine, Koichiro Tatsumi, Masatoshi Tagawa

  Jul. 2015, SPRINGERPLUS, 4, 358, English

  [Refereed]

  Scientific journal


• Azithromycin Resistance and Its Mechanism in Neisseria gonorrhoeae Strains in Hyogo, Japan

  Katsumi Shigemura, Kayo Osawa, Makiko Miura, Kazushi Tanaka, Soichi Arakawa, Toshiro Shirakawa, Masato Fujisawa

  May 2015, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(5) (5), 2695 - 2699, English

  [Refereed]

  Scientific journal


• Molecular Characteristics of Extended-Spectrum beta-Lactamase-Producing Escherichia coli in a University Teaching Hospital

  Kayo Osawa, Katsumi Shigemura, Rika Shimizu, Ayaka Kato, Mari Kusuki, Takumi Jikimoto, Tatsuya Nakamura, Hiroyuki Yoshida, Soichi Arakawa, Masato Fujisawa, Toshiro Shirakawa

  Apr. 2015, MICROBIAL DRUG RESISTANCE, 21(2) (2), 130 - 139, English

  [Refereed]

  Scientific journal


• Genotyping and clinical factors in pediatric diarrhea caused by rotaviruses: one-year surveillance in Surabaya, Indonesia

  Subijanto Marto Sudarmo, Katsumi Shigemura, Alpha Fardah Athiyyah, Kayo Osawa, Oktavian Prasetia Wardana, Andy Darma, Reza Ranuh, Dadik Raharjo, Soichi Arakawa, Masato Fujisawa, Toshiro Shirakawa

  Feb. 2015, GUT PATHOGENS, 7, 3, English

  [Refereed]

  Scientific journal


• [Development of the novel oral vaccine against hepatitis C virus utilizing bifidobacteria]

  Shirakawa Toshiro

  日本臨床社, Feb. 2015, Nihon Rinsho, 73(2) (2), 239 - 242, English

  Scientific journal


• Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms

  Fukashi Yamamichi, Katsumi Shigemura, Hosny M. Behnsawy, Masuo Yamashita, Toshiro Shirakawa, Masato Fujisawa

  2015, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 8(9) (9), 11863 - 11870, English

  [Refereed]

  Scientific journal


• Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer

  Fukashi Yamamichi, Katsumi Shigemura, Hosny M. Behnsawy, Fatma Y. Meligy, Wen-Chin Huang, Xiangyan Li, Kunito Yamanaka, Keisuke Hanioka, Hideaki Miyake, Kazushi Tanaka, Masato Kawabata, Toshiro Shirakawa, Masato Fujisawa

  Dec. 2014, SCANDINAVIAN JOURNAL OF UROLOGY, 48(6) (6), 523 - 532, English

  [Refereed]

  Scientific journal


• 兵庫県におけるアジスロマイシン(AZM)耐性淋菌の分子遺伝学的解析

  三浦 真希子, Shigemura Katsumi, 大澤 佳代, 吉田 弘之, 藤原 美樹, 澤村 暢, 奈須 聖子, 荒川 創一, 藤澤 正人, 白川 利朗

  (一社)日本性感染症学会, Oct. 2014, 日本性感染症学会誌, 25(2号) (2号), 78 - 78, Japanese

  Research society


• セフェム系薬剤感受性低下Neisseria gonorrhoeaeの遺伝解析

  大澤 佳代, Shigemura Katsumi, 額田 雪絵, 吉田 弘之, 藤原 美樹, 奈須 聖子, 白川 利朗, 藤澤 正人, 荒川 創一

  Oct. 2014, 日本性感染症学会誌, 25(2号) (2号), 78, Japanese

  Research society


• Comparison between phage-open-reading frame typing and automated repetitive-sequence-based PCR for typing MRSA isolates

  Kayo Osawa, Katsumi Shigemura, Takumi Jikimoto, Toshiro Shirakawa, Masato Fujisawa, Soichi Arakawa

  Aug. 2014, JOURNAL OF ANTIBIOTICS, 67(8) (8), 565 - 569, English

  [Refereed]

  Scientific journal


• A Combined Lymphokine-activated Killer (LAK) Cell Immunotherapy and Adenovirus-p53 Gene Therapy for Head and Neck Squamous Cell Carcinoma

  Hiroki Saito, Satoshi Ando, Naoya Morishita, Kyung-Mi Lee, Dante Dator, David Dy, Katsumi Shigemura, Zainal Adhim, Ken-Ichi Nibu, Masato Fujisawa, Toshiro Shirakawa

  Jul. 2014, ANTICANCER RESEARCH, 34(7) (7), 3365 - 3370, English

  [Refereed]

  Scientific journal


• 兵庫県下で分離されたメタロβラクタマーゼ産生腸内細菌の解析

  大澤 佳代, Shigemura Katsumi, 吉田 弘之, 藤原 美樹, 荒川 創一, 藤澤 正人, 白川 利朗

  May 2014, 日本化学療法学会雑誌, 62(Suppl.A) (Suppl.A), 402, Japanese

  Research society


• 当院で分離されたESBLs産生Escherichia coliの遺伝子解析

  大澤 佳代, 吉田 弘之, Shigemura Katsumi, 楠木 まり, 直本 拓己, 中村 竜也, 荒川 創一, 藤澤 正人, 白川 利朗

  May 2014, 日本化学療法学会雑誌, 62(Suppl.A) (Suppl.A), 400, Japanese

  Research society


• Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice

  Saki Takei, Chika Omoto, Koichi Kitagawa, Naoya Morishita, Takane Katayama, Katsumi Shigemura, Masato Fujisawa, Masato Kawabata, Hak Hotta, Toshiro Shirakawa

  May 2014, VACCINE, 32(25) (25), 3066 - 3074, English

  [Refereed]

  Scientific journal


• DEVELOPMENT OF MULTIPLEX PCR FOR RAPID IDENTIFICATION OF FOUR SALMONELLA SEROVARS MOST COMMONLY ISOLATED IN JAPAN

  Rika Shimizu, Kayo Osawa, Katsumi Shigemura, Hiroyuki Yoshida, Miki Fujiwara, Yoshio Iijima, Masato Fujisawa, Toshiro Shirakawa

  May 2014, SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 45(3) (3), 654 - 661, English

  [Refereed]

  Scientific journal


• 前立腺癌増悪において上皮ならびに間質でのShhとandrogenシグナル伝達が上皮間葉移行を作動させる

  山道 深, Shigemura Katsumi, ホスニー・ベンソイ, ファトマ・メリジ, ウェンチン・ファン, シャン・ギアン・リ, リーランド・チャン, 川端 眞人, 後藤 章暢, 三宅 秀明, 田中 一志, 白川 利朗, 藤澤 正人

  Apr. 2014, 日本泌尿器科学会総会 102回, 415, Japanese

  Research society


• Biosafety studies of carrier cells infected with a replication-competent adenovirus introduced by IAI.3B promoter

  Katsuyuki Hamada, Toshiro Shirakawa, Shuji Terao, Akinobu Gotoh, Kenzaburo Tani, Wenlin Huang

  2014, MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 1, 14019, English

  [Refereed]

  Scientific journal


• Antimicrobial Resistance in Salmonella Strains Clinically Isolated in Hyogo, Japan (2009-2012)

  Kayo Osawa, Katsumi Shigemura, Rika Shimizu, Ayaka Kato, Mayuha Kimura, Yuki Katayama, Yuma Okuya, Shunichiro Yutaka, Akiko Nishimoto, Akane Kishi, Miki Fujiwara, Hiroyuki Yoshida, Yoshio Iijima, Masato Fujisawa, Toshiro Shirakawa

  Jan. 2014, JAPANESE JOURNAL OF INFECTIOUS DISEASES, 67(1) (1), 54 - 57, English

  [Refereed]

  Scientific journal


• BPH/LUTSに対するデュタステリドの有用性に関する検討

  Tanaka Kazushi

  Sep. 2013, 日本排尿機能学会誌, 24(1号) (1号), 282, Japanese

  [Refereed]

  Research society


• Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized multicenter study

  Toshiro Shirakawa, Takahiro Haraguchi, Katsumi Shigemura, Shinichi Morishita, Kohji Minayoshi, Jiro Miyazaki, Yuji Yamada, Hideaki Miyake, Kazushi Tanaka, Masato Fujisawa

  Sep. 2013, INTERNATIONAL JOURNAL OF UROLOGY, 20(9) (9), 903 - 910, English

  [Refereed]

  Scientific journal


• Modulation of O-antigen chain length by the wzz gene in Escherichia coli O157 influences its sensitivities to serum complement

  Kayo Osawa, Katsumi Shigemura, Atsushi Iguchi, Hiroki Shirai, Toru Imayama, Kazuko Seto, Dadik Raharjo, Masato Fujisawa, Ro Osawa, Toshiro Shirakawa

  Sep. 2013, MICROBIOLOGY AND IMMUNOLOGY, 57(9) (9), 616 - 623, English

  [Refereed]

  Scientific journal


• Frequency of Diarrheagenic Escherichia coli among Children in Surabaya, Indonesia

  Kayo Osawa, Dadik Raharjo, Eddy Bagus Wasito, Sugeng Harijono, Katsumi Shigemura, Ro Osawa, Subijanto Marto Sudarmo, Yoshio Iijima, Toshiro Shirakawa

  Sep. 2013, JAPANESE JOURNAL OF INFECTIOUS DISEASES, 66(5) (5), 446 - 448, English

  [Refereed]

  Scientific journal


• Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines

  Zainal Adhim, Naoki Otsuki, Junko Kitamoto, Naoya Morishita, Masato Kawabata, Toshiro Shirakawa, Ken-Ichi Nibu

  Jul. 2013, Acta Oto-Laryngologica, 133(7) (7), 761 - 771, English

  [Refereed]

  Scientific journal


• Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression

  Hosny M. Behnsawy, Katsumi Shigemura, Fatma Y. Meligy, Fukashi Yamamichi, Masuo Yamashita, Wen-Chin Haung, Xiangyan Li, Hideaki Miyake, Kazushi Tanaka, Masato Kawabata, Toshiro Shirakawa, Masato Fujisawa

  Jun. 2013, Korean Journal of Urology, 54(8) (8), 547 - 554, English

  [Refereed]

  Scientific journal


• 尿路感染症患者より分離したPseudomonas aeruginosa薬剤耐性株におけるefflux pump遺伝子の発現についての検討

  加藤 綾香, 大澤 佳代, Shigemura Katsumi, 田中 一志, 荒川 創一, 藤澤 正人, 白川 利朗

  May 2013, 感染症学雑誌, 87(臨増) (臨増), 297, Japanese

  Research society


• Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study

  Katsumi Shigemura, Kazushi Tanaka, Fukashi Yamamichi, Toshiro Shirakawa, Hideaki Miyake, Masato Fujisawa

  Dec. 2012, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 40(6) (6), 516 - 520, English

  [Refereed]

  Scientific journal


• Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography

  Minori Matsumoto, Katsumi Shigemura, Toshiro Shirakawa, Yuzo Nakano, Hideaki Miyake, Kazushi Tanaka, Shohiro Kinoshita, Soichi Arakawa, Masato Kawabata, Masato Fujisawa

  Nov. 2012, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 40(5) (5), 440 - 444, English

  [Refereed]

  Scientific journal


• Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2

  Chung Hee Sonn, Jong Rip Choi, Tae-Jin Kim, Young-Bin Yu, Kwanghee Kim, Suk Chul Shin, Gil-Hong Park, Toshiro Shirakawa, Hee Sun Kim, Kyung-Mi Lee

  Nov. 2012, JOURNAL OF RADIATION RESEARCH, 53(6) (6), 823 - 829, English

  [Refereed]

  Scientific journal


• Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B).

  Fukashi Yamamichi, Takayuki Matsuoka, Katsumi Shigemura, Masato Kawabata, Toshiro Shirakawa, Masato Fujisawa

  OBJECTIVE: To establish a mouse xenograft model of metastatic prostate cancer (PCa) and investigate the relationship between metastasis and circulating tumor cells. METHODS: Flow cytometry (FACS) was used to detect suitable PCa cells and markers for detecting circulating tumor cells in vivo. We orthotopically injected androgen receptor-positive and androgen-independent C4-2B PCa cells into 12 severe combined immunodeficiency (SCID) mouse prostates, including 1 vehicle control. We measured the serum prostate-specific antigen levels biweekly after tumor inoculation. Circulating tumor cells (CTCs) were measured qualitatively by fluorescent microscopy immediately after the mice were sacrificed. The mouse prostates and lungs were examined for tumor formation using immunohistochemistry because we found no apparent metastasis, except in the lung. RESULTS: FACS analyses in vitro identified the marker, prostate-specific membrane antigen, and C4-2B cells to be appropriate for additional in vivo study. We confirmed that the serum prostate-specific antigen increase was dependent on time and prostate tumor weight in mice. Of the 11 mice, 6 could be used as the mouse PCa xenograft model. Fluorescent microscopy detected CTCs in the peripheral blood in 5 of the 6 mice constituting the PCa model. Human prostate-specific antigen expression was detected by immunohistochemistry in the prostates of all the mice and in the lung of 2 of the 6 mice, suggesting 2 mice with lung metastasis. CONCLUSION: We have shown the potential establishment of a mouse lung metastatic xenograft model of androgen receptor-positive and androgen-independent C4-2B PCa tumor. However, the present model requires improvement to be a more reproducible, accurate and complete experimental model. Additional study is necessary to verify the relationship between metastasis and CTCs.

  Oct. 2012, Urology, 80(4) (4), 951.e1-7 - 7, English, International magazine

  [Refereed]

  Scientific journal


• 排尿障害患者におけるデュタステリド内服療法の性機能および血中テストステロン値への影響についての検討

  Chiba Koji, Nakano Yuzo, Haraguchi Takahiro, Shirakawa Toshiro, Tanaka Kazushi, Arakawa Soichi, Fujisawa Masato

  (一社)日本性機能学会, Sep. 2012, 日本性機能学会雑誌, 27(2号) (2号), 175 - 175, Japanese

  Research society


• BPH/LUTSに対するデュタステリドの有用性に関する検討

  Haraguchi Takahiro, Miyake Hideaki, Shirakawa Toshiro, Tanaka Kazushi, Fujisawa Masato

  Aug. 2012, 日本排尿機能学会誌, 23(1号) (1号), 194, Japanese

  Research society


• Detection of tumor markers in prostate cancer and comparison of sensitivity between real time and nested PCR.

  Takayuki Matsuoka, Katsumi Shigemura, Fukashi Yamamichi, Masato Fujisawa, Masato Kawabata, Toshiro Shirakawa

  The objective of this study is to investigate and compare the sensitivity in conventional PCR, quantitative real time PCR, nested PCR and western blots for detection of prostate cancer tumor markers using prostate cancer (PCa) cells. We performed conventional PCR, quantitative real time PCR, nested PCR, and western blots using 5 kinds of PCa cells. Prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and androgen receptor (AR) were compared for their detection sensitivity by real time PCR and nested PCR. In real time PCR, there was a significant correlation between cell number and the RNA concentration obtained (R(2)=0.9944) for PSA, PSMA, and AR. We found it possible to detect these markers from a single LNCaP cell in both real time and nested PCR. By comparison, nested PCR reached a linear curve in fewer PCR cycles than real time PCR, suggesting that nested PCR may offer PCR results more quickly than real time PCR. In conclusion, nested PCR may offer tumor maker detection in PCa cells more quickly (with fewer PCR cycles) with the same high sensitivity as real time PCR. Further study is necessary to establish and evaluate the best tool for PCa tumor marker detection.

  Jun. 2012, The Kobe journal of medical sciences, 58(2) (2), E51-9 - 9, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The efficiency of in vitro isolation and myogenic differentiation of MSCs derived from adipose connective tissue, bone marrow, and skeletal muscle tissue

  Fatma Y. Meligy, Katsumi Shigemura, Hosny M. Behnsawy, Masato Fujisawa, Masato Kawabata, Toshiro Shirakawa

  Apr. 2012, IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 48(4) (4), 203 - 215, English

  [Refereed]

  Scientific journal


• Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells

  K. Iguchi, F. Sakurai, K. Tomita, K. Katayama, T. Yamaguchi, K. Kawabata, M. Tagawa, M. Kawabata, T. Shirakawa, H. Mizuguchi

  Feb. 2012, CANCER GENE THERAPY, 19(2) (2), 118 - 125, English

  [Refereed]

  Scientific journal


• E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma

  Z. Adhim, X. Lin, W. Huang, N. Morishita, T. Nakamura, H. Yasui, N. Otsuki, K. Shigemura, M. Fujisawa, K. Nibu, T. Shirakawa

  Feb. 2012, CANCER GENE THERAPY, 19(2) (2), 144 - 152, English

  Scientific journal


• Mechanisms of and Risk Factors for Fluoroquinolone Resistance in Clinical Enterococcus faecalis Isolates from Patients with Urinary Tract Infections

  Tomihiko Yasufuku, Katsumi Shigemura, Toshiro Shirakawa, Minori Matsumoto, Yuzo Nakano, Kazushi Tanaka, Soichi Arakawa, Masato Kawabata, Masato Fujisawa

  Nov. 2011, JOURNAL OF CLINICAL MICROBIOLOGY, 49(11) (11), 3912 - 3916, English

  [Refereed]

  Scientific journal


• In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines

  Z. Adhim, T. Matsuoka, T. Bito, K. Shigemura, K-M Lee, M. Kawabata, M. Fujisawa, K. Nibu, T. Shirakawa

  Jul. 2011, BRITISH JOURNAL OF CANCER, 105(3) (3), 393 - 402, English

  [Refereed]

  Scientific journal


• Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model

  Aya Saito, Naoya Morishita, Chihomi Mitsuoka, Shunichi Kitajima, Katsuyuki Hamada, Kyung-Mi Lee, Masato Kawabata, Masato Fujisawa, Toshiro Shirakawa

  Jun. 2011, JOURNAL OF GENE MEDICINE, 13(6) (6), 353 - 361, English

  Scientific journal


• Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections

  Tomihiko Yasufuku, Katsumi Shigemura, Toshiro Shirakawa, Yuzo Nakano, Kazushi Tanaka, Soichi Arakawa, Shouhiro Kinoshita, Kunihiro Nishimura, Masato Kawabata, Masato Fujisawa

  Feb. 2011, SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 43(2) (2), 83 - 88, English

  [Refereed]

  Scientific journal


• PP-344 尿路感染症由来緑膿菌臨床株における高速液体クロマトグラフィー法によるフルオロキノロン系抗菌薬耐性の迅速診断法確立への検討(一般演題ポスター発表・討論,一般演題ポスター,第99回日本泌尿器科学会総会)

  松本 穣, 重村 克巳, 白川 利朗, 安福 富彦, 中野 雄造, 田中 一志, 木下 承皓, 川端 眞人, 荒川 創一, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 461 - 461, Japanese


• OP-106 腸球菌の尿路感染症臨床株におけるgyrA,parC遺伝子変異とフルオロキノロン系抗菌薬耐性の相関についての検討(感染症1,一般演題口演,第99回日本泌尿器科学会総会)

  安福 富彦, 重村 克巳, 白川 利朗, 松本 穰, 中野 雄造, 田中 一志, 木下 承皓, 川端 眞人, 荒川 創一, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 358 - 358, Japanese


• Phenotypic and Genotypic Characterization of Vibrio cholerae Clinically Isolated in Surabaya, Indonesia

  Tomoyuki Nishibori, Garry Cores de Vries, Dadik Rahardjo, Eddy Bagus Wasito, Ismoedijanto De, Shouhiro Kinoshita, Yoshitake Hayashi, Hak Hotta, Masato Kawabata, Toshiro Shirakawa, Yoshio Iijima, Ro Osawa

  Jan. 2011, JAPANESE JOURNAL OF INFECTIOUS DISEASES, 64(1) (1), 7 - 12, English

  [Refereed]

  Scientific journal


• Correlation of Overexpression of Efflux Pump Genes with Antibiotic Resistance in Escherichia coli Strains Clinically Isolated from Urinary Tract Infection Patients

  Tomihiko Yasufuku, Katsumi Shigemura, Toshiro Shirakawa, Minori Matsumoto, Yuzo Nakano, Kazushi Tanaka, Soichi Arakawa, Shouhiro Kinoshita, Masato Kawabata, Masato Fujisawa

  Jan. 2011, JOURNAL OF CLINICAL MICROBIOLOGY, 49(1) (1), 189 - 194, English

  [Refereed]

  Scientific journal


• Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

  Sakura Yamamoto, Jun Wada, Takane Katayama, Takumi Jikimoto, Masakuni Nakamura, Shohiro Kinoshita, Kyung-Mi Lee, Masato Kawabata, Toshiro Shirakawa

  Sep. 2010, VACCINE, 28(41) (41), 6684 - 6691, English

  [Refereed]

  Scientific journal


• Ultraviolet light induces Stat3 activation in human keratinocytes and fibroblasts through reactive oxygen species and DNA damage

  Toshinori Bito, Naoko Sumita, Taro Masaki, Toshiro Shirakawa, Masato Ueda, Ryutaro Yoshiki, Yoshiki Tokura, Chikako Nishigori

  Jul. 2010, EXPERIMENTAL DERMATOLOGY, 19(7) (7), 654 - 660, English

  [Refereed]

  Scientific journal


• NRAMP1/SLC11A1 GENE POLYMORPHISMS AND HOST SUSCEPTIBILITY TO MYCOBACTERIUM TUBERCULOSIS AND M. LEPRAE IN SOUTH SULAWESI, INDONESIA

  Mochammad Hatta, Ratnawati, Motoko Tanaka, Jun Ito, Toshiro Shirakawa, Masato Kawabata

  Mar. 2010, SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 41(2) (2), 386 - 394, English

  [Refereed]

  Scientific journal


• OP-008 尿路感染症由来緑膿菌臨床株におけるgyrA、parC遺伝子変異とキノロン系抗菌薬耐性の関連についての検討(感染症1,一般演題口演,第98回日本泌尿器科学会総会)

  松本 穣, 重村 克巳, 白川 利朗, 安福 富彦, 中野 雄造, 田中 一志, 武中 篤, 荒川 創一, 水下 承皓, 川端 眞人, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 234 - 234, Japanese


• APP-001 尿路感染症由来大腸菌の臨床株における薬剤排出ポンプ遺伝子の発現と各種抗菌薬耐性との関連の解析(発表・討論,総会賞応募ポスター,第98回日本泌尿器科学総会)

  安福 富彦, 重村 克巳, 白川 利朗, 中野 雄造, 田中 一志, 武中 篤, 荒川 創一, 木下 承皓, 川端 眞人, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 181 - 181, Japanese


• Emergence of fluoroquinolone-resistant strains of Salmonella enterica in Surabaya, Indonesia

  Daisuke Yanagi, Garry Cores de Vries, Dadik Rahardjo, Lindawati Alimsardjono, Eddy Bagus Wasito, Ismoedijanto De, Shouhiro Kinoshita, Yoshitake Hayashi, Hak Hotta, Ro Osawa, Masato Kawabata, Toshiro Shirakawa

  Aug. 2009, DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 64(4) (4), 422 - 426, English

  [Refereed]

  Scientific journal


• A Pilot Study of Quality of Life of Patients with Hormone-refractory Prostate Cancer after Gene Therapy

  Shuji Terao, Toshiro Shirakawa, Bishnu Acharya, Masahiro Miyata, Nobuyuki Hinata, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Michio Naoe, Kohzo Fuji, Takatsugu Okegawa, Eiji Higashihara, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh

  May 2009, ANTICANCER RESEARCH, 29(5) (5), 1533 - 1537, English

  [Refereed]

  Scientific journal


• Differential expression of osteocalcin during the metastatic progression of prostate cancer

  Thomas A. Gardner, Sang-Jin Lee, Sang-Don Lee, Xiong Li, Toshihiro Shirakawa, Dong Deuk Kwon, Ra Young Park, Kyu Youn Ahn, Chaeyong Jung

  Apr. 2009, ONCOLOGY REPORTS, 21(4) (4), 903 - 908, English

  [Refereed]

  Scientific journal


• Cyclooxygenase 2 Promoter-Based Replication-Selective Adenoviral Vector for Hypopharyngeal Cancer

  Takahiro Nakagawa, Hironori Tanaka, Toshiro Shirakawa, Akinobu Gotoh, Yoshitake Hayashi, Katsuyuki Hamada, Mamoru Tsukuda, Ken-ichi Nibu

  Mar. 2009, ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 135(3) (3), 282 - 286, English

  [Refereed]

  Scientific journal


• OP-021 大腸菌の臨床株におけるgyrA,parC遺伝子変異とフルオロキノロン系抗菌薬耐性の相関についての検討(尿路性器感染症,一般演題口演,第97回日本泌尿器科学会総会)

  安福 富彦, 重村 克巳, 白川 利朗, 中野 雄造, 田中 一志, 武中 篤, 荒川 創一, 木下 承皓, 川端 眞人, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2009, 日本泌尿器科学会雑誌, 100(2) (2), 194 - 194, Japanese


• OP-078 前立腺肥大症患者におけるシロドシンおよびナフトピジルの臨床効果に関する比較検討(BPH/Male LUTS2,一般演題口演,第97回日本泌尿器科学会総会)

  白川 利朗, 原口 貴裕, 松本 穣, 竹田 雅, 森下 真一, 山道 深, 源吉 顕治, 原田 健一, 田中 一志, 武中 篤, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2009, 日本泌尿器科学会雑誌, 100(2) (2), 208 - 208, Japanese


• Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma

  Noboru Okamura, Taro Masuda, Akinobu Gotoh, Toshiro Shirakawa, Shuji Terao, Naoki Kaneko, Kazuki Suganuma, Makoto Watanabe, Toshiya Matsubara, Ryota Seto, Jun Matsumoto, Megumi Kawakami, Motohiro Yamamori, Tsutomu Nakamura, Tatsurou Yagami, Toshiyuki Sakaeda, Masato Fujisawa, Osamu Nishimura, Katsuhiko Okumura

  Aug. 2008, PROTEOMICS, 8(15) (15), 3194 - 3203, English

  [Refereed]

  Scientific journal


• Clinical study results of a phase I/II study of AD-OC-TK/VAL gene therapy for the patients with metastatic or local recurrent prostate cancer

  Toshiro Shirakawa, Akinobu Gotoh, Shuji Terao, Nobuyuki Hinata, Kazumasa Goda, Kazushi Tanka, Atsushi Takenaka, Isao Hara, Sadao Kamidono, Masato Fujisawa

  Apr. 2008, JOURNAL OF GENE MEDICINE, 10(4) (4), 433 - 434, English

  [Refereed]


• Impact and perspective on chronic kidney disease in an Asian developing country: A large-scale survey in north Vietnam

  Jun Ito, Dinh Thi Kim Dung, Mai Tuyet Vuong, Do Gia Tuyen, Le Danh Vinh, Nguyen Thi Huong, Tran Bich Ngoc, Nguyen Thi Bich Ngoc, Mai Thi Hien, Dang Duc Hao, Lam Thi Kim Oanh, Do Thi Lieu, Masato Fujisawa, Masato Kawabata, Toshiro Shirakawa

  2008, NEPHRON CLINICAL PRACTICE, 109(1) (1), C25 - C32, English

  [Refereed]

  Scientific journal


• Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam

  Fujisawa Masato, Shirakawa Toshiro

  2008, Nephron Clinical practice, Vol. 109, No. 1, pp. c25-32(1) (1), c25 - 32, English

  [Refereed]

  Scientific journal


• Etodolac, a selective cyclooxygenase-2 inhibitor, induces Upregulation of e-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo

  Asako Okamoto, Toshiro Shirakawa, Toshinori Bito, Katsumi Shigemura, Katsuyuki Hamada, Akinobu Gotoh, Masato Fujisawa, Masato Kawabata

  Jan. 2008, UROLOGY, 71(1) (1), 156 - 160, English

  [Refereed]

  Scientific journal


• Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer

  Toshiro Shirakawa, Shuji Terao, Nobuyuki Hinata, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Kazuro Sugimura, Masafumi Matsuo, Katsuyuki Hamada, Kohzo Fuji, Takatsugu Okegawa, Eiji Higashihara, Thomas A. Gardner, Chinghai Kao, Leland W. K. Chung, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh

  Dec. 2007, HUMAN GENE THERAPY, 18(12) (12), 1225 - 1232, English

  [Refereed]

  Scientific journal


• Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model

  Shuji Terao, Toshiro Shirakawa, Shuji Kubo, Acharya Bishunu, Sang-Jin Lee, Kazumasa Goda, Mamoru Tsukuda, Katsuyuk Hamada, Masatoshi Tagawa, Atsushi Takenaka, Masato Fujisawa, Akinobu Gotoh

  Nov. 2007, UROLOGY, 70(5) (5), 1009 - 1013, English

  [Refereed]

  Scientific journal


• Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy

  Katsuyuki Hamada, Junzo Desaki, Kou Nakagawa, Ting Zhang, Toshiro Shirakawa, Akinobu Gotoh, Masatoshi Tagawa

  Jun. 2007, MOLECULAR THERAPY, 15(6) (6), 1121 - 1128, English

  [Refereed]

  Scientific journal


• Induction of immunological antitumor effects by adenovirus-mediated gene transfer of B7-1 in a murine squamous cell carcinoma cell line

  Yasuhiko Hoshitani, Haruhiko Ishida, Naoki Otsuki, Toshiro Shirakawa, Akinobu Gotoh, Ken-ichi Nibu

  Mar. 2007, ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 133(3) (3), 270 - 275, English

  [Refereed]

  Scientific journal


• OP-318 ヒト膀胱癌細胞における選択的 Cox-2阻害剤、Etodolac のE-cadherin 発現増強および抗腫瘍効果の検討(第95回日本泌尿器科学会総会)

  白川 利朗, 岡本 明子, 重村 克巳, 寺尾 秀治, 後藤 章暢, 川端 眞人, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 370 - 370, Japanese


• PP-329 マウス前立腺癌モデルに対するPETを用いたAd-OC-TK/VAL遺伝子治療効果および遺伝子導入効率の評価に関する有用性の検討(第95回日本泌尿器科学会総会)

  寺尾 秀治, 白川 利朗, 久保 秀司, 田沢 周作, 富永 英之, 千田 道雄, 武中 篤, 藤澤 正人, 後藤 章暢

  一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 479 - 479, Japanese


• PP-302 選択的 cyclooxygenase-II (COX-2) 阻害剤 etodolac のヒト前立腺がん細胞株における抗腫瘍効果の検討(第95回日本泌尿器科学会総会)

  重村 克巳, 白川 利朗, 和田 義孝, 後藤 章暢, 藤澤 正人

  一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 472 - 472, Japanese


• Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer

  Katsuyuki Hamada, Toshiro Shirakawa, Akinobu Gotoh, Jack A. Roth, Michele Follen

  Dec. 2006, GYNECOLOGIC ONCOLOGY, 103(3) (3), 820 - 830, English

  [Refereed]

  Scientific journal


• Sccmec typing and detection of visa-related genes in methicillin-resistant staphylococcus aureus clinical strains from Kobe University Hospital, Japan

  Tetsuo Takata, Toshiro Shirakawa, Jun Ito, Asako Okamoto, Muh Nasrum Massi, Shohiro Kinoshita, Mochammad Hatta, Masato Kawabata

  Nov. 2006, Southeast Asian Journal of Tropical Medicine and Public Health, 37(6) (6), 1149 - 1155, English

  [Refereed]

  Scientific journal


• Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosat immunization in a mouse model

  Tetsuo Takata, Toshiro Shirakawa, Yoshiko Kawasaki, Shohiro Kinoshita, Akinobu Gotoh, Yasunobu Kano, Masato Kawabata

  Nov. 2006, JOURNAL OF GENE MEDICINE, 8(11) (11), 1341 - 1346, English

  [Refereed]

  Scientific journal


• 内分泌療法抵抗性前立腺癌に対するAd-OC-TK plus Valacyclovir遺伝子治療臨床研究におけるquality of lifeの評価

  寺尾 秀治, 白川 利朗, 日向 信行, 和田 義孝, 宮田 賢宏, 久保 秀司, 田中 一志, 武中 篤, 荒川 創一, 原 勲, 藤澤 正人, 後藤 章暢

  (一社)西日本泌尿器科学会, Oct. 2006, 西日本泌尿器科, 68(増刊) (増刊), 159 - 159, Japanese


• Enumeration of bacterial cell numbers and detection of significant bacteriuria by use of a new flow cytometry-based device

  Hiroshi Okada, Toshiro Shirakawa, Akinobu Gotoh, Yutaka Kamiyama, Satoru Muto, Hisamitsu Ide, Yukio Hamaguchi, Shigeo Horie

  Oct. 2006, JOURNAL OF CLINICAL MICROBIOLOGY, 44(10) (10), 3596 - 3599, English

  [Refereed]

  Scientific journal


• Study of AZFc partial deletion gr/gr in fertile and infertile Japanese males

  Claudia Marcia Benedetto de Carvalho, Luciana Werneck Zuccherato, Masato Fujisawa, Toshiro Shirakawa, Andrea Kely Campos Ribeiro-dos-Santos, Sidney E. B. Santos, Sergio Danilo Junho Pena, Fabricio Rodrigues Santos

  Sep. 2006, JOURNAL OF HUMAN GENETICS, 51(9) (9), 794 - 799, English

  [Refereed]

  Scientific journal


• Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University

  Nobuyuki Hinata, Toshiro Shirakawa, Shuji Terao, Kazumasa Goda, Kazushi Tanaka, Yuji Yamada, Isao Hara, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh

  Jun. 2006, INTERNATIONAL JOURNAL OF UROLOGY, 13(6) (6), 834 - 837, English

  [Refereed]

  Scientific journal


• Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients

  M Miyata, T Shirakawa, B Acharya, S Terao, A Gotoh

  May 2006, ASAIO JOURNAL, 52(3) (3), 272 - 275, English

  [Refereed]

  Scientific journal


• Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar Typhi and Paratyphi A isolated in Katmandu, Nepal, in 2003

  T Shirakawa, B Acharya, S Kinoshita, S Kumagai, A Gotoh, M Kawabata

  Apr. 2006, DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 54(4) (4), 299 - 303, English

  [Refereed]

  Scientific journal


• 視床下部下垂体精巣軸におけるNeuropeptide YおよびPancreatic polypeptideの役割

  合田上政, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 土橋正樹, 大岡均至, OKADA,Hiroshi, 上野尚彦, INUI,Akio, FUJISAWA, Masato

  一般社団法人 日本泌尿器科学会, Mar. 2006, 日本泌尿器科学会雑誌, 97巻, 2号, pp.378-378(2) (2), 378 - 378, Japanese

  International conference proceedings


• α1受容体遮断薬による前立腺肥大症の薬物療法についての排尿症状(I-PSS)を中心とした長期薬効の検討

  SHIRAKAWA, Toshiro, 寺尾秀治, 大場健司, YAMADA,Yuji, 日向信之, WADA,Yoshitaka, 合田上政, OKADA,Hiroshi, GOTOH,Akinobu, FUJISAWA, Masato

  (一社)日本泌尿器科学会, Mar. 2006, 日本泌尿器科学会雑誌, 97巻, 2号, pp.506-506(2) (2), 506 - 506, Japanese

  International conference proceedings


• ヒト膀胱癌細胞に対するミドカインプロモーターを組み込んだ増殖制限型アデノウイルスベクター(AD-MK-E1a)の有用性の検討

  寺尾秀治, SHIRAKAWA, Toshiro, 合田上政, 濱田雄行, 田川雅敏, GOTOH,Akinobu, FUJISAWA, Masato

  一般社団法人 日本泌尿器科学会, Mar. 2006, 日本泌尿器科学会雑誌, 97巻, 2号, pp.513-513(2) (2), 513 - 513, Japanese

  International conference proceedings


• Rapid detection of the fluoroquinolone resistance-associated ParC mutation in Neisseria gonorrhoeae using TaqMan probes

  K Shigemura, T Shirakawa, K Tanaka, S Arakawa, A Gotoh, M Fujisawa

  Mar. 2006, INTERNATIONAL JOURNAL OF UROLOGY, 13(3) (3), 277 - 281, English

  [Refereed]

  Scientific journal


• Mitochondrial DNA determines androgen dependence in prostate cancer cell lines

  M Higuchi, T Kudo, S Suzuki, TT Evans, R Sasaki, Y Wada, T Shirakawa, Sawyer, JR, A Gotoh

  Mar. 2006, ONCOGENE, 25(10) (10), 1437 - 1445, English

  Scientific journal


• Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo

  K Shigemura, T Shirakawa, Y Wada, S Kamidono, M Fujisawa, A Gotoh

  Dec. 2005, UROLOGY, 66(6) (6), 1239 - 1244, English

  [Refereed]

  Scientific journal


• 腎臓癌におけるVEGF発現量と遺伝子型

  田中久登, OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 山森元博, 瀬戸亮太, 中村任, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  Nov. 2005, 臨床薬理, 36巻, Suppl., pp.S268-S268, Japanese

  International conference proceedings


• 前立腺肥大症に対するα1受容体遮断薬長期投与症例における排尿症状動態に関する検討

  SHIRAKAWA, Toshiro, 寺尾秀治, 日向信之, 合田上政, OOBA, Takeshi, WADA,Yoshitaka, YAMADA,Yuji, GOTOH,Akinobu, OKADA,Hiroshi, FUJISAWA, Masato

  (一社)日本排尿機能学会, Oct. 2005, 日本排尿機能学会誌, 16巻, 1号, pp.92-92(1) (1), 92 - 92, Japanese

  International conference proceedings


• 視床下部下垂体精巣軸におけるNeuropeptide YおよびPancreatic polypeptideの役割に関する検討

  合田上政, 寺尾秀治, 山口耕平, 土橋正樹, OOBA, Takeshi, KAMIDONO,Sadao, FUJISAWA, Masato, GOTOH,Akinobu, SHIRAKAWA, Toshiro, OKADA,Hiroshi

  Oct. 2005, 日本不妊学会雑誌, 50巻, 4号, pp.321-321, Japanese

  International conference proceedings


• EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients

  T Sakaeda, N Okamura, A Gotoh, T Shirakawa, S Terao, M Morioka, K Tokui, H Tanaka, T Nakamura, M Yagi, Y Nishimura, M Yokoyama, K Okumura

  Oct. 2005, PHARMACEUTICAL RESEARCH, 22(10) (10), 1757 - 1761, English

  [Refereed]

  Scientific journal


• 視床下部下垂体精巣軸におけるNeuropeptide YおよびPancreatic polypeptideの役割

  合田上政, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 山口耕平, 土橋正樹, OOBA, Takeshi, OKADA,Hiroshi, 上野尚彦, INUI,Akio, KAMIDONO,Sadao, FUJISAWA, Masato

  Sep. 2005, 日本内分泌学会雑誌, 81巻, 2号, pp.493-493, Japanese

  International conference proceedings


• ヒト膀胱癌細胞株に対するフラロデンドリマーを用いた光線力学療法の可能性

  合田上政, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 高口豊, FUJISAWA, Masato

  Sep. 2005, 日本癌治療学会誌, 40巻, 2号, pp.627-627, Japanese

  International conference proceedings


• ヒト膀胱癌細胞株に対するフラロデンドリマーを用いた光線力学療法の可能性

  合田上政, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 高口豊, FUJISAWA, Masato

  Sep. 2005, 日本癌学会64回総会記事, pp.393-393, Japanese

  International conference proceedings


• ヒト膀胱癌細胞に対するミドカインプロモーターを組み込んだ増殖制限型アデノウイルスベクター(AdMKE1a)の有用性の検討

  寺尾秀治, SHIRAKAWA, Toshiro, 合田上政, FUJISAWA, Masato, GOTOH,Akinobu

  Sep. 2005, 日本癌学会64回総会記事, pp.506-506, Japanese

  International conference proceedings


• バングラデシュ,ランガマティ県における熱帯熱マラリアのクロロキン プリマキン治療の有効性

  松本安代, SHIRAKAWA, Toshiro, 高田哲男, KAWABATA, Masato

  (一社)日本感染症学会, Sep. 2005, 感染症学雑誌, 79巻, 9号, pp.717-718(9) (9), 717 - 718, Japanese

  International conference proceedings


• Real-time PCR法を用いた腸チフスの血中細菌定量法の開発

  SHIRAKAWA, Toshiro, 松本安代, 高田哲男, ARAKAWA, Souichi, 木下承晧, KUMAGAI, Syunichi, GOTOH,Akinobu, KAWABATA, Masato

  (一社)日本感染症学会, Sep. 2005, 感染症学雑誌, 79巻, 9号, pp.794-794(9) (9), 794 - 794, Japanese

  International conference proceedings


• 2003年臨床分離MRSAにおけるバンコマイシン耐性関連遺伝子保有状況

  高田哲男, SHIRAKAWA, Toshiro, 松本安代, 木下承晧, KUMAGAI, Syunichi, GOTOH,Akinobu, KAWABATA, Masato

  (一社)日本感染症学会, Aug. 2005, 感染症学雑誌, 79巻, 8号, pp.581-582(8) (8), 581 - 582, Japanese

  International conference proceedings


• Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model

  S Terao, T Shirakawa, K Goda, S Kamidono, M Fujisawa, A Gotoh

  Jul. 2005, ANTICANCER RESEARCH, 25(4) (4), 2757 - 2760, English

  Scientific journal


• A replication-selective adenoviral vector for head and neck cancers

  H Tanaka, T Shirakawa, ZJ Zhang, K Hamada, A Gotoh, K Nibu

  Jul. 2005, ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 131(7) (7), 630 - 634, English

  [Refereed]

  Scientific journal


• ラット副腎皮質細胞のMicroencapsulationによるホルモン補充の可能性

  合田上政, 寺尾秀治, 山口耕平, 近藤有, 土橋正樹, KAMIDONO,Sadao, FUJISAWA, Masato, SHIRAKAWA, Toshiro, GOTOH,Akinobu, OKADA,Hiroshi

  Jun. 2005, 泌尿器科紀要, 51巻, 6号, pp.429-429, Japanese

  International conference proceedings


• Quantitative detection of Salmonella enterica serovar Typhi from blood of suspected typhoid fever patients by real-time PCR

  MN Massi, T Shirakawa, A Gotoh, A Bishnu, M Hatta, M Kawabata

  Jun. 2005, INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 295(2) (2), 117 - 120, English

  Scientific journal


• 前立腺癌骨転移巣に対する遺伝子治療臨床研究 神戸大学医学部附属病院での実施例の報告

  SHIRAKAWA, Toshiro, GOTOH,Akinobu, 寺尾秀治, 日向信之, HARA, Isao, KAMIDONO,Sadao

  医学図書出版(株), May 2005, 泌尿器外科, 18巻, 臨増, pp.498-498(臨増) (臨増), 498 - 498, Japanese

  International conference proceedings


• Granulocyte-colony stimulating factor producing urothelial carcinoma of renal pelvis

  S Terao, Y Yamada, T Shirakawa, Hara, I, N Kanomata, S Kamidono

  May 2005, INTERNATIONAL JOURNAL OF UROLOGY, 12(5) (5), 500 - 502, English

  [Refereed]

  Scientific journal


• Rapid detection and differentiation of Gram-negative and Gram-positive pathogenic bacteria in urine using TaqMan probe

  K Shigemura, T Shirakawa, H Okada, K Tanaka, S Kamidono, S Arakawa, A Gotoh

  Mar. 2005, CLINICAL AND EXPERIMENTAL MEDICINE, 4(4) (4), 196 - 201, English

  [Refereed]

  Scientific journal


• 腎癌における各種遺伝子のmRNA発現変動及び遺伝子型

  OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 中村任, 盛岡正志, 徳井健次, 田中久登, YAGI, Mariko, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  Mar. 2005, 薬剤学, 65巻, Suppl., pp. 189-189, Japanese

  International conference proceedings


• マウス膀胱癌におけるADV/RSV-HSV-TK遺伝子治療とRecombinant IL-2免疫療法との併用療法

  寺尾秀治, SHIRAKAWA, Toshiro, 合田上政, 日向信之, KAMIDONO,Sadao, GOTOH,Akinobu

  (一社)日本泌尿器科学会, Mar. 2005, 日本泌尿器科学会雑誌, 96巻, 2号, pp. 284-284(2) (2), 284 - 284, Japanese

  International conference proceedings


• マウス造精機能障害モデルにおけるTRAIL発現抑制の効果

  合田上政, FUJISAWA, Masato, SHIRAKAWA, Toshiro, 寺尾秀治, 山口耕平, 近藤有, 土橋正樹, OOBA, Takeshi, GOTOH,Akinobu, OKADA,Hiroshi, KAMIDONO,Sadao

  日本生殖内分泌学会, Mar. 2005, 日本泌尿器科学会雑誌, 96巻, 2号, pp. 220-220, 37 - 42, Japanese

  International conference proceedings


• バングラデシュ,ランガマティ県における熱帯熱マラリアのクロロキン プリマキン治療の有効性

  松本安代, SHIRAKAWA, Toshiro, 高田哲男, KAWABATA, Masato

  (一社)日本感染症学会, Mar. 2005, 感染症学雑誌, 79巻, 臨増, pp. 214-214(臨増) (臨増), 214 - 214, Japanese

  International conference proceedings


• Real-time PCR法を用いた腸チフスの血中細菌定量法の開発

  SHIRAKAWA, Toshiro, 松本安代, 高田哲男, ARAKAWA, Souichi, 木下承晧, KUMAGAI, Syunichi, GOTOH,Akinobu, KAWABATA, Masato

  (一社)日本感染症学会, Mar. 2005, 感染症学雑誌, 79巻, 臨増, pp. 303-303(臨増) (臨増), 303 - 303, Japanese

  International conference proceedings


• 2003年臨床分離MRSAにおけるバンコマイシン耐性関連遺伝子保有状況

  高田哲男, SHIRAKAWA, Toshiro, 松本安代, 木下承晧, KUMAGAI, Syunichi, GOTOH,Akinobu, KAWABATA, Masato

  (一社)日本感染症学会, Mar. 2005, 感染症学雑誌, 79巻, 臨増, pp. 141-141(臨増) (臨増), 141 - 141, Japanese

  International conference proceedings


• [Gene therapy].

  Akinobu Gotoh, Toshiro Shirakawa, Yoshitaka Wada, Nobuyuki Hinata, Shuji Terao, Isao Hara, Soichi Arakawa, Sadao Kamidono, Hiroshi Okada, Atsushi Takenaka, Masato Fujisawa

  We selected bone-metastatic prostate cancer as the target form of recurrent prostate cancer and developed a suicide-gene therapy based on an adenovirus vector with an organ-specific osteocalcin promoter. Related clinical studies have already been conducted in the United States at the University of Virginia, where results so far have established the safety of this therapy. In the present paper, in addition to presenting the results of these gene-therapy studies from the basic research to the clinical stage, we discuss the clinical studies begun by our group in August 2003. In the 21st century, therapeutic systems in use are undergoing major changes. Gene therapy is likely to become an important therapeutic option in recurrent prostate cancer. In terms of theory and technology however, this form of treatment is still at a very immature stage of development. We look forward to evolution in this field to provide an established treatment for recurrent prostate cancer and are committed to actively continuing with the development of gene therapy through translational research.

  Feb. 2005, Hinyokika kiyo. Acta urologica Japonica, 51(2) (2), 75 - 9, Japanese, Domestic magazine

  [Refereed]


• ホルモン抵抗性前立腺癌転移巣に対する治療法について

  GOTOH,Akinobu, SHIRAKAWA, Toshiro, WADA,Yoshitaka, 日向信之, 寺尾秀治, HARA, Isao, ARAKAWA, Souichi, KAMIDONO,Sadao, OKADA,Hiroshi, TAKENAKA, Atsushi, FUJISAWA, Masato

  泌尿器科紀要刊行会, 2005, 泌尿器科紀要, 51巻, pp.75-79(2) (2), 75 - 79, Japanese

  Scientific journal


• Identification and sequencing of Salmonella Enterica serotype typhi isolates obtained from patients with perforation and non-perforation typhoid fever

  Muhammad Nasrum Massi, Toshiro Shirakawa, Akinobu Gotoh, Mochammad Hatta, Masato Kawabata

  Jan. 2005, Southeast Asian Journal of Tropical Medicine and Public Health, 36(1) (1), 118 - 122, English

  Scientific journal


• Measles encephalitis in early pregnancy and after delivery

  Yasuyo Matsumoto, Ippei Morimoto, Takahiro Shibutani, Masaaki Mukubou, Toshiro Shirakawa, Akinobu Gotoh, Masato Kawabata

  Springer Japan, 2005, Journal of Infection and Chemotherapy, 11(2) (2), 97 - 100, English

  [Refereed]

  Scientific journal


• Presence of a mutation in ponA1 of Neisseria gonorrhoeae in numerous clinical samples resistant to various β-lactams and other, structurally unrelated, antimicrobials

  Katsumi Shigemura, Toshiro Shirakawa, Nasrum Massi, Kazushi Tanaka, Soichi Arakawa, Akinobu Gotoh, Masato Fujisawa

  Springer Japan, 2005, Journal of Infection and Chemotherapy, 11(5) (5), 226 - 230, English

  [Refereed]

  Scientific journal


• 遺伝子治療が奏功した進行性前立腺癌の1例

  SHIRAKAWA, Toshiro, GOTOH,Akinobu, 寺尾秀治, 日向信之, 重村克己, 合田上政, WADA,Yoshitaka, MURAMAKI,Mototsugu, TANAKA, Kazushi, YAMADA,Yuji, HARA, Isao, KAMIDONO,Sadao

  泌尿器科紀要刊行会, Dec. 2004, 泌尿器科紀要, 50巻, 12号, pp. 911-911(12) (12), 911 - 911, Japanese

  International conference proceedings


• Rapid detection of gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae by denaturing high-performance liquid chromatography

  K Shigemura, T Shirakawa, H Okada, K Tanaka, T Udaka, S Kamidono, S Arakawa, A Gotoh

  Dec. 2004, JOURNAL OF MICROBIOLOGICAL METHODS, 59(3) (3), 415 - 421, English

  [Refereed]

  Scientific journal


• Association of VEGF genotype with mRNA level in colorectal adenocarcinomas

  M Yamamori, T Sakaeda, T Nakamura, N Okamura, T Tamura, N Aoyama, T Kamigaki, M Ohno, T Shirakawa, A Gotoh, Y Kuroda, M Matsuo, M Kasuga, K Okumura

  Dec. 2004, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 325(1) (1), 144 - 150, English

  [Refereed]

  Scientific journal


• Inhibition mechanism of Gosha-jinki-gan on the micturition reflex in rats

  A Gotoh, K Goto, A Sengoku, T Shirakawa, Y Akao, M Fujisawa, H Okada, S Arakawa, S Kamidono

  Oct. 2004, JOURNAL OF PHARMACOLOGICAL SCIENCES, 96(2) (2), 115 - 123, English

  [Refereed]

  Scientific journal


• 膀胱癌におけるAd-RSV-tk遺伝子治療とIL-2免疫療法との併用療法(Interleukin-2 enhanced the anti-tumor effect of adenoviral-mediated HSV-tk gene therapy in a murine bladder cancer model)(英語)

  Shirakawa Toshiro, Hinata Nobuyuki

  日本癌学会, Sep. 2004, 日本癌学会総会記事, 63回(63回) (63回), 518 - 518, Japanese

  Research society


• 膀胱癌におけるAd-RSV-tk遺伝子治療とIL-2免疫療法との併用療法(Interleukin-2 enhanced the anti-tumor effect of adenoviral-mediated HSV-tk gene therapy in a murine bladder cancer model)(英語)

  寺尾秀治, KAMIDONO,Sadao, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 日向信之, 合田上政

  日本癌学会, Sep. 2004, Cancer Science, 95巻, Suppl., pp. 518-518, 518 - 518, Japanese

  International conference proceedings


• 前立腺癌治療戦略 ホルモン抵抗性前立腺癌転移巣に対する遺伝子治療臨床研究

  GOTOH,Akinobu, SHIRAKAWA, Toshiro, HARA, Isao, KAMIDONO,Sadao

  Sep. 2004, 日本癌治療学会誌, 39巻, 2号, pp. 315-315, Japanese

  International conference proceedings


• マウス造精機能障害モデルにおけるTRAIL発現抑制の効果

  合田上政, FUJISAWA, Masato, SHIRAKAWA, Toshiro, 近藤有, 土橋正樹, GOTOH,Akinobu, OKADA,Hiroshi, KAMIDONO,Sadao

  Sep. 2004, 日本内分泌学会雑誌, 80巻, 2号, pp. 454-454, Japanese

  International conference proceedings


• ヒト前立腺小細胞癌株(SO-MI)に対するp53遺伝子導入の効果

  合田上政, SHIRAKAWA, Toshiro, GOTOH,Akinobu, OKADA,Hiroshi, HARA, Isao, KAMIDONO,Sadao, FUJISAWA, Masato

  Sep. 2004, Cancer Science, 95巻, Suppl., pp. 515-515, Japanese

  International conference proceedings


• Adenoviral-mediated HGF expression inhibits germ cell apoptosis in rats with cryptorchidism

  K Goda, M Fujisawa, T Shirakawa, M Dobashi, G Shiota, ZJ Zhang, A Gotoh, S Kamidono

  Aug. 2004, JOURNAL OF GENE MEDICINE, 6(8) (8), 869 - 876, English

  [Refereed]

  Scientific journal


• Serum testosterone levels in patients with nonmosaic Klinefelter syndrome after testicular sperm extraction for intracytoplasmic sperm injection

  H Okada, T Shirakawa, T Ishikawa, K Goda, M Fujisawa, S Kamidono

  Jul. 2004, FERTILITY AND STERILITY, 82(1) (1), 237 - 238, English

  [Refereed]

  Scientific journal


• Antiproliferative activity of Rhinacanthus nasutus (L.) kurz extracts and the active moiety, rhinacanthin C

  A Gotoh, T Sakaeda, T Kimura, T Shirakawa, Y Wada, A Wada, T Kimachi, Y Takemoto, A Iida, S Iwakawa, M Hirai, H Tomita, N Okamura, T Nakamura, K Okumura

  Jul. 2004, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 27(7) (7), 1070 - 1074, English

  [Refereed]

  Scientific journal


• A Cox-2 promoter-based replication-selective adenoviral vector to target the Cox-2-expressing human bladder cancer cells

  T Shirakawa, K Hamada, ZJ Zhang, H Okada, M Tagawa, S Kamidono, M Kawabata, A Gotoh

  Jul. 2004, CLINICAL CANCER RESEARCH, 10(13) (13), 4342 - 4348, English

  [Refereed]

  Scientific journal


• 薬剤耐性淋菌性尿道炎の分子生物学的検討およびDHPLCを用いた迅速遺伝子診断法の開発

  重村克巳, OKADA,Hiroshi, TANAKA, Kazushi, ARAKAWA, Souichi, KAMIDONO,Sadao, SHIRAKAWA, Toshiro, GOTOH,Akinobu, 木下承皓

  May 2004, 泌尿器科紀要, 50巻, 5号, pp. 381-381, Japanese

  International conference proceedings


• nafamostat mesilateの血小板凝集解離作用

  Shirakawa Toshiro, Hinata Nobuyuki

  (一社)日本透析医学会, May 2004, 日本透析医学会雑誌, 37(Suppl.1) (Suppl.1), 856 - 856, Japanese

  Research society


• Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma

  A Gotoh, T Shirakawa, N Hinata, Y Wada, Hara, I, M Fujisawa, G Kawabata, H Okada, S Akakawa, S Kamidono

  May 2004, INTERNATIONAL JOURNAL OF UROLOGY, 11(5) (5), 257 - 263, English

  [Refereed]

  Scientific journal


• 泌尿器科における漢方医学 漢方薬の基礎研究と臨床応用 頻尿に対する牛車腎気丸の効果

  GOTOH,Akinobu, SHIRAKAWA, Toshiro, 日向信之, WADA,Yoshitaka, KAMIDONO,Sadao

  (株)医学書院, Apr. 2004, 臨床泌尿器科, 58巻, 5号, pp. 301-306(5) (5), 301 - 306, Japanese

  [Refereed]

  Scientific journal


• Susceptibilities of Neisseria gonorrhoeae to fluoroquinolones and other antimicrobial agents in Hyogo and Osaka, Japan

  K Shigemura, H Okada, T Shirakawa, K Tanaka, S Arakawa, S Kinoshita, A Gotoh, S Kamidono

  Apr. 2004, SEXUALLY TRANSMITTED INFECTIONS, 80(2) (2), 105 - 107, English

  [Refereed]

  Scientific journal


• Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan

  K Shigemura, T Shirakawa, H Okada, N Hinata, B Acharya, S Kinoshita, T Kofuku, M Kawabata, S Kamidono, S Arakawa, A Gotoh

  Mar. 2004, SEXUALLY TRANSMITTED DISEASES, 31(3) (3), 180 - 184, English

  [Refereed]

  Scientific journal


• Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer

  T Shirakawa, A Gotoh, ZJ Zhang, CH Kao, LWK Chung, TA Gardner

  Mar. 2004, UROLOGY, 63(3) (3), 613 - 618, English

  [Refereed]

  Scientific journal


• Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas

  T Nakahara, T Sakaeda, T Nakamura, T Tamura, C Nishioka, N Aoyama, N Okamura, T Shirakawa, A Gotoh, T Kamigaki, M Ohno, Y Kuroda, M Matsuo, M Kasuga, K Okumura

  Mar. 2004, PHARMACEUTICAL RESEARCH, 21(3) (3), 406 - 412, English

  [Refereed]

  Scientific journal


• 外傷性膀胱・直腸破裂術後,回腸Blind loop部に小腸膀胱瘻を生じた1例

  熊野晶文, SHIRAKAWA, Toshiro, TANAKA, Kazushi, HARA, Isao, KAWABATA,Gaku, OKADA,Hiroshi, KAMIDONO,Sadao, 生田繁, FUJISAWA, Masato

  Feb. 2004, 泌尿器科紀要, 50巻, 2号, pp. 140-140, Japanese

  International conference proceedings


• PP4-143 ラットSertoli細胞へのErythropoietin遺伝子導入とその生理学的意義(一般演題(ポスター))

  合田 上政, 藤澤 正人, 白川 利朗, 土橋 正樹, 近藤 有, 岡田 弘, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 2004, 日本泌尿器科学会雑誌, 95(2) (2), 566 - 566, Japanese


• Effects of Gosha-Jinki-Gan on the pollakisuria

  Gotoh A, Shirakawa T, Hinata N, Wada Y, Kamidono S

  2004, Japanese Journal of Clinical Urology, 58(5) (5), 301 - 306

  [Refereed]


• Quantitative detection of Escherichia coli from urine of patients with bacteriuria by real-time PCR.

  Nobuyuki Hinata, Toshiro Shirakawa, Hiroshi Okada, Katsumi Shigemura, Sadao Kamidono, Akinobu Gotoh

  INTRODUCTION: Compared with the classical urine culture method, PCR is more rapid, and can detect smaller numbers of bacteria, however it is inferior for quantification. Because of the lack of quantification in routine PCR, the meaning of a positive PCR test result has not been validated for all infections. We report on the development of a novel quantitative detection system for the urinary tract infection (UTI) Escherichia coli using real-time PCR. PATIENTS: We enrolled 200 patients with suspected bacteriuria. METHODS: The gene encoding the universal stress protein (uspA) was found to be highly specific for E. coli. We quantified the copy numbers of E. coli in the urine of patients with UTI by using a real-time PCR assay (the TaqMan system) targeting uspA genes in genomic DNAs isolated from urine samples (n=200). To evaluate the feasibility of this method, the results were compared with those of a standard urine culture. RESULTS: The incidence of positive urine cultures was 75% (150 of 200), and various doses of E. coli were detected in 84 of 150 specimens. The real-time PCR method also detected 84 cases of urinary infections of E. coli in the same specimens. Furthermore, the result of the quantification of E. coli using real-time PCR strongly correlated (r2=0.925) with the result of urine culture. CONCLUSION: Our results suggest that using quantitative-PCR means a faster and simpler diagnosis of E. coli urinary infection can be made compared with the traditional urine culture method.

  2004, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 8(3) (3), 179 - 84, English, International magazine

  [Refereed]

  Scientific journal


• Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overactive bladder.

  Nobuyuki Hinata, Toshiro Shirakawa, Hiroshi Okada, Bishnu Achaya, Sadao Kamidono, Akinobu Gotoh

  INTRODUCTION: Antimuscarinic drugs have frequently been used for the treatment for patients with an overactive bladder (OAB) and there have been many studies on the distribution of muscarinic receptor subtypes in the bladder. However, the distribution of muscarinic receptor subtypes in OAB patients has not been well investigated. In this study we investigated the distribution of muscarinic receptor subtypes with mRNA and protein expressions in patients with and without OAB, and investigated both the dome and trigone area. METHODS: Samples of bladder smooth muscle were obtained from 10 individuals, five patients with OAB and a non-OAB group consisting of five patients who received radical cystectomy. RESULTS: The M2 receptor was predominant, but there was no significant difference in the level of M2 expression between the groups in the dome area. M5 expression in the dome area was significantly higher in the OAB group than in the non-OAB group. In the trigone area, the level of M2 mRNA expression was the highest in the non-OAB group, and was significantly lower in the OAB group. The levels of M1 and M5 mRNA expression were also observed in samples obtained from the trigone area. CONCLUSION: The multiformity of the muscarinic receptor subtypes in human bladder smooth muscle was confirmed, and our results suggest that the efficacy of a given pharmacologic therapy differs from patient to patient.

  2004, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 8(1) (1), 17 - 22, English, International magazine

  [Refereed]

  Scientific journal


• Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue

  T Shirakawa, H Okada, B Acharya, ZJ Zhang, N Hinata, Y Wada, T Uji, S Kamidono, A Gotoh

  Jan. 2004, PROSTATE, 58(1) (1), 33 - 40, English

  [Refereed]

  Scientific journal


• Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type-p53 but not in p53-mutated bladder cancer cells

  N Hinata, T Shirakawa, ZJ Zhang, A Matsumoto, M Fujisawa, H Okada, S Kamidono, A Gotoh

  Dec. 2003, UROLOGICAL RESEARCH, 31(6) (6), 387 - 396, English

  [Refereed]

  Scientific journal


• 前立腺癌骨転移巣におけるオステオカルシン発現の意義

  Shirakawa Toshiro, Hinata Nobuyuki

  泌尿器科紀要刊行会, Nov. 2003, 泌尿器科紀要, 49(11号) (11号), 696 - 696, Japanese

  Research society


• Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation

  ZJ Zhang, T Shirakawa, N Hinata, A Matsumoto, M Fujisawa, H Okada, S Kamidono, M Matsuo, A Gotoh

  Oct. 2003, JOURNAL OF GENE MEDICINE, 5(10) (10), 860 - 867, English

  [Refereed]

  Scientific journal


• 前立腺癌細胞内の亜鉛分布状態の変化 ホルモンと亜鉛の関係

  SHIRAKAWA, Toshiro, GOTOH,Akinobu, 北村ゆり, SUGIMURA, Kazuro, 川上拓男, 井手亜里

  Sep. 2003, Biomedical Research on Trace Elements, 14巻, 3号, pp. 215-218, Japanese

  [Refereed]

  Scientific journal


• 前立腺癌骨転移巣に対する遺伝子治療臨床研究の現況

  Shirakawa Toshiro, Hinata Nobuyuki, Hara Isao

  (一社)日本癌治療学会, Sep. 2003, 日本癌治療学会誌, 38(2号) (2号), 239 - 239, Japanese

  Research society


• ホルモン抵抗性前立腺癌に対するEstramustine,COX-2阻害剤併用療法の治療効果の検討

  Shirakawa Toshiro, Hinata Nobuyuki

  (一社)日本癌治療学会, Sep. 2003, 日本癌治療学会誌, 38(2号) (2号), 659 - 659, Japanese

  Research society


• irritative symptomを主症状とするBPH患者に対する塩酸プロピベリンの効果

  Hinata Nobuyuki, Shirakawa Toshiro

  (一社)日本排尿機能学会, Sep. 2003, 日本排尿機能学会誌, 14(1) (1), 86 - 86, Japanese

  Research society


• Investigations on Distribution and Quantity of Zinc in Prostate Cancer Using Synchrotron Radiation Microbeams

  Takuo Kawakami, Ari Ide-Ektessabi, Kazurou Sugimura, Yuri Kitamura, Akinobu Gotoh, Toshiro Shirakawa

  American Institute of Physics Inc., Aug. 2003, AIP Conference Proceedings, 680, 526 - 529, English

  [Refereed]

  International conference proceedings


• The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells

  A Gotoh, T Shirakawa, Y Wada, M Fujisawa, H Okada, S Kamidono, K Hamada

  Aug. 2003, BJU INTERNATIONAL, 92(3) (3), 314 - 318, English

  [Refereed]

  Scientific journal


• Establishment of a prostatic small-cell carcinoma cell line (SO-MI)

  H Okada, T Shirakawa, H Miyake, A Gotoh, M Fujisawa, S Arakawa, S Kamidono

  Aug. 2003, PROSTATE, 56(3) (3), 231 - 238, English

  [Refereed]

  Scientific journal


• Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis

  AH Zhou, H Ueno, M Shimomura, R Tanaka, T Shirakawa, H Nakamura, M Matsuo, K Iijima

  Jul. 2003, KIDNEY INTERNATIONAL, 64(1) (1), 92 - 101, English

  [Refereed]

  Scientific journal


• 尿中分離菌に対するフローサイトメトリーを用いた迅速薬剤感受性試験について

  Shigemura Katsumi, Tanaka Kazushi, Hinata Nobuyuki, Shirakawa Toshiro, Arakawa Soichi

  (一社)日本感染症学会, May 2003, 感染症学雑誌, 77(5号) (5号), 363 - 364, Japanese

  Research society


• 尿中分離菌に対するフローサイトメトリーを用いた迅速薬剤感受性試験について

  Shigemura Katsumi, Tanaka Kazushi, Hinata Nobuyuki, Shirakawa Toshiro, Arakawa Soichi

  尿路感染症研究会, Apr. 2003, 尿路感染症研究会記録集, (11号) (11号), 18 - 18, Japanese

  Research society


• Complete resection of synovial sarcoma of prostatic fascia

  SHIRAKAWA TOSHIRO, FUJISAWA MASATO, Gotoh Akinobu

  Mar. 2003, Urology, Vol. 61, No. 3, pp. 644-644, English

  [Refereed]

  Scientific journal


• 定量的PCR法を用いた細菌尿中の大腸菌の定量

  Hinata Nobuyuki, Shirakawa Toshiro, Shigemura Katsumi

  (一社)日本泌尿器科学会, Feb. 2003, 日本泌尿器科学会雑誌, 94(2号) (2号), 384 - 384, Japanese

  Research society


• Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines

  T Nakamura, T Sakaeda, N Ohmoto, Y Moriya, C Komoto, T Shirakawa, A Gotoh, M Matsuo, K Okumura

  Feb. 2003, PHARMACEUTICAL RESEARCH, 20(2) (2), 324 - 327, English

  [Refereed]

  Scientific journal


• Lack of association between Y chromosome haplogroups and male infertility in Japanese men

  Cláudia M.B. Carvalho, Masato Fujisawa, Toshiro Shirakawa, Akinobu Gotoh, Sadao Kamidono, Tatiana Freitas Paulo, Sidney E.B. Santos, Juliane Rocha, Sérgio D.J. Pena, Fabrício R. Santos

  Jan. 2003, American Journal of Medical Genetics, 116(2) (2), 152 - 158, English

  [Refereed]

  Scientific journal


• ラット造精機能障害モデルにおけるHepatocyte Growth Factor遺伝子導入の効果

  合田 上政, 藤澤 正人, 土橋 正樹, 山崎 隆文, 張 竹君, 白川 利朗, 後藤 章暢, 岡田 弘, 荒川 創一, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 2003, 日本泌尿器科学会雑誌, 94(2) (2), 173 - 173, Japanese


• Lack of association between Y chromosome haplogroups and male infertility in Japanese men

  CMB Carvalho, M Fujisawa, T Shirakawa, A Gotoh, S Kamidono, TF Paulo, SEB Santos, J Rocha, SDJ Pena, FR Santos

  Jan. 2003, AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 116A(2) (2), 152 - 158, English

  [Refereed]

  Scientific journal


• Effects of mefloquine usage on genetic polymorphism of Plasmodium falciparum in Thai-Myanmarese border

  Matsuo Toshiaki, SHIRAKAWA, Toshiro, Singhasivanon Pratap, Looareesuwan Sornchai, KAWABATA, Masato

  We studied the polymorphism of msp-1, which encodes a major surface protein onthe merozoite, isolated from blood samples from western Thailand in 1999. Our studyarea was a low-transmission area for malaria, where mefloquine has been used as anantimalarial drug since 1994. Forty-nine patients were confirmed to have contractedfalciparum malaria twice within 24 weeks. The number of detected haplotypes in 49patients was 89 at the first diagnosis and 68 at the second diagnosis. The mean numberof haplotypes per patient significantly decreased from 1.82 to 1.39 but the frequencydistributions of msp-1 haplotypes did not change significantly with the use ofmefloquine. Our study strongly suggests that the antigenic diversity of Plasmodium falciparum is retained during mefloquine therapy in low-transmission areas.

  Kobe University, 2003, The Kobe Journal Of Medical Sciences, Vol. 49, No. 5-6, pp. 143-151(5) (5), 143 - 151, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Rapid diagnosis of typhoid fever by PCR assay using one pair of primers from flagellin gene of Salmonella typhi

  Muhammad Nasrum Massi, Toshiro Shirakawa, Akinobu Gotoh, Acharya Bishnu, Mochammad Hatta, Masato Kawabata

  Springer Japan, 2003, Journal of Infection and Chemotherapy, 9(3) (3), 233 - 237, English

  [Refereed]

  Scientific journal


• Inhibition of urinary bladder motility by a spinal action of U-50488H in rats

  A Gotoh, K Goto, A Sengoku, T Shirakawa, Y Akao, M Fujisawa, H Okada, S Arakawa, H Sasaki, S Kamidono

  Dec. 2002, JOURNAL OF PHARMACY AND PHARMACOLOGY, 54(12) (12), 1645 - 1650, English

  [Refereed]

  Scientific journal


• [Gene therapy for prostate cancer].

  Akinobu Gotoh, Toshiro Shirakawa, Yoshitaka Wada, Nobuyuki Hinata, Shigeji Matsubara, Isao Hara, Masato Fujisawa, Hiroshi Okada, Soichi Arakawa, Sadao Kamidono

  The substantial advances made in recent years in the molecular biology of malignant urological tumors and the associated progressive analysis of these conditions at a molecular level have spurred research aimed at gene-based treatment. In the field of prostate cancer, while there have been many ground-breaking studies particularly in the United States, none has yet led to a revolutionary treatment for recurrent prostate cancer. Gene-based treatment is being applied seriously in clinical settings, especially in the United States, but so far without significant effect. Many researchers worldwide are devoting energy to the development of effective vectors. By adjusting the promoter, which has the function of directing the vector, we have developed organ-specific vectors for the treatment of prostate cancer. In the present study, which targeted prostate cancer with bone metastasis, we developed a suicide-gene therapy using an adenovirus vector with an organ-specific osteocalcin promoter. Clinical trials of this vector have already been conducted at the University of Virginia in the United States and have so far confirmed the safety of the therapy. In the present paper we present the results of this gene-therapy research from the basic to the clinical phase alongside an outline of related research at our institution. Gene therapy for cancer is now being targeted not only against the primary tumor but systemic cancers including distant metastases; systemic administration of adenovirus vectors with organ-specific promoters may become one of the most promising systemic anti-tumor therapies of the next-generation.

  Nov. 2002, Hinyokika kiyo. Acta urologica Japonica, 48(11) (11), 729 - 32, Japanese, Domestic magazine

  [Refereed]


• Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects

  Y Moriya, T Nakamura, M Horinouchi, T Sakaeda, T Tamura, N Aoyama, T Shirakawa, A Gotoh, S Fujimoto, M Matsuo, M Kasuga, K Okumura

  Oct. 2002, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 25(10) (10), 1356 - 1359, English

  [Refereed]

  Scientific journal


• MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling

  T Sakaeda, T Nakamura, M Hirai, T Kimura, A Wada, T Yagami, H Kobayashi, S Nagata, N Okamura, T Yoshikawa, T Shirakawa, A Gotoh, M Matsuo, K Okumura

  Sep. 2002, PHARMACEUTICAL RESEARCH, 19(9) (9), 1323 - 1329, English

  [Refereed]

  Scientific journal


• Flavonoids differentially regulate IFN gamma-induced ICAM-1 expression in human keratinocytes: molecular mechanisms of action

  T Bito, S Roy, CK Sen, T Shirakawa, A Gotoh, M Ueda, M Ichihashi, L Packer

  Jun. 2002, FEBS LETTERS, 520(1-3) (1-3), 145 - 152, English

  [Refereed]

  Scientific journal


• Estrogen levels influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle

  S Matsubara, H Okada, T Shirakawa, A Gotoh, T Kuno, S Kamidono

  Apr. 2002, UROLOGY, 59(4) (4), 621 - 625, English

  [Refereed]

  Scientific journal


• Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects

  T Nakamura, T Sakaeda, M Horinouchi, T Tamura, N Aoyama, T Shirakawa, M Matsuo, M Kasuga, K Okumura

  Apr. 2002, CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(4) (4), 297 - 303, English

  [Refereed]

  Scientific journal


• Gene therapy

  Gotoh, A., Shirakawa, T., Wada, Y., Hinata, N., Matsubara, S., Hara, I., Fujisawa, M., Okada, H., Arakawa, S., Kamidono, S.

  2002, Acta Urologica Japonica, 48(11) (11), 729 - 732

  [Refereed]

  Scientific journal


• 尿路生殖器へ浸潤をきたした骨盤内他臓器疾患に対する泌尿器科術式について

  藤澤 正人, 白川 利朗, 田中 一志, 後藤 章暢, 原 勲, 川端 岳, 岡田 弘, 荒川 創一, 八尾 昭久, 松本 修, 原口 貴裕, 山中 望, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 2002, 日本泌尿器科学会雑誌, 93(2) (2), 245 - 245, Japanese


• Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas

  T Nakamura, T Sakaeda, N Ohmoto, T Tamura, N Aoyama, T Shirakawa, T Kamigaki, T Nakamura, KI Kim, Kim, SR, Y Kuroda, M Matsuo, M Kasuga, K Okumura

  Jan. 2002, DRUG METABOLISM AND DISPOSITION, 30(1) (1), 4 - 6, English

  [Refereed]

  Scientific journal


• Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells

  R Sasaki, T Shirakawa, ZJ Zhang, A Tamekane, A Matsumoto, K Sugimura, M Matsuo, S Kamidono, A Gotoh

  Dec. 2001, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 51(5) (5), 1336 - 1345, English

  [Refereed]

  Scientific journal


• [Prospects for molecular research in urological oncology: gene therapy].

  A Gotoh, T Shirakawa, Y Wada, N Hinata, I Hara, M Fujisawa, H Okada, S Arakawa, S Kamidono

  The recent great advances in genetic engineering are now making possible the identification and isolation of the trigger genes of many hereditary illnesses, and the clarification of the relevant molecular mechanisms. The idea that if the genetic abnormalities responsible for illness could be established at a DNA level, treatment at the genetic level repairing damaged genes or supplying absent ones would also be possible was the incentive for the recent boom in gene therapy. Clinical research into gene therapy began in 1990 and currently over 3,000 patient cases are being studied. Some 70% of these are cancer patients. This is not simply because such patients are relatively numerous, but is also a sign of the wish, held earnestly by many researchers and clinicians as well as cancer patients and their families, to at last overcome this intractable disease. Gene therapy, so far conducted mainly in the United States, has hitherto not lived up to initial expectations in its concrete results. The reason for this results mainly in technical factors, such as the rate of success in implanting genes into target cells, the rate of successful expression of the implanted genes, and the successful achievement of specific expression at the target site. Gene therapy in the form of clinical research into renal cancer and lung cancer is now under way in Japan. It is too early at this stage to evaluate this work, but the present paper takes this opportunity to give an outline of gene therapy, and to examine its current state, future prospects and problem areas with particular reference to cancer.

  Nov. 2001, Hinyokika kiyo. Acta urologica Japonica, 47(11) (11), 829 - 32, Japanese, Domestic magazine

  [Refereed]

  Scientific journal


• Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells

  T Shirakawa, R Sasaki, TA Gardner, CH Kao, ZJ Zhang, K Sugimura, M Matsuo, S Kamidono, A Gotoh

  Oct. 2001, INTERNATIONAL JOURNAL OF CANCER, 94(2) (2), 282 - 289, English

  [Refereed]

  Scientific journal


• Y-chromosome microdeletion and phenotype in cytogenetically normal men with idiopathic azoospermia

  M Fujisawa, T Shirakawa, M Kanzaki, H Okada, S Arakawa, S Kamidono

  Sep. 2001, FERTILITY AND STERILITY, 76(3) (3), 491 - 495, English

  [Refereed]

  Scientific journal


• Adenovirus-mediated p53 gene transfer to rat testis impairs spermatogenesis

  M Fujisawa, T Shirakawa, H Fujioka, A Gotoh, H Okada, S Arakawa, S Kamidono

  May 2001, ARCHIVES OF ANDROLOGY, 46(3) (3), 223 - 231, English

  [Refereed]

  Scientific journal


• Breast cancer working group

  R. Sasaki, H. Nishimura, T. Soejima, Y. Ejima, E. Yoden, T. Shirakawa, A. Gotoh, Y. Ota, A. Matsumoto, K. Sugimura

  2001, International Journal of Radiation Oncology Biology Physics, 51, 56 - 57, English

  [Refereed]

  Scientific journal


• Adenovirus-mediated p53 gene transfer to rat testis impairs spermatogenesis

  M. Fujisawa, T. Shirakawa, H. Fujioka, A. Gotoh, H. Okada, S. Arakawa, S. Kamidono

  2001, Systems Biology in Reproductive Medicine, 46(3) (3), 223 - 231, English

  [Refereed]

  Scientific journal


• Gene therapy for bladder cancer using adenoviral vector

  Y. Wada, A. Gotoh, T. Shirakawa, K. Hamada, S. Kamidono

  Mary Ann Liebert Inc., 2001, Molecular Urology, 5(2) (2), 47 - 52, English

  [Refereed]

  Scientific journal


• Gene therapy for prostate cancer; Development of tissue specific promoter-based gene therapy

  A Gotoh, T Shirakawa, Y Wada, SC Ko, CH Kao, LWK Chung, S Kamidono

  2001, FRONTIERS IN HUMAN GENETICS: DISEASES AND TECHNOLOGIES, 363 - 376, English

  [Refereed]

  International conference proceedings


• p53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model

  T Shirakawa, A Gotoh, TA Gardner, CH Kao, ZJ Zhang, S Matsubara, Y Wada, N Hinata, M Fujisawa, K Hanioka, M Matsuo, S Kamidono

  Nov. 2000, JOURNAL OF GENE MEDICINE, 2(6) (6), 426 - 432, English

  [Refereed]

  Scientific journal


• Tissue-specific promoters in gene therapy for the treatment of prostate cancer

  T. Shirakawa, A. Gotoh, Y. Wada, S. Kamidono, S. C. Ko, C. Kao, T. A. Gardner, L. W.K. Chung

  Mary Ann Liebert Inc., 2000, Molecular Urology, 4(2) (2), 73 - 82, English

  [Refereed]

  International conference proceedings


• Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model

  T Shirakawa, TA Gardner, SC Ko, N Bander, S Woo, A Gotoh, S Kamidono, LWK Chung, C Kao

  Sep. 1999, JOURNAL OF UROLOGY, 162(3) (3), 949 - 954, English

  [Refereed]

  Scientific journal


• In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy

  T Shirakawa, SC Ko, TA Gardner, J Cheon, T Miyamoto, A Gotoh, LWK Chung, CH Kao

  Sep. 1998, CANCER GENE THERAPY, 5(5) (5), 274 - 280, English

  [Refereed]

  Scientific journal


• Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer

  A Gotoh, SC Ko, T Shirakawa, J Cheon, CH Kao, T Miyamoto, TA Gardner, LJ Ho, CBJ Cleutjens, J Trapman, FL Graham, LWK Chung

  Jul. 1998, JOURNAL OF UROLOGY, 160(1) (1), 220 - 229, English

  [Refereed]

  Scientific journal


• Osteocalcin Promoter を用いたAdenovirus Vector (Ad-OC-TK) による前立腺癌に対する遺伝子治療 : 第86回日本泌尿器科学会総会

  白川 利朗, 後藤 章暢, Chung Leland W.K., 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 1998, 日本泌尿器科学会雑誌, 89(2) (2), 303 - 303, Japanese


• Assessment of proliferating cell nuclear antigen expression and prognosis in patients with renal cell carcinoma with pulmonary metastases

  Akinobu Gotoh, Keisuke Hanioka, Toshiro Shirakawa, Yoshitaka Wada, Kazuo Gohji, Hiroshi Okada, Soichi Arakawa, Sadao Kamidono

  Blackwell Publishing, 1998, International Journal of Urology, 5(3) (3), 214 - 218, English

  [Refereed]

  Scientific journal


• Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model

  J Cheon, SC Ko, TA Gardner, T Shirakawa, A Gotoh, C Kao, LWK Chung

  Nov. 1997, CANCER GENE THERAPY, 4(6) (6), 359 - 365, English

  [Refereed]

  Scientific journal


• Y chromosome (Yq11) microdeletions in idiopathic azoospermia

  Toshiro Shirakawa, Masato Fujisawa, Masanori Kanzaki, Hiroshi Okada, Soichi Arakawa, Sadao Kamidono

  Blackwell Publishing, 1997, International Journal of Urology, 4(2) (2), 198 - 201, English

  [Refereed]

  Scientific journal


• Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models

  SC Ko, J Cheon, CH Kao, A Gotoh, T Shirakawa, RA Sikes, G Karsenty, LWK Chung

  Oct. 1996, CANCER RESEARCH, 56(20) (20), 4614 - 4619, English

  [Refereed]

  Scientific journal


• Hyperprolactinaemia among infertile patients and its effect on sperm functions

  H Okada, T Iwamoto, H Fujioka, T Shirakawa, N Tatsumi, M Kanzaki, K Minayoshi, K Ohya, M Fujisawa, S Arakawa, S Kamidono, J Ishigami

  Jul. 1996, ANDROLOGIA, 28(4) (4), 197 - 202, English

  [Refereed]

  Scientific journal


• 不妊患者にみられたImmotile spermatozoaに関する臨床的検討

  岡田 弘, 藤岡 一, 龍見 昇, 白川 利朗, 神崎 正徳, 岩本 孝弘, 藤澤 正人, 荒川 創一, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 1996, 日本泌尿器科学会雑誌, 87(2) (2), 208 - 208, Japanese


• 特発性男性不妊のY染色体遺伝子異常について

  白川 利朗, 藤澤 正人, 藤岡 一, 龍見 昇, 神崎 正徳, 岩本 孝弘, 岡田 弘, 荒川 創一, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 1996, 日本泌尿器科学会雑誌, 87(2) (2), 479 - 479, Japanese


• Sertoli cellにおけるNeuropeptide Yの発言とその制御

  神崎 正徳, 藤澤 正人, 白川 利朗, 龍見 昇, 源吉 顕治, 岩本 孝弘, 岡田 弘, 荒川 創一, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 1995, 日本泌尿器科学会雑誌, 86(3) (3), 557 - 557, Japanese


• Sertoli cellにおけるInterleukin 6 receptor(IL-6-R)mRNAの発現とその制御

  奥田 喜啓, 藤澤 正人, 白川 利朗, 神崎 正徳, 源吉 顕治, 岩本 孝弘, 岡田 弘, 荒川 創一, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 1995, 日本泌尿器科学会雑誌, 86(3) (3), 763 - 763, Japanese


• 乏精子症患者におけるLH-RH testの意義について

  藤澤 正人, 白川 利朗, 龍見 昇, 神崎 正徳, 岩本 孝弘, 源吉 顕治, 岡田 弘, 荒川 創一, 守殿 貞夫

  一般社団法人 日本泌尿器科学会, 1995, 日本泌尿器科学会雑誌, 86(3) (3), 760 - 760, Japanese


• Image cytometryによるヒト精巣DNAの定量的解析

  岩本 孝弘, 藤澤 正人, 白川 利朗, 神崎 正徳, 源吉 顕治, 岡田 弘, 荒川 創一, 守殿 貞夫, 日中 宏和, 松本 修

  一般社団法人 日本泌尿器科学会, 1995, 日本泌尿器科学会雑誌, 86(3) (3), 761 - 761, Japanese

• インドネシアにおけるヒト及び環境由来のESBL産生Escherichia coliの分布調査

  坂本夏那, 大澤佳代, 重村克巳, 重村克巳, 北川孝一, 木下承晧, 亀岡正典, 楠木まり, 楠木まり, 宮良高維, 藤沢正人, 白川利朗, 白川利朗

  2021, 日本化学療法学会雑誌, 69(Supplement-A) (Supplement-A)


• Preclinical Study of Oral Cancer Vaccine Using Recombinant Bifidobacterium Expressing WT1 Protein in Murine Bladder Cancer Model and Non-Human Primate

  Koichi Kitagawa, Mako Kato, Shota Komai, Ryota Sako, Hazuki Doi, Yoshiko Hashii, Takane Katayama, Toshiro Shirakawa

  Apr. 2020, MOLECULAR THERAPY, 28(4) (4), 35 - 36, English

  Summary international conference


• Genetic diagnosis of urinary tract infection

  Toshiro Shirakawa, Masato Fujisawa

  Lead, Feb. 2020, 泌尿器外科, 33(2) (2), 117 - 120, Japanese

  [Invited]

  Introduction scientific journal


• The anti-tumor effect of oral cancer vaccine using Bifidobacterium as a platform for displaying Wilms' tumor 1 protein.

  Hikaru Minagawa, Yoshiko Hashii, Natsuki Nakagawa, Hiroko Nakajima, Yoshihiro Oka, Takane Katayama, Toshiro Shirakawa, Keiichi Ozono

  Mar. 2019, JOURNAL OF CLINICAL ONCOLOGY, 37(8) (8), English

  Summary international conference


• Cancer immunotherapy combining oral vaccination of recombinant Bifidobacterium longum displaying human Wilms' tumor 1 protein and anti-PD-1 checkpoint blockade for solid tumors in mice experimental model

  Koichi Kitagawa, Maho Tatsumi, Mako Kato, Shota Komai, Yoshiko Hashii, Takane Katayama, Toshiro Shirakawa

  Feb. 2019, CANCER IMMUNOLOGY RESEARCH, 7(2) (2), English

  Summary international conference


• Combination of Oral WT1 Cancer Vaccine and Anti-PD-1 Antibody Induced the Synergistic Anti-Tumor Effect in Mouse Prostate Cancer Model

  Koichi Kitagawa, Reina Gonoi, Hiroki Saito, Maho Tatsumi, Yoshiko Hashii, Takane Katayama, Toshiro Shirakawa

  May 2017, MOLECULAR THERAPY, 25(5) (5), 156 - 156, English

  Summary international conference


• INTERNATIONAL COMPARISON OF CAUSATIVE BACTERIA AND ANTIMICROBIAL SUSCEPTIBILITIES OF URINARY TRACT INFECTIONS BETWEEN DEVELOPED AND DEVELOPING COUNTRIES

  Katsumi Shigemura, Koichi Kitagawa, Kuntaman Kuntaman, Toshiro Shirakawa, Masato Fujisawa

  Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E295 - E295, English

  Summary international conference


• Development of Novel Cancer Therapy Combination of Ad-SOCS Gene Therapy and LAK Cell Immunotherapy for the Treatment of Prostate Cancer

  Hiroki Saito, Koichi Kitagawa, Tetsuji Naka, Satoshi Serada, Toshiro Shirakawa

  May 2016, MOLECULAR THERAPY, 24, S49 - S49, English

  Summary international conference


• Development of the Novel Oral Tumor Vaccine Using Bifidobacterium longum Displaying Wilms' Tumor 1 Protein

  Koichi Kitagawa, Tsugumi Oda, Ayame Araki, Reina Gonoi, Hiroki Saito, Yoshiko Hashii, Takane Katayama, Keiichi Ozono, Toshiro Shirakawa

  May 2016, MOLECULAR THERAPY, 24, S157 - S157, English

  Summary international conference


• MOLECULAR CHARACTERISTICS OF EXTENDED-SPECTRUM ?-LACTAMASE-PRODUCING ESCHERICHIA COLI ISOLATED URINARY TRACT INFECTION IN A UNIVERSITY TEACHING HOSPITAL

  Katsumi Shigemura, Kayo Osawa, Kazushi Tanaka, Yuzo Nakano, Toshiro Shirakawa, Soichi Arakawa, Masato Fujisawa

  Apr. 2016, JOURNAL OF UROLOGY, 195(4) (4), E274 - E274, English

  Summary international conference


• The Combination of p53 Dendritic Cell Vaccine and Ad-p53 Gene Therapy Against p53 Overexpressing and p53 Deleted Tumor Cell Lines

  Hiroki Saito, Koichi Kitagawa, Risa Yamasaki, Nami Katai, Naoya Morishita, Masato Kawabata, Dody Bautista, Dante Dator, Toshiro Shirakawa

  May 2015, MOLECULAR THERAPY, 23, S167 - S167, English

  Summary international conference


• Development of Combination Therapy of Bifidobacterium-Based Oral Vaccine Displaying HCV-NS3 with Interferon-alpha

  Koichi Kitagawa, Hiroki Ishikawa, Tsugumi Oda, Hiroki Saito, Naoya Morishita, Kouske Shimamoto, Norihisa Nishida, Yoichi Matsuura, Hak Hotta, Toshiro Shirakawa

  May 2015, MOLECULAR THERAPY, 23, S259 - S259, English

  Summary international conference


• 神戸大学インドネシア拠点のあゆみと実績

  内海 孝子, 清水 一史, 小瀧 将裕, 亀岡 正典, 白川 利朗, HOTTA HAK, 林 祥剛

  Apr. 2015, 最新医学, 74(4) (4), 745 - 743, Japanese

  [Refereed][Invited]

  Others


• Indonesia-Kobe University Collaborative Research Center for Emerging and Reemerging Infectious Diseases (CRC-ERID) J-GRID (Japan initiative for Global Research Network on Infectious Diseases)

  Toshiro Shirakawa, Kazufumi Shimizu, Takako Utsumi, Masanori Kameoka, Hak Hotta, Yoshitake Hayashi

  Fuji Technology Press, 01 Oct. 2014, Journal of Disaster Research, 9(5) (5), 828 - 835, English

  Book review


• META-ANALYSIS OF EFFICACY AND SAFETY OF AD-P53 and E1B 55KD REGION DELETED ADENOVIRUS GENE THERAPIES

  Yasuhiro Endo, Toshiro Shirakawa

  Jul. 2014, JOURNAL OF GENE MEDICINE, 16(7-8) (7-8), 275 - 276, English

  Summary international conference


• E10A, AN ADENOVIRUS CARRYING ENDOSTATIN GENE, DRAMATICALLY INCREASED THE TUMOR DRUG CONCENTRATION OF METRONOMIC CHEMOTHERAPY WITH LOW DOSE CISPLATIN IN A XENOGRAFT MOUSE MODEL FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA

  Zainal Adhim, Xubin Lin, Wenlin Huang, Tsutomu Nakamura, Hiroyuki Yasui, Naoki Otsuki, Ken-ichi Nibu, Masato Fujisawa, Toshiro Shirakawa

  Jul. 2014, JOURNAL OF GENE MEDICINE, 16(7-8) (7-8), 238 - 239, English

  Summary international conference


• REGULATORY PATHWAY FOR THE DEVELOPMENT OF ADVANCED THERAPY

  Toshiro Shirakawa, Yasuhiro Endo

  Jul. 2014, JOURNAL OF GENE MEDICINE, 16(7-8) (7-8), 269 - 270, English

  Summary international conference


• SIGNIFICANT RECEPTORS OR BIOMARKERS FOR THE SYMPTOMS OF OVERACTIVE BLADDER

  Fukashi Yamamichi, Katsumi Shigemura, Toshiro Shirakawa, Hosny Behnsawy, Masuo Yamashita, Hideaki Miyake, Kazushi Tanaka, Masato Fujisawa

  Apr. 2014, JOURNAL OF UROLOGY, 191(4) (4), E50 - E50, English

  Summary international conference


• 【C型肝炎治療update】 基礎研究の進歩 ビフィズス菌を利用したC型肝炎経口ワクチンの開発(解説/特集)

  Shirakawa Toshiro

  Feb. 2014, 日本臨床, 73(2) (2), 239 - 242, Japanese

  Introduction scientific journal


• SIGNIFICANT BIOMARKER FOR LOWER URINARY TRACT SYMPTOMS OR PAIN FROM CHRONIC PROSTATITIS

  Fukashi Yamamichi, Minori Matsumoto, Katsumi Shigemura, Toshiro Shirakawa, Hideaki Miyake, Soichi Arakawa, Kazushi Tanaka, Masato Fujisawa

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E480 - E481, English

  Summary international conference


• DOES MUTATION IN GYRA OR PARC OR EFFLUX PUMP EXPRESSION PLAY THE MAIN ROLE IN FLUOROQUINOLONE-RESISTANT ESCHERICHIA COLI URINARY TRACT INFECTIONS?

  Katsumi Shigemura, Kazushi Tanaka, Toshiro Shirakawa, Soichi Arakawa, Hideaki Miyake, Masato Fujisawa

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E472 - E472, English

  Summary international conference


• MUTATIONS IN THE GYRA AND PARC GENES AND IN VITRO ACTIVITIES OF FLUOROQUINOLONES IN CLINICAL ISOLATES OF PSEUDOMONAS AERUGINOSA DERIVED FROM URINARY TRACT INFECTIONS AND THEIR RAPID DETECTION BY DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

  Minori Matsumoto, Katsumi Shigemura, Toshiro Shirakawa, Hideaki Miyake, Soichi Arakawa, Kazushi Tanaka, Masato Fujisawa

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E472 - E472, English

  Summary international conference


• Post-operative infection and prophylactic antibiotic administration after radical cystectomy with orthotopic neobladder urinary diversion

  Katsumi Shigemura, Kazushi Tanaka, Minori Matsumoto, Yuzo Nakano, Toshiro Shirakawa, Masahiro Miyata, Masuo Yamashita, Soichi Arakawa, Masato Fujisawa

  Aug. 2012, JOURNAL OF INFECTION AND CHEMOTHERAPY, 18(4) (4), 479 - 484, English

  [Refereed]

  Introduction scientific journal


• Sonic hedgehog signaling and Androgens are linked in tumor-stromal interaction through Epithelial-Mesenchymal transition (EMT) in prostate cancer progression

  Katsumi Shigemura, Fatma Meligy, Hosny Behnsawy, Fukashi Yamamichi, Wen-Chin Haung, Xiangyan Li, Leland Chung, Kunito Yamanaka, Keisuke Hanioka, Masuo Yamashita, Toshiro Shirakawa, Kazushi Tanaka, Soichi Arakawa, Masato Fujisawa

  Apr. 2012, CANCER RESEARCH, 72, English

  Summary international conference


• SONIC HEDGEHOG SIGNALING AND ANDROGENS ARE LINKED IN TUMOR-STROMAL INTERACTION THROUGH EPITHELIAL-MESENCHYMAL TRANSITION (EMT) IN PROSTATE CANCER PROGRESSION

  Meligy Fatma, Katsumi Shigemura, Hosny Behnsawy, Fukashi Yamamichi, Wen-chin Haung, Xiangyan Li, Leland Chung, Masuo Yamashita, Masato Fujisawa, Masato Kawabata, Toshiro Shirakawa

  Apr. 2012, JOURNAL OF UROLOGY, 187(4) (4), E395 - E395, English

  Summary international conference


• POSSIBLE ROLE OF SONIC HEDGEHOG SIGNALING AND THE LINK WITH EPITHELIAL-MESENCHYMAL TRANSITION (EMT) IN RENAL CANCER PROGRESSION

  Fatma Meligy, Katsumi Shigemura, Hosny Behnsawy, Fukashi Yamamichi, Masuo Yamashita, Wen-chin Haung, Li Xiangyan, Leland Chung, Masato Fujisawa, Masato Kawabata, Toshiro Shirakawa

  Apr. 2012, JOURNAL OF UROLOGY, 187(4) (4), E60 - E61, English

  Summary international conference


• THE MECHANISMS AND RISK FACTORS FOR FLUOROQUINOLONE-RESISTANCE IN ENTEROCOCCUS FAECALIS STRAINS CLINICALLY ISOLATED FROM URINARY TRACT INFECTION PATIENTS

  Tomihiko Yasufuku, Katsumi Shigemura, Minori Matsumoto, Yuzo Nakano, Toshiro Shirakawa, Kazushi Yanaka, Masato Kawabata, Soichi Arakawa, Masato Fujisawa

  Apr. 2012, JOURNAL OF UROLOGY, 187(4) (4), E372 - E372, English

  Summary international conference


• Rapid detection of the gyrA and parC mutations in fluoroquinolone-resistant pseudomonas aeruginosa strain by denaturing high-performance liquid chromatography in UTI patients in Japan

  M. Matsumoto, K. Shigemura, T. Shirakawa, T. Yasufuku, Y. Nakano, K. Tanaka, S. Kinoshita, M. Kawabata, S. Arakawa, M. Fujisawa

  Feb. 2012, EUROPEAN UROLOGY SUPPLEMENTS, 11(1) (1), E295 - E295, English

  Summary international conference


• Gene therapy for the treatment of prostate cancer using osteocalcin promoter

  後藤 章暢, 寺尾 秀治, 白川 利朗

  日本臨床社, Jun. 2011, Japanese journal of clinical medicine, 69, 550 - 553, Japanese


• エンドスタチン遺伝子導入による腫瘍内プラチナ濃度の増大

  中村 任, Adhim Zainal, Lin Xubin, Huang Wenlin, 安井 裕之, 大月 直樹, 丹生 健一, 藤澤 正人, 白川 利朗

  (公社)日本薬剤学会, May 2011, 日本薬剤学会年会講演要旨集, 26年会, 229 - 229, Japanese


• 前立腺癌患者末梢血中Circulating tumor cells(CTCs)の検出法の開発

  山道深, 森下真一, 白川利朗, 藤澤正人, 松岡孝幸, 川端眞人

  泌尿器科紀要刊行会, May 2011, 泌尿器科紀要, 57(5) (5), 275 - 275, Japanese


• CORRELATION OF OVEREXPRESSION OF EFFLUX PUMP GENES WITH ANTIBIOTIC RESISTANCE IN ESCHERICHIA COLI STRAINS CLINICALLY ISOLATED FROM URINARY TRACT INFECTION PATIENTS

  Tomihiko Yasufuku, Katsumi Shigemura, Toshiro Shirakawa, Minori Matsumoto, Yuzo Nakano, Kazushi Tanaka, Soichi Arakawa, Shouhiro Kinoshita, Masato Kawabata, Masato Fujisawa

  Apr. 2011, JOURNAL OF UROLOGY, 185(4) (4), E544 - E545, English

  Summary international conference


• INTRAVENOUS INJECTION OF THE CARRIER-CELL BASED ONCOLYTIC ADENOVIRUS SUPPRESSES THE GROWTH OF MULTIPLE LUNG TUMORS IN MOUSE SQUAMOUS CELL CARCINOMA MODEL

  Toshiro Shirakawa, Katsuyuki Hamada, Shunichi Kitajima, Chihomi Mitsuoka, Naya Saito, Tadayuki Matsuoka, Zainal Adhim, Shuji Terao, Akinobu Gotoh, Ken-ichi Nibu, Masato Fujisawa, Kyung-Mi Lee

  Dec. 2010, JOURNAL OF GENE MEDICINE, 12(12) (12), 1034 - 1035, English

  Summary international conference


• RISK FACTORS FOR URINARY TRACT INFECTION WITH FLUOROQUINOLONE-RESISTANT ESCHERICHIA COLI STRAINS

  Tomihiko Yasufuku, Katsumi Shigemura, Toshiro Shirakawa, Minori Matsumoto, Yuzo Nakano, Kazushi Tanaka, Soichi Arakawa, Shouhiro Kinoshita, Masato Kawabata, Masato Fujisawa

  Apr. 2010, JOURNAL OF UROLOGY, 183(4) (4), E236 - E236, English

  Summary international conference


• ヒト膀胱癌細胞におけるCox‐2阻害剤,3剤の抗腫瘍効果の比較検討

  白川利朗, アドヒム ザイナル, 松岡孝幸, 重村克己, 丹生健一, 川端眞人, 藤澤正人

  (一社)日本泌尿器科学会, Feb. 2010, 日本泌尿器科学会雑誌, 101(2) (2), 250 - 250, Japanese


• Intravenous Injection of Allogeneic Tumor Cell Vaccine Carrying Oncolytic Adenovirus (AdE3-IAI.3B) Suppresses the Growth of Multiple Lung Tumors in Mouse Squamous Cell Carcinoma Model

  Toshiro Shirakawa, Katsuyuki Hamada, Shunichi Kitajima, Chihomi Mitsuoka, Naoya Morishita, Norie Yamaoka, Aya Saito, Tadayuki Matsuoka, Zainal Adhim, Shuji Terao, Akinobu Gotoh, Ken-ichi Nibu, Masato Fujisawa, Kyung-Mi Lee, Wenlin Huang

  May 2009, MOLECULAR THERAPY, 17, S159 - S159, English

  Summary international conference


• Pharmacological and biosafety test of cancer gene therapy by oncolytic adenovirus-infected carrier cell

  Katsuyuki Hamada, Ting Zhang, Toshiro Shirakawa, Wenlin Huang

  May 2009, CANCER RESEARCH, 69, English

  Summary international conference


• EMERGENCE OF FLUOROQUINOLONE-RESISTANT E. COLT STRAIN AND THEIR RELATED MUTATIONS OF THE GYRA AND PARC GENES IN UTI PATIENTS IN JAPAN

  Tomihiko Yasufuku, Katsumi Shigemura, Toshiro Shirakawa, Yuzo Nakano, Kazushi Tanaka, Soichi Arakawa, Shouhiro Kinoshita, Masato Kawabata, Masato Fujisawa

  Apr. 2009, JOURNAL OF UROLOGY, 181(4) (4), 140 - 140, English

  Summary international conference


• CLINICAL TRIAL DESIGN FOR ADENOVIRAL GENE THERAPY PRODUCTS

  Toshiro Shirakawa

  Apr. 2009, DRUG NEWS & PERSPECTIVES, 22(3) (3), 140 - 145, English

  [Refereed]

  Introduction scientific journal


• 【がん化学療法個別化の現状と展望】 泌尿器科腫瘍の遺伝子診断と個別化治療を目指した分子標的療法

  Shirakawa Toshiro

  医薬ジャ-ナル社, Dec. 2008, 医薬ジャーナル, 44巻, 12号, pp. 83-86(12) (12), 67 - 71, Japanese

  Introduction scientific journal


• 腎臓がん患者におけるsorcinの発現低下(Suppression of sorcin mRNA in patients with renal cell carcinoma)

  川上 恵, 中村 任, 岡村 昇, 寺尾 秀治, 後藤 章暢, 白川 利朗, 藤澤 正人, 山森 元博, 栄田 敏之

  日本癌学会, Sep. 2008, 日本癌学会総会記事, 67回, 390 - 391, English


• The current status of adenovirus-based cancer gene therapy

  Toshiro Shirakawa

  Jun. 2008, MOLECULES AND CELLS, 25(4) (4), 462 - 466, English

  [Refereed]

  Book review


• Therapeutic efficacy of midkine promoter-based conditionally replicative adenovirus vector for targetting the midkine-expressing human bladder cancer cells

  Shuji Terao, Toshiro Shirakawa, Kazushi Tanaka, Atsushi Takenaka, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh

  Apr. 2008, JOURNAL OF UROLOGY, 179(4) (4), 374 - 374, English

  Summary international conference


• 腎癌におけるSorcin発現の検討とVEGF発現に及ぼす影響

  寺尾 秀治, 岡村 昇, 白川 利朗, 中村 任, 栄田 敏之, 奥村 勝彦, 武中 篤, 藤澤 正人, 後藤 章暢

  (一社)日本泌尿器科学会, Feb. 2008, 日本泌尿器科学会雑誌, 99(2) (2), 485 - 485, Japanese


• Gene therapy in prostate cancer: past, present and future

  Toshiro Shirakawa, Masato Fujisawa, Akinobu Gotoh

  Jan. 2008, FRONTIERS IN BIOSCIENCE-LANDMARK, 13, 2115 - 2119, English

  [Refereed]

  Introduction scientific journal


• Human gene therapy for prostate cancer: present and future

  後藤 章暢, 寺尾 秀治, 白川 利朗

  日本臨床社, Dec. 2007, Japanese journal of clinical medicine, 65, 517 - 521, Japanese


• Ad-OC-TK gene therapy for the treatment of prostate cancer

  白川 利朗, 後藤 章暢, 藤澤 正人

  日本臨床社, Dec. 2007, Japanese journal of clinical medicine, 65, 528 - 532, Japanese


• ホルモン不応性再燃前立腺癌の治療 骨転移を有するホルモン不応性前立腺癌に対する遺伝子治療臨床研究の長期成績

  白川 利朗, 後藤 章暢, 寺尾 秀治, 日向 信之, 田中 一志, 武中 篤, 原 勲, 守殿 貞夫, 藤澤 正人

  (一社)日本癌治療学会, Sep. 2007, 日本癌治療学会誌, 42(2) (2), 337 - 337, Japanese


• 腎癌におけるSorcinおよびVEGFの発現に関する検討(Effect of sorcin on VEGF expression in renal cell carcinoma)

  寺尾 秀治, 岡村 昇, 白川 利朗, 中村 任, 栄田 敏之, 武中 篤, 藤澤 正人, 後藤 章暢

  日本癌学会, Aug. 2007, 日本癌学会総会記事, 66回, 182 - 182, English


• 新しい抗癌剤の臨床研究 ホルモン療法抵抗性の転移性前立腺癌の患者に対するAd-OC-TK遺伝子療法の臨床試験成績(Clinical Studies of New Anticancer Drugs Results of clinical study of Ad-OC-TK gene therapy for the patients with hormone refractory metastatic prostate cancer)

  白川 利朗, 後藤 章暢, 寺尾 秀治, 日向 信之, 田中 一志, 武中 篤, 原 勲, 守殿 貞夫, 藤澤 正人

  日本癌学会, Aug. 2007, 日本癌学会総会記事, 66回, 71 - 71, English


• プロテオーム解析による腎臓癌に対する新規診断マーカー・創薬ターゲットの探索

  松本 隼, 岡村 昇, 増田 太郎, 金子 直樹, 渡辺 真, 後藤 章暢, 白川 利朗, 寺尾 秀治, 瀬戸 亮太, 中村 任, 矢上 達郎, 藤澤 正人, 栄田 敏之, 西村 紀, 奥村 勝彦

  (公社)日本薬学会, Mar. 2007, 日本薬学会年会要旨集, 127年会(3) (3), 232 - 232, Japanese


• Improvement of quality of life of patients with metastatic or local recurrent prostate cancer after phase I/II clinical trial of Ad-OC-TK plus valacyclovir

  Shuji Terao, Toshiro Shirakawa, Masahiro Miyata, Shuji Kubo, Masato Fujisawa, Akinobu Gotoh

  Dec. 2006, JOURNAL OF GENE MEDICINE, 8(12) (12), 1470 - 1470, English

  Summary international conference


• 腎臓癌のタンパク発現プロファイル解析

  瀬戸 亮太, 岡村 昇, 増田 太郎, 西村 紀, 後藤 章暢, 白川 利朗, 寺尾 秀治, 中村 任, 田中 久登, 栄田 敏之, 奥村 勝彦

  (一社)日本TDM学会, Jul. 2006, TDM研究, 23(3) (3), s138 - s138, Japanese


• Genetically Engineered Bifidobacterium animalis Expressing Salmonella flagellin Gene for the Mucosal Immunization in Mouse Model

  Toshiro Shirakawa, Tetsuo Takata, Akinobu Gotoh, Yasunobu Kano, Masato Kawabata

  May 2006, MOLECULAR THERAPY, 13, S424 - S424, English

  Summary international conference


• Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer

  A Gotoh, S Terao, T Shirakawa

  Mar. 2006, JOURNAL OF GENE MEDICINE, 8(3) (3), 371 - 372, English

  Summary international conference


• Therapeutic efficacy of midkine promoter-based replication-selective adenovirus vector to target the midkine-expressing human bladder cancer cells

  S Terao, T Shirakawa, K Goda, M Fujisawa, A Gotoh

  Mar. 2006, JOURNAL OF GENE MEDICINE, 8(3) (3), 389 - 389, English

  Summary international conference


• 【再燃前立腺癌に対する治療戦略】 遺伝子治療の現状と展望

  SHIRAKAWA, Toshiro, GOTOH,Akinobu

  Feb. 2006, Urology View, 4巻, 1号, pp.71-75, Japanese

  Introduction scientific journal


• 内分泌療法抵抗性前立腺癌に対するAd-OC-TK plus Valacyclovir遺伝子治療臨床研究におけるquality of lifeの評価

  寺尾秀治, 白川利朗, 日向信行, 和田義孝, 宮田賢宏, 久保秀司, 田中一志, 武中篤, 荒川創一, 原勲, 藤澤正人, 後藤章暢

  2006, 西日本泌尿器科, 68


• 連載講座、なくならない感染症⑫、クラミジア

  SHIRAKAWA, Toshiro

  福田商店広告部, Dec. 2005, Circles, 7巻, 3, pp.21-23(3) (3), 21 - 23, Japanese

  Introduction scientific journal


• P-492 腎臓癌におけるEGFR発現量およびゲフィチニブ感受性関連体細胞変異(3.医薬品適正使用5,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)

  大松 秀明, 岡村 昇, 後藤 章暢, 白川 利朗, 寺尾 秀治, 中村 任, 徳井 健次, 田中 久登, 八木 麻理子, 大石 美惠, 西口 工司, 栄田 敏之, 奥村 勝彦

  日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 351 - 351, Japanese


• マウス造精機能障害モデルにおけるTRAIL発現抑制の効果

  合田上政, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾秀治, 土橋正樹, OKADA,Hiroshi, KAMIDONO,Sadao, FUJISAWA, Masato

  日本生殖内分泌学会, Sep. 2005, 日本生殖内分泌学会雑誌, 10巻, pp.37-42, 37 - 42, Japanese

  Introduction scientific journal


• NAFAMOSTAT MESILATE NOT ONLY INHIBITS PLATELET AGGREGATIONS BUT ALSO DISAGGREGATES ALREADY AGGREGATED PLATELETS

  Masahiro Miyata, Toshiro Shirakawa, Bishnu Acharya, Kengou Nagamitsu, Masateru Horimoto, Akinobu Gotoh

  Jun. 2005, NEPHROLOGY, 10, A181 - A181, English

  Summary international conference


• COX-2臓器特異性プロモーターを組み込んだ増殖型アデノウイルスベクターによる頭頸部扁平上皮癌に対する治療法の検討

  田中博紀, NIBU, Kenichi, ZhangZhujun, SHIRAKAWA, Toshiro, 後藤彰暢

  May 2005, 日本耳鼻咽喉科学会会報, 108巻, 5増刊, pp.595-595, Japanese

  Introduction scientific journal


• Overexpression of erythropoietin increases intratesticular testosterone levels in rats with unilateral cryptorchidism

  K Goda, M Dobashi, T Shirakawa, H Maruyama, S Terao, Y Kondo, H Okada, A Gotoh, M Fujisawa

  Apr. 2005, JOURNAL OF UROLOGY, 173(4) (4), 410 - 410, English

  Summary international conference


• Establishment of a human prostate small cell cancer cell line and p53 adenoviral gene therapy

  K Goda, T Shirakawa, A Gotoh, S Terao, M Dobashi, H Okada, Hara, I, S Kamidono, M Fujisawa

  Apr. 2005, JOURNAL OF UROLOGY, 173(4) (4), 122 - 122, English

  Summary international conference


• Microencapsulation of adrenocortical cells for corticosteroid supplementation in rat bilateral adrenalectomized model

  K Goda, T Shirakawa, M Dobashi, S Terao, H Okada, A Gotoh, S Kamidono, M Fujisawa

  Apr. 2005, JOURNAL OF UROLOGY, 173(4) (4), 142 - 142, English

  Summary international conference


• Interleukin-2 enhanced the anti-tumor effect of adenoviral-mediated HSV-tk gene therapy in murine bladder cancer model.

  S Terao, T Shirakawa, K Goda, S Kamidono, A Gotoh

  Apr. 2005, JOURNAL OF UROLOGY, 173(4) (4), 214 - 214, English

  Summary international conference


• Polymorphism of the interleukin-4, interleukin-13, and signal transducer and activator of transcription 6 genes in Indonesian children with minimal change nephrotic syndrome

  Bishnu Acharya, Toshiro Shirakawa, Ardanykusuma Pungky, Parlin Damanik, Muh. Nasrum Massi, Masahiro Miyata, Masafumi Matsuo, Akinobu Gotoh

  2005, American Journal of Nephrology, 25(1) (1), 30 - 35, English

  [Refereed]

  Introduction scientific journal


• Phase I/II clinical trial of Ad-OC-TK plus VAL for the patients with metastatic or local recurrent prostate cancer: Initial experience in Japan

  T Shirakawa, N Hinata, S Terao, K Shigemura, N Taniguch, K Fukushima, K Sugimoto, K Sugimura, M Matsuo, S Maeda, S Kamidono, CH Kao, TA Gardner, LWK Chung, A Gotoh

  May 2004, MOLECULAR THERAPY, 9, S228 - S229, English

  Summary international conference


• Overexpression of erythropoietin in sertoli cells enhances testosterone production in leydig cells through activation of JAK2/STAT5 but not map kinases

  K Goda, M Fujisawa, T Shirakawa, M Dobashi, Y Kondo, A Gotoh, H Okada, S Kamidono

  Apr. 2004, JOURNAL OF UROLOGY, 171(4) (4), 362 - 362, English

  Summary international conference


• Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia

  H Okada, T Shirakawa, S Mato, T Iizumi, N Hinata, A Gotoh, S Kamidono, S Horie

  Apr. 2004, JOURNAL OF UROLOGY, 171(4) (4), 357 - 358, English

  Summary international conference


• Age is the limiting factor for successful sperm retrieval in nonmosaic Klinefelter syndrome

  H Okada, T Shirakawa, T Ishikawa, K Goda, Y Kondo, Y Yamamoto, N Sofikitis, M Fujisawa, Miyagawa, I, S Kamidono, S Horie

  Apr. 2004, JOURNAL OF UROLOGY, 171(4) (4), 511 - 511, English

  Summary international conference


• Rapid detection of GYRA and PARC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae urethritis by denaturing high-performance liquid chromatography (DHPLC)

  K Shigemura, T Shirakawa, H Okada, K Tanaka, S Arakawa, S Kamidono, A Gotoh

  Apr. 2004, JOURNAL OF UROLOGY, 171(4) (4), 31 - 31, English

  Summary international conference


• 【泌尿器科ガイドラインの背景と現況】 学会とガイドライン

  KAMIDONO,Sadao, SHIRAKAWA, Toshiro, GOTOH,Akinobu, HARA, Isao

  Nov. 2003, Urology View, 1巻, 6号, pp. 45-49, Japanese

  Introduction scientific journal


• GBS distribution of Kobe city

  TAKATA Tetsuo, SHIRAKAWA Toshiro, KIMURA Hiroyuki, KINOSHITA Shohiro, KAWABATA Masato

  30 Sep. 2003, 地理情報システム学会講演論文集 = Papers and proceedings of the Geographic Information Systems Association, 12, 63 - 66, Japanese


• A conditional replication-competent adenoviral vector, Ad-COX2-E1a, to target the COX-2 expressing human bladder cancer cells

  ZJ Zhang, T Shirakawa, K Hamada, S Kamidono, M Matsuo, A Gotoh

  May 2003, MOLECULAR THERAPY, 7(5) (5), S356 - S357, English

  Summary international conference


• A new rapid bacteral drug susceptibility testing method in the urinary tract infection using flow-cytometry

  H Okada, K Shigemura, K Tanaka, N Hinata, N Hinata, T Shirakawa, A Gotoh, Y Hamaguchi, S Arakawa, S Kamidono

  Apr. 2003, JOURNAL OF UROLOGY, 169(4) (4), 7 - 7, English

  Summary international conference


• Quantitative detection of Escherichia coli from urine samples of urinary tract infection(UTI) patients by real-time PCR method

  N Hinata, T Shirakawa, A Gotoh, H Okada, S Kamidono

  Apr. 2003, JOURNAL OF UROLOGY, 169(4) (4), 10 - 10, English

  Summary international conference


• Messnger RNA levels and enzyme activities of 5 alpha-reductase type 1 and 2 in the human benign prostatic hyperplasia (BPH) tissue

  T Shirakawa, H Okada, A Gotoh, N Hinata, Y Wada, S Kamidono, T Uji, A Yamamoto

  Apr. 2003, JOURNAL OF UROLOGY, 169(4) (4), 284 - 284, English

  Summary international conference


• In vivo gene transfer of hepatocyte growth factor accelerates restoration of spermatogenesis in rat cryptorchid model

  K Goda, M Fujisawa, M Dobashi, T Yamazaki, T Shirakawa, ZJ Zhang, A Gotoh, H Okada, S Arakawa, S Kamidono, G Shiota

  Apr. 2003, JOURNAL OF UROLOGY, 169(4) (4), 411 - 411, English

  Summary international conference


• 前立腺癌に対するカテキン及びアントシアニンの抗腫瘍効果の比較検討

  後藤 章暢, 和田 義孝, 松本 浩彦, 白川 利朗, 日向 信之, 荒川 創一, 守殿 貞夫, 藤澤 正人

  日本腎泌尿器疾患予防医学研究会, Mar. 2003, 日本腎泌尿器疾患予防医学研究会誌, 11(1) (1), 90 - 91, Japanese


• 前立腺肥大症組織における5-Alpha-Reductaseのサブタイプ、Type-1およびType-2の発現と酵素活性に関する検討

  白川 利朗, 岡田 弘, 後藤 章暢, 日向 信之, 和田 義孝, 守殿 貞夫, 宇治 達哉, 山本 明良

  社団法人日本泌尿器科学会, 15 Feb. 2003, 日本泌尿器科學會雜誌, 94(2) (2), 133 - 133, Japanese


• 前立腺癌に対する遺伝子治療臨床研究--臓器特異性プロモーターを用いて (第1土曜特集 遺伝子治療--現状とその近未来) -- (現在審査中の遺伝子臨床研究)

  後藤 章暢, 白川 利朗

  医歯薬出版, 02 Nov. 2002, 医学のあゆみ, 203(5) (5), 344 - 348, Japanese


• 定量的PCR法を用いた細菌尿中の大腸菌の定量

  日向 信之, 白川 利朗, 和田 義孝, 守殿 貞夫, 後藤 章暢

  西日本泌尿器科学会, Nov. 2002, 西日本泌尿器科, 64(増刊) (増刊), 174 - 174, Japanese


• 難治性前立腺癌に対する治療の現状と問題点 遺伝子治療

  後藤 章暢, 白川 利朗, 和田 義孝, 日向 信之, 松原 重治, 原 勲, 藤澤 正人, 岡田 弘, 荒川 創一, 守殿 貞夫

  泌尿器科紀要刊行会, Nov. 2002, 泌尿器科紀要, 48(11) (11), 729 - 732, Japanese


• MDR1遺伝子多型に依存したジゴキシン体内動態

  堀之内 正則, 中村 任, 栄田 敏之, 阪井 俊介, 森田 圭紀, 田村 孝雄, 青山 伸郎, 白川 利朗, 松尾 雅文, 春日 雅人

  (一社)日本臨床薬理学会, Mar. 2002, 臨床薬理, 33(2) (2), 255S - 256S, Japanese


• ヒト十二指腸上皮におけるCYP3A4ならびにMDR1遺伝子発現量に対するMDR1遺伝子型の影響

  守屋 友加, 中村 任, 栄田 敏之, 堀之内 正則, 田村 孝雄, 青山 伸郎, 白川 利朗, 松尾 雅文, 藤本 貞毅, 春日 雅人

  (一社)日本臨床薬理学会, Mar. 2002, 臨床薬理, 33(2) (2), 377S - 378S, Japanese


• CD/5-FC遺伝子治療による,膀胱癌の放射線感受性増強効果についての基礎的検討

  白川 利朗, 後藤 章暢, 張 竹君, 日向 信之, 和田 義孝, 原 勲, 藤澤 正人, 川端 岳, 岡田 弘, 荒川 創一

  社団法人日本泌尿器科学会, 20 Feb. 2002, 日本泌尿器科学会雑誌, 93(2) (2), 168 - 168, Japanese


• 膀胱癌細胞株におけるp53変異と放射線感受性に関する検討

  日向 信之, 白川 利朗, 後藤 章暢, 原 勲, 藤澤 正人, 川端 岳, 岡田 弘, 荒川 創一, 守殿 貞夫

  社団法人日本泌尿器科学会, 20 Feb. 2002, 日本泌尿器科学会雑誌, 93(2) (2), 321 - 321, Japanese


• 泌尿器科腫瘍学における分子研究の展望 遺伝子治療

  後藤 章暢, 白川 利朗, 和田 義孝, 日向 信之, 原 勲, 藤澤 正人, 岡田 弘, 荒川 創一, 守殿 貞夫

  泌尿器科紀要刊行会, Nov. 2001, 泌尿器科紀要, 47(11) (11), 829 - 832, Japanese


• 自殺遺伝子を用いた癌遺伝子治療における臓器特異性プロモーターの有用性についての基礎研究

  後藤 章暢, 和田 義孝, 白川 利朗, 日向 信之, 藤澤 正人, 岡田 弘, 守殿 貞夫

  日本癌学会, Sep. 2001, 日本癌学会総会記事, 60回, 619 - 619, Japanese


• 膀胱癌に対するCD/5-FC遺伝子治療及び放射線療法の併用療法の有用性についての基礎的検討

  白川 利朗, 後藤 章暢, 日向 信之, 藤澤 正人, 岡田 弘, 守殿 貞夫

  日本癌学会, Sep. 2001, 日本癌学会総会記事, 60回, 618 - 618, Japanese


• ヒト大腸がん及び大腸ポリープにおける薬物輸送担保のリアルタイムPCR解析

  角本 幹夫, 中村 任, 大本 暢子, 栄田 敏之, 森田 圭紀, 田村 孝雄, 青山 伸郎, 春日 雅人, 白川 利朗, 松尾 雅文

  (公社)日本薬学会, Mar. 2001, 日本薬学会年会要旨集, 121年会(3) (3), 28 - 28, Japanese


• Caco-2細胞及びヒト十二指腸上皮細胞における薬物輸送担体・代謝酵素発現量のリアルタイムPCR解析

  大本 暢子, 角本 幹夫, 中村 任, 栄田 敏之, 森田 圭紀, 田村 孝雄, 青山 伸郎, 白川 利朗, 松尾 雅文, 春日 雅人

  (公社)日本薬学会, Mar. 2001, 日本薬学会年会要旨集, 121年会(3) (3), 113 - 113, Japanese


• 前立腺癌細胞に対する放射線・アデノウイルスp53遺伝子併用療法の検討

  佐々木 良平, 白川 利朗, 後藤 章暢, 松尾 雅文, 杉村 和朗

  (公社)日本医学放射線学会, Feb. 2001, 日本医学放射線学会雑誌, 61(2) (2), S201 - S201, Japanese


• カテキン及びアントシアニンの前立腺癌に対する抗腫瘍効果の比較検討

  松本 浩彦, 後藤 章暢, 白川 利朗, 和田 義孝, 日向 信之, 藤澤 正人, 荒川 創一, 守殿 貞夫

  日本癌学会, Sep. 2000, 日本癌学会総会記事, 59回, 607 - 607, Japanese


• 【がん遺伝子治療の進展と現状での問題点】 前立腺癌に対する新しい遺伝子治療法の確立

  和田 義孝, 後藤 章暢, 白川 利朗, 日向 信之, 岡田 弘, 荒川 創一, 守殿 貞夫, Kao Chinghai, Gardner Thomas A, Chung Leland

  (一社)日本癌治療学会, Sep. 2000, 日本癌治療学会誌, 35(2) (2), 249 - 249, Japanese


• 癌遺伝子治療におけるアデノウイルスベクターの毒性比較

  和田 義孝, 後藤 章暢, 白川 利朗, 日向 信之, 原 勲, 藤澤 正人, 岡田 弘, 荒川 創一, 守殿 貞夫, Gardner Thomas

  日本癌学会, Sep. 2000, 日本癌学会総会記事, 59回, 404 - 405, Japanese


• 膀胱癌に対する放射線療法及びp53遺伝子治療による併用療法の検討

  日向 信之, 白川 利朗, 佐々木 良平, 後藤 章暢, 和田 義孝, 藤澤 正人, 荒川 創一, 松尾 雅文, 守殿 貞夫

  日本癌学会, Sep. 2000, 日本癌学会総会記事, 59回, 63 - 64, Japanese


• 抗癌剤抵抗性ヒト膀胱腫瘍に対するp53アデノウイルスベクターを用いた遺伝子治療の検討

  白川 利朗, 後藤 章暢, 佐々木 良平, 日向 信之, 和田 義孝, 藤澤 正人, 岡田 弘, 荒川 創一, 松尾 雅文, 守殿 貞夫

  日本癌学会, Sep. 2000, 日本癌学会総会記事, 59回, 407 - 407, Japanese


• 前立腺肥大症に対する遺伝子治療の検討

  日向 信之, 白川 利朗, 後藤 章暢, 松原 重治, 和田 義孝, 藤澤 正人, 荒川 創一, 守殿 貞夫

  泌尿器科紀要刊行会, Sep. 2000, 泌尿器科紀要, 46(9) (9), 681 - 681, Japanese


• 抗癌剤抵抗性ヒト膀胱腫瘍に対するp53アデノウイルスベクターを用いた遺伝子治療の検討

  白川 利朗, 後藤 章暢, 佐々木 良平, 日向 信之, 和田 義孝, 藤澤 正人, 岡田 弘, 荒川 創一, 内藤 誠二, 松尾 雅文

  社団法人日本泌尿器科学会, 20 Mar. 2000, 日本泌尿器科学会雑誌, 91(3) (3), 250 - 250, Japanese


• 前立腺癌骨転移モデルを想定した癌遺伝子治療

  和田 義孝, 後藤 章暢, 白川 利朗, 日向 信之, Chung Leland, Gardner Thomas, 守殿 貞夫

  社団法人日本泌尿器科学会, 20 Mar. 2000, 日本泌尿器科学会雑誌, 91(3) (3), 354 - 354, Japanese


• ぼうこう癌に対する放射線療法およびp53遺伝子治療による併用療法の検討

  日向信之, 白川利朗, 佐々木良平, 後藤章暢, 和田義孝, 藤沢正人, 荒川創一, 松尾雅文, 守殿貞夫

  2000, Japanese Journal of Cancer Research, 91(Supplement (Sept)) (Supplement (Sept))


• カテキンおよびアントシアニンの前立腺癌に対する抗腫よう効果の比較検討

  松本浩彦, 後藤章暢, 白川利朗, 和田義孝, 日向信之, 藤沢正人, 荒川創一, 守殿貞夫

  2000, Japanese Journal of Cancer Research, 91(Supplement (Sept)) (Supplement (Sept))


• 癌遺伝子治療における,アデノウイルスベクターの毒性比較

  和田義孝, 後藤章暢, 白川利朗, 日向信之, 原勲, 守殿貞夫, GARDNER T, KAO C, CHUNG L

  2000, Japanese Journal of Cancer Research, 91(Supplement (Sept)) (Supplement (Sept))


• 抗癌剤抵抗性ヒトぼうこう腫ように対するp53アデノウイルスベクターを用いた遺伝子治療の検討

  白川利朗, 後藤章暢, 佐々木良平, 日向信之, 和田義孝, 藤沢正人, 岡田弘, 荒川創一, 守殿貞夫

  2000, Japanese Journal of Cancer Research, 91(Supplement (Sept)) (Supplement (Sept))


• Ablative gene therapy treatment of human renal cell carcinoma: Cytosine deaminase plus 5-fluorocytosine has superior bystander effect over thymidine kinase plus acyclovir.

  T Shirakawa, TA Gardner, C Kao, SC Ko, T Miyamoto, LWK Chung, NH Bander, S Woo, A Gotoh, S Kamidono

  May 1998, JOURNAL OF UROLOGY, 159(5) (5), 147 - 147, English

  Summary international conference


• A PATHOLOGICAL STUDY OF PRIMARY AND METASTATIC LESIONS IN CASES OF RENAL CELL CARCINOMA

  GOTOH AKINOBU, GOHJI KAZUO, SHIRAKAWA TOSHIRO, WADA YOSHITAKA, MIZUNO YOSHIHITO, OKADA HIROSHI, ARAKAWA SOICHI, KAMIDONO SADAO, HANIOKA KEISUKE

  20 Dec. 1997, 西日本泌尿器科, 59(12) (12), 881 - 884, Japanese


• FUNDAMENTAL AND CLINICAL STUDIES ON THE EFFECT OF COMBINATION THERAPY WITH IMIPENEM/CILASTATIN AND VANCOMYCIN IN PATIENTS WITH MRSA INFECTIONS IN THE UROLOGICAL FIELD

  IMAI TOSHIO, TANAKA KAZUSHI, CHOKYU HIROFUMI, MIYAZAKI SHIGENORI, MATSUI TAKASHI, ARAKAWA SOICHI, KAMIDONO SADAO, SAITO HIROSHI, HARADA KENJI, TACHIBANA YUJI, KATAOKA NOBUO, TAKENAKA ATSUSHI, KOBAYASHI MAKI, OMAE HIROSHI, SHINOZAKI MASAFUMI, MIZUNO YOSHIHITO, TATSUMI NOBORU, OGAWA TAKAYOSHI, YAMANAKA KUNITO, KONDO KANEYASU, NAKAGAWA HIROSHI, SHIRAKAWA TOSHIRO, GOTO KIYOHIKO

  20 Mar. 1997, 西日本泌尿器科, 59(3) (3), 192 - 198, Japanese


• Boari変法による尿管再建術 : 一般演題 : 第43回中部総会

  川端 岳, 下垣 博義, 山中 望, 近藤 兼安, 中川 泰始, 白川 利朗, 岡 泰彦, 岡本 恭行, 斎藤 宗吾

  社団法人日本泌尿器科学会, 20 Jun. 1994, 日本泌尿器科學會雜誌, 85(6) (6), 1039 - 1039, Japanese

• Development of Cell Surface Engineering

  Toshiro Shirakawa, Koichi Kitagawa

  Contributor, 第2章 医療応用 ２ ビフィズス菌を用いた新規経口ワクチンの開発, 株式会社CMC出版, Apr. 2020


• 先端治療技術の実用化と開発戦略

  SHIRAKAWA TOSHIRO, KITAGAWA KOICHI

  Others, (株)技術情報協会, Apr. 2017, Japanese

  Scholarly book


• 第7章 経口ワクチン

  SHIRAKAWA TOSHIRO

  Others, 株式会社 情報機構, Oct. 2013, Japanese

  Scholarly book


• Cancer Gene Therapy / 14.Current therapeutic strategies in gene therapy for prostate cancer

  Shirakawa Toshiro

  Joint work, Research Signpost, Jan. 2010, English

  Scholarly book


• Welcome to ゲノムワールド / 5-3 遺伝子治療 5-4 再生医療

  Shirakawa Toshiro

  Joint work, 廣川書店, Oct. 2009, Japanese

  Textbook


• Gene Therapy 2007 / Gene Therapy in prostate cancer: past, present and future

  SHIRAKAWA TOSHIRO, FUJISAWA MASATO

  Joint work, 21st Century's Center of Excellence Program of Japanese Ministry of Education and Science, Jan. 2007, English

  Scholarly book

• WT1 oral cancer vaccine combined with anti-PD-1 antibody completely suppressed tumor growth in a murine bladder cancer model

  SHIRAKAWA TOSHIRO, KITAGAWA KOICHI, 辰巳 真帆, 門脇 雅英, 片山 高嶺, 橋井 佳子, FUJISAWA MASATO

  CIMT 2019 Annual Meeting, May 2019, English, ドイツ, International conference

  Oral presentation


• Cross-resistance and the mechanisms of cephalosporine-resistant urinary tract infection (UTI)-causative bacteria isolated in Indonesia

  katsumi Shigemura, Koichi Kitagawa, Toshiro Shirakawa, Masato Fujisawa

  34th Annual EAU Congress, Mar. 2019, English, Barcelona, International conference

  Poster presentation


• Comparison of molecular characteristics of carbapenem-resistant urinary tract infection- causing pathogens between Japan, Taiwan and Indonesia

  katsumi Shigemura, Kento Nishimoto, Kayo Osawa, Kuntaman K, Sung S, Chen K, Kitagawa K, Huang T, Toshiro Shirakawa, Masato Fujisawa

  34th Annual EAU Congress, Mar. 2019, English, Barcelona, International conference

  Poster presentation


• 尿路感染症におけるカルバペネム耐性腸内細菌科細菌の分子生物学的検討ならびに迅速診断法の確立

  SHIGEMURA KATSUMI, OSAWA KAYO, 江夏 徳寿, 北川 孝一, SHIRAKAWA TOSHIRO, NAKANO YUZO, FUJISAWA MASATO

  第28回 泌尿器科分子・細胞研究会, Feb. 2019, Japanese, 下関, Domestic conference

  Poster presentation


• 日本（神戸）とインドネシア（Yogyakarta）における尿路感染症の国際間比較

  KITAGAWA KOICHI, SHIGEMURA KATSUMI, 西本 健人, 山田 尚輝, Prahara Yuri, Andy Zulfiqqar, OSAWA KAYO, 宇田 篤史, SHIRAKAWA TOSHIRO, ARAKAWA SOICHI, MIYARA TAKAYUKI, FUJISAWA MASATO

  第34回日本環境感染学会総会・学術集会, Feb. 2019, Japanese, 神戸, Domestic conference

  Poster presentation


• 改変型ヒトWilms’ tumor 1タンパク表層発現ビフィズス菌を用いた経口癌ワクチンの各種固形癌に対する抗腫瘍免疫誘導効果に関する検討

  辰巳 真帆, KITAGAWA KOICHI, 加藤 真子, 駒井 翔太, 橋井 佳子, 片山 高嶺, SHIRAKAWA TOSHIRO

  第22回日本ワクチン学会学術集会, Dec. 2018, Japanese, 神戸, Domestic conference

  Oral presentation


• 遺伝子組換えビフィズス菌を用いた次世代型経口結核ワクチンの開発

  古田 拓也, 門脇 雅英, KITAGAWA KOICHI, 土井 教生, 片山 高嶺, SHIRAKAWA TOSHIRO

  第22回日本ワクチン学会学術集会, Dec. 2018, Japanese, 神戸, Domestic conference

  Oral presentation


• Cancer immunotherapy combining oral vaccination of recombinant Bifidobacterium longum displaying human Wilms’ tumor 1 protein and anti-PD-1 checkpoint blockade for solid tumors in mice experimental model.

  KITAGAWA KOICHI, 辰巳 真帆, 加藤 真子, 駒井 翔太, 橋井 佳子, 片山 高嶺, SHIRAKAWA TOSHIRO

  CRI-CIMT-EATI-AACR Fourth International Cancer Immunotherapy Conference, Sep. 2018, English, New York, USA, International conference

  Poster presentation


• インドネシアの尿路感染症患者より分離されたカルバペネマーゼ産生グラム陰性桿菌の 分子疫学的調査

  OSAWA KAYO, SHIGEMURA KATSUMI, KITAGAWA KOICHI, FUJISAWA MASATO, SHIRAKAWA TOSHIRO

  第13回日本臨床検査学教育学会学術大会, Aug. 2018, Japanese, 札幌, Domestic conference

  Oral presentation


• インドネシアで分離されたCTX-M-15型ESBL産生Escherichia coliにおける染色体性およびプラスミド性についての分子疫学調査

  OSAWA KAYO, SHIGEMURA KATSUMI, FUJISAWA MASATO, SHIRAKAWA TOSHIRO

  第13回日本臨床検査学教育学会学術大会, Aug. 2018, Japanese, 札幌, Domestic conference

  Oral presentation


• Overexpression of SOCS3 mediated by adenovirus vector in prostate cancer cells increased the sensitivity to lymphokine-activated killer cells in vitro and in vivo.

  KITAGAWA KOICHI, 米田 智美, 石河 求己, 門脇 雅英, OTSUKI NAOKI, NIBU KENICHI, FUJISAWA MASATO, 世良田 聡, 仲 哲治, SHIRAKAWA TOSHIRO

  第24回日本遺伝子細胞治療学会, Jul. 2018, Japanese, 東京, Domestic conference

  Oral presentation


• Analysis of antimicrobial resistance mechanism in successive infections of Pseudomonas aeruginosa

  Noriko Nakanishi, Ryohei Nomoto, Kanako Sato, Chihiro Koike, Mari Kusuki, Tatsuya Nakamura, Shigemura Katsumi, Shirakawa Toshiro, Tokimatsu Issei, Osawa Kayo

  第91回日本細菌学会総会, Mar. 2018, Japanese, 日本細菌学会, 福岡, Domestic conference

  Poster presentation


• Anti-tumor effect against prostate cancer induced by oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein in mice

  五ノ井 玲菜, 北川 孝一, 古田 拓也, 辰巳 真帆, 斉藤 大樹, 橋井 佳子, 片山 高嶺, Shirakawa Toshiro

  第40回日本分子生物学会年会, Dec. 2017, Japanese, The Molecular Biology Society of Japan, 神戸, Domestic conference

  Poster presentation


• Anti-tumor effect and suppression of immune escapeby adenovirus carrying SOCS3 gene in prostate cancer

  米田 智美, 斉藤 大樹, 福井 悠夏, 北川 孝一, 世良田 聡, 仲 哲治, Shirakawa Toshiro

  第40回日本分子生物学会年会, Dec. 2017, Japanese, The Molecular Biology Society of Japan, 神戸, Domestic conference

  Poster presentation


• Enhanced anti-tumor effect by combining oral cancer vaccine using Bifidobacterium displaying WT1 protein with anti-PD-1 antibody therapy in mouse prostate cancer model.

  KITAGAWA KOICHI, 斉藤 大樹, 五ノ井 玲菜, 辰巳 真帆, 古田 拓也, 橋井 佳子, 片山 高嶺, SHIRAKAWA TOSHIRO

  Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 2017, Sep. 2017, English, Mainz, Germany, International conference

  Poster presentation


• Enhanced anti-tumor effect by combining oral cancer vaccine using Bifidobacterium displaying WT1 protein with anti-PD-1 antibody therapy in mouse prostate cancer model.

  北川 孝一, 斉藤 大樹, 五ノ井 玲菜, 辰巳 真帆, 古田 拓也, 橋井 佳子, 片山 高嶺, Shirakawa Toshiro

  Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Sep. 2017, English, Association for Cancer Immunotherapy, Mainz, ドイツ, International conference

  Poster presentation


• Development of novel oral cancer vaccine using Bifidobacterium

  Shirakawa Toshiro

  Hwasun Adenoviral Cancer Therapeutics Symposium, Sep. 2017, English, Chonnam National University, 光州, 韓国, International conference

  [Invited]

  Nominated symposium


• 兵庫県内で分離されたPseudomonas aeruginosaの薬剤耐性機構の解析

  佐藤加奈子, Osawa Kayo, Shigemura Katsumi, 中村竜也, Fujisawa Masato, Tokimatsu Issei, Shirakawa Toshiro

  第12回日本臨床検査学教育学会学術大会, Aug. 2017, Japanese, 日本臨床検査学教育学会, 埼玉, Domestic conference

  Oral presentation


• Clostridium difficileの薬剤感受性と遺伝子解析

  衣川真矢, Osawa Kayo, Shigemura Katsumi, 中村竜也, Tokimatsu Issei, Fujisawa Masato, Shirakawa Toshiro

  第12回日本臨床検査学教育学会学術大会, Aug. 2017, Japanese, 日本臨床検査学教育学会, 埼玉, Domestic conference

  Oral presentation


• 腸管免疫を利用した新規経口がんワクチンと免疫チェックポイント阻害剤の併用療法の開発

  Shirakawa Toshiro, 北川孝一, Fujisawa Masato

  Development of combinational cancer immunotherapy comprising WT1 oral cancer vaccine and immune checkpoint inhibitor, Jul. 2017, English, Japan Society of Gene and Cell Therapy, 岡山, Domestic conference

  Public symposium


• Wilms’ tumor 1タンパク発現ビフィズス菌を用いた経口癌ワクチンの抗腫瘍免疫誘導効果に関する検討

  北川 孝一, 辰巳 真帆, 五ノ井 玲菜, 斉藤 大樹, 橋井 佳子, 片山 高嶺, Shirakawa Toshiro

  第21回腸内細菌学会, Jun. 2017, Japanese, The Japan Bifidus Foundation, 神戸, Domestic conference

  Poster presentation


• The level of urinary titin of DMD patients is >100-times higher than that of healthy control

  Hiroyuki Awano, Matsumoto M, Nagai M, Shirakawa Toshiro, Takasaki T, Maruyama N, Nabeshima Y, Matsuo M, Iijima Kazumoto

  第59回日本小児神経学会学術集会, Jun. 2017, Japanese, 日本小児神経学会, 大阪, Domestic conference

  Oral presentation


• Urinaty titin reveals persistent proteolysis in Duchenn Muscular Dystrophy

  Hiroyuki Awano, Matsumoto M, Nagai M, Shirakawa Toshiro, Maruyama K, Iijima Kazumoto, Nabeshima Y, Matsuo M

  22nd International Congress of the World Muscle society,, May 2017, English, The World Muscle Society, Saint-Malo, France, International conference

  Poster presentation


• Urinary exceation of 8-OHdG, a biomarker of oxdative DNA damage, increases with age in DMD patients

  Matsumoto M, Hiroyuki Awano, Nagai Takayuki, Shirakawa Toshiro, Iijima Kazumoto, Matsuo M

  22nd International Congress of the World Muscle society,, May 2017, English, The World Muscle Society, Saint-Malo, France, International conference

  Poster presentation


• International comparison of causative bacteria and antimicrobial susceptibilities of UTIs between developed and developing countries

  SHIGEMURA KATSUMI, KITAGAWA KOICHI, K Kuntaman, NAKANO YUZO, SHIRAKAWA TOSHIRO, TOKIMATSU ISSEI, FUJISAWA MASATO

  American Urological Association (AUA) 2017 Annual Meeting 112th, May 2017, English, Boston, USA, International conference

  Poster presentation


• International comparison of causative bacteria and antimicrobial susceptibilities of UTIs between developed and developing countries

  Shigemura Katsumi, Koichi Kitagawa, Kuntman Kuntaman, Nakano Yuzo, Shirakawa Toshiro, Tokimatsu Issei, Fujisawa Masato

  The112nd American Urological Association Annual Meeting, May 2017, English, American Urological Association, ボストン, アメリカ, International conference

  Poster presentation


• Combination of Oral WT1 Cancer Vaccine and Anti-PD-1 Antibody Induced the Synergistic Anti-tumor Effect in Mouse Prostate Cancer Model

  北川 孝一, 五ノ井 玲菜, 辰巳 真帆, 斉藤 大樹, 橋井 佳子, 片山 高嶺, Shirakawa Toshiro

  American Society of Gene & Cell Therapy 20th Annual Meeting, May 2017, English, American Society of Gene & Cell Therapy, Washington DC, USA, International conference

  Poster presentation


• 尿路感染症における原因菌と薬剤感受性の国際比較

  Shigemura Katsumi, Osawa Kayo, Nakano Yuzo, 小瀧 将広, L. Alimsardjono, D. Rahadjo, U. Hadi, F. Setiawan, E.B.Wasito, Ni Made Merta Niasih, K. Kuntaman, M.Rusli, Tokimatsu Issei, 荒川 創一, Shirakawa Toshiro, Fujisawa Masato

  第64回 日本化学療法学会西日本支部総会第86回日本感染症学会西日本地方会学術集会, Nov. 2016, Japanese, 日本化学療法学会, 沖縄, Domestic conference

  Oral presentation


• Development of the novel oral cancer vaccine using Bifidobacterium longum displaying Wilms’ tumor 1 protein

  KITAGAWA KOICHI, 小田 麗未, 荒木 綾芽, 五ノ井 玲菜, 斉藤 大樹, 橋井 佳子, 片山 高嶺, SHIRAKAWA TOSHIRO

  第22回日本遺伝子細胞治療学会学術集会, Jul. 2016, Japanese, 東京, Domestic conference

  Oral presentation


• Molecular characteristics of extended-spectrum ?-lactamase-producing Escherichia coli isolated urinary tract infection in a university teaching hospital

  Shigemura Katsumi, Osawa Kayo, Kazushi Tanaka, Nakano Yuzo, Shirakawa Toshiro, Soichi Arakawa, Fujisawa Masato

  American Urological Association 2016 Annual Meeting L74:AA74, May 2016, English, American Urological Association, San Diego, USA, International conference

  Poster presentation


• Development of the novel oral tumor vaccine using Bifidobacterium longum displaying Wilms’ tumor 1 protein.

  KITAGAWA KOICHI, 小田 麗未, 荒木 綾芽, 五ノ井 玲菜, 斉藤 大樹, 橋井 佳子, 片山 高嶺, SHIRAKAWA TOSHIRO

  American Society of Gene & Cell Therapy 19th Annual Meeting, May 2016, English, Washington DC, USA, International conference

  Poster presentation


• Azithromycinに対する Neisseria gonorrhoeae薬剤感受性の 最近7年間の変遷について

  Osawa Kayo, Shigemura Katsumi, 吉田 弘之, Shirakawa Toshiro, Fujisawa Masato, Arakawa Soichi

  第28回 日本性感染症学会学術大会, Dec. 2015, Japanese, 日本性感染症学会, 東京, Domestic conference

  Oral presentation


• Development of Combination Therapy of Bifidobacterium-based Oral Vaccine Displaying HCV-NS3 with Interferon-α

  KITAGAWA KOICHI, 石川 博規, 小田 麗未, 斉藤 大樹, 森下 直矢, 島本 康介, 西田 典永, 松浦 洋一, HOTTA HAK, SHIRAKAWA TOSHIRO

  American Society of Gene & Cell Therapy 18th Annual Meeting, May 2015, English, New Orleans, Louisiana, USA, International conference

  Poster presentation


• 兵庫県における淋菌の薬剤感受性の最近13年間の変遷についての検討

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第89回日本感染症学会学術講演会, Apr. 2015, Japanese, 京都, Domestic conference

  Poster presentation


• 経尿道的前立腺レーザー核出術(HoLEP)における術後尿失禁に関連する因子についてのurodynamic studyを用いた検討

  Shigemura Katsumi, Tanaka Kazushi, 桃園 宏之, 長富 俊孝, 江夏 徳寿, Muramaki Mototsugu, Shirakawa Toshiro, Miyake Hideaki, Fujisawa Masato

  第103回日本泌尿器科学会総会, Apr. 2015, Japanese, 日本泌尿器科学会, 金沢, Domestic conference

  Poster presentation


• ビフィズス菌を応用した 新規経口ワクチン･プラットフォーム の開発

  Shirakawa Toshiro

  第88回日本細菌学会総会, Mar. 2015, Japanese, 日本細菌学会, 岐阜, Domestic conference

  [Invited]

  Invited oral presentation


• 兵庫県下におけるアジスロマイシン耐性淋菌の 分子遺伝学的解析

  三浦 真希子, Shigemura Katsumi, Osawa Kayo, 吉田 弘之, 藤原 美樹, 澤村 暢, 奈須 聖子, Arakawa Soichi, Fujisawa Masato, Shirakawa Toshiro

  第28回日本性感染症学会学術大会, Dec. 2014, Japanese, 日本性感染症学会, 神戸, Domestic conference

  Oral presentation


• 兵庫県におけるアジスロマイシン(AZM)耐性淋菌の分子遺伝学的解析

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第27回日本性感染症学会学術大会, Dec. 2014, Japanese, Domestic conference

  Oral presentation


• セフェム系薬剤感受性低下の遺伝解析

  Osawa Kayo, Shigemura Katsumi, 額田 雪絵, 吉田 弘之, 藤原 美樹, 奈須 聖子, Shirakawa Toshiro, Fujisawa Masato, Arakawa Soichi

  第27回日本性感染症学会学術大会, Dec. 2014, Japanese, 日本性感染症学会, 神戸, Domestic conference

  Oral presentation


• セフェム系薬剤感受性低下Neisseria gonorrhoeaeの遺伝解析

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第27回日本性感染症学会学術大会, Dec. 2014, Japanese, Domestic conference

  Oral presentation


• Prenatal diagnosis of holoprosencephaly with proboscis and synophthalmia caused by monosomy 18p

  Yamasaki Y, Shirakawa Toshiro, Miyahara Yoshiya, Morita Hiroki, Yamada Hideto

  20th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), Nov. 2014, English, Ho Chi Minh, Vietnam, International conference

  Poster presentation


• Expression of epithelial-mesenchymal transition-related factors in adherent placenta

  Shirakawa Toshiro, Miyahara Yoshiya, Yamasaki Y, Morita Hiroki, Yamada Hideto

  20th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), Nov. 2014, English, Ho Chi Minh, Vietnam, International conference

  Poster presentation


• Diagnosis and post-operative management of the giant ovarian tumors

  Miyahara Yoshiya, Yamasaki Y, Shirakawa Toshiro, Morita Hiroki, Yamada Hideto

  20th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), Nov. 2014, English, Ho Chi Minh, Vietnam, International conference

  Poster presentation


• 前立腺肥大症患者の下部尿路症状（LUTS）に対するシロドシンおよびナフトピジルの臨床効果に関する比較検討

  Shirakawa Toshiro, Shigemura Katsumi, 原口 貴裕, 江夏 徳寿, 森下 真一, 源吉 顕治, 宮崎 治郎, Miyake Hideaki, Tanaka Kazushi, Fujisawa Masato

  第21回日本排尿機能学会総会, Sep. 2014, Japanese, 日本排尿機能学会, 岡山, Domestic conference

  Poster presentation


• Development of the novel cancer therapeutic strategy incorporating the gene therapy and immune cellular therapy

  Shirakawa Toshiro

  CNUH International Symposium for Urogenital Translational Research, Sep. 2014, English, Chonnam National University Hospital, Gwangju, Korea, International conference

  [Invited]

  Invited oral presentation


• Development of Combination Therapy of Bifidobacterium Displaying HCV-NS3 Oral Vaccine with Interferon-Alpha

  Koichi Kitagawa, Chika Omoto, Hiroki Ishikawa, Tsugumi Oda, Naoya Morishita, Hotta Hak, Shirakawa Toshiro

  第20回日本遺伝子治療学会, Aug. 2014, Japanese, 日本遺伝子治療学会, 東京, Domestic conference

  Oral presentation


• COMBINATION THERAPY OF BIFIDOBACTERIUM DISPLAYING HCV-NS3 ORAL VACCINE WITH INTERFERON-ALPHA IN MICE

  KITAGAWA KOICHI, 大本 知佳, 石川 博規, 小田 麗未, 森下 直矢, HOTTA HAK, SHIRAKAWA TOSHIRO

  第20回日本遺伝子治療学会学術集会, Aug. 2014, Japanese, Domestic conference

  Oral presentation


• 兵庫県下で分離されたメタロβラクタマーゼ産生腸内細菌の解析

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第88回日本感染症学会学術講演会, Jun. 2014, Japanese, 福岡, Domestic conference

  Poster presentation


• 当院で分離されたESBLｓ産生Escherichia coli の遺伝子解析

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第88回日本感染症学会学術講演会, Jun. 2014, Japanese, 福岡, Domestic conference

  Poster presentation


• SIGNIFICANT RECEPTORS OR BIOMARKERS FOR THE SYMPTOMS OF OVERACTIVE BLADDER

  Yamamichi F, Shigemura Katsumi, Shirakawa Toshiro, Behnsawy H, Yamashita M, Miyake Hideaki, Tanaka Kiwamu, Fujisawa Masato

  109thAUA(American Urological Association)annual meeting, May 2014, English, American Urological Association, オーランド, アメリカ, International conference

  Poster presentation


• 前立腺癌増悪において上皮ならびに間質でのSonic hedgehogとandrogenシグナル伝達が上皮間葉移行を作動させる

  山道 深, Shigemura Katsumi, Hosny M. Behnsawy, Fatma Y. Meligy, Wen-chin Huang, Xiangyan Li, Lel, W.K.Chung, 川端 眞人, 後藤 章暢, Miyake Hideaki, Tanaka Kazushi, Shirakawa Toshiro, Fujisawa Masato

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会, 神戸, Domestic conference

  Poster presentation


• Does mutation in gyrA or parC or efflux pump expression play the main role in fluoroquinolone-resistant Escherichia coli causing urinary tract infections?

  Shigemura Katsumi, Tanaka Kiwamu, Shirakawa Toshiro, Arakawa Soichi, Miyake Hideaki, Fujisawa Masato

  29thEAU(European Association of Urology) Annual Congress, Apr. 2014, English, European Association of Urology, ストックホルム, スウェーデン, International conference

  Poster presentation


• Expression of epithelial-mesenchymal transition-related factors in placenta accreta

  Shirakawa Toshiro, Mihayara Y, Niiya Kiyoshi, Morita Hiroki, Ebina Yasuhiko, Yamada Hideto

  19th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), Feb. 2014, English, Macau, China, International conference

  Poster presentation


• Bacterial identification using the ssrA gene encoding tmRNA

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  Asian-African Research Forum on Emerginｇ and Reemerging Infections 2014, Jan. 2014, English, 仙台, International conference

  Poster presentation


• Bacterial identification using the ssrA gene encoding tmRNA

  Ayaka Kayo, Osawa Kayo, Shigemura Katsumi, Hiroyuki Yoshida, Miki Fujiwara, Yoshio Iijima, Fujisawa Masato, Dadik Raharjo, Subijanto Marto Sudarmo, Kawabata Masato, Shirakawa Toshiro

  Asian-African Research Forum on Emerginｇ and Reemerging Infections 2014, Jan. 2014, English, 仙台, International conference

  Public symposium


• Active surveillance of children's acute diarrheal disease using a novel molecular diagnostic multiplexing system in Surabaya, Indonesia

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  Asian-African Research Forum on Emerginｇ and Reemerging Infections 2014, Jan. 2014, English, 仙台, International conference

  Poster presentation


• Current status and perspective of personalized cancer therapy incorporating the gene therapy and immune-cellular therapy

  SHIRAKAWA TOSHIRO

  第17回 国際個別化医療学会, Nov. 2013, English, Domestic conference

  [Invited]

  Invited oral presentation


• Current status and perspective of personalized cancer therapy incorporating the gene therapy and immune-cellular therapy

  Shirakawa Toshiro

  The 17th International Congress of Personalized Medicine, Nov. 2013, Japanese, International Society of Personalized Medicine, 神戸, Domestic conference

  [Invited]

  Invited oral presentation


• The p53-specific CTL induced by Ad-p53 infected dendritic cells showed the high cytotoxicity in p53-overexpressed and Ad-53 infected tumor cell lines

  斉藤 大樹, 山崎 里沙, 森下 直矢, Dody Bautista, Dante Dator, Kawabata Masato, Shigemura Katsumi, Fujisawa Masato, Shirakawa Toshiro

  The 17th International Congress of Personalized Medicine, Nov. 2013, Japanese, International Society of Personalized Medicine, 神戸, Domestic conference

  Poster presentation


• Synergistic antitumor effect of the combination of adenoviral gene therapy and immunotherapy for head and neck cancer

  安藤 聡志, 斉藤 大樹, 森下 直矢, Kawabata Masato, Ohtsuki Naoki, Nibu Ken-ichi, Fujisawa Masato, Shirakawa Toshiro

  The 17th International Congress of Personalized Medicine, Nov. 2013, Japanese, International Society of Personalized Medicine, 神戸, Domestic conference

  Poster presentation


• BPH/LUTSに対するデュタステリドの有用性に関する検討

  Haraguchi Takahiro, Miyake Hideaki, 江夏 徳寿, Shirakawa Toshiro, Tanaka Kazushi, Fujisawa Masato

  第20回日本排尿機能学会, Sep. 2013, Japanese, 日本排尿機能学会, 静岡, Domestic conference

  Poster presentation


• The p53-specific CTL induced by Ad-p53 infected dendritic cells showed the high cytotoxicity in p53-overexpressED and Ad-p53 infected tumor cell lines.

  斉藤 大樹, 山崎 里沙, 森下 直矢, Kawabata Masato, Dody Bautista, Dante Dator, Shirakawa Toshiro

  19th Annual Meeting of Japan Society of Gene Therapy, Jul. 2013, Japanese, Japan Society of Gene Therapy, 岡山, Domestic conference

  Oral presentation


• SYNERGISTIC ANITITUMOR EFFECT OF THE COMBINATIION OF ADENOVIRAL GENE THERAPY AND IMMUNOTHERAPY FOR HEAD AND NECK CANCER

  安藤 聡志, 斉藤 大樹, 森下 直矢, Kawabata Masato, Ohtsuki Naoki, Nibu Ken-ichi, Fujisawa Masato, Shirakawa Toshiro

  19th Annual Meeting of Japan Society of Gene Therapy, Jul. 2013, Japanese, Japan Society of Gene Therapy, 岡山, Domestic conference

  Poster presentation


• ORAL ADMINISTRATION OF GENETICALLY MODIFIED BIFIDOBACTERIUM DISPLAYING HCV-NS3 MULTI-EPITOPE FUSION PROTEIN CAN INDUCE THE HCV-NS3 SPECIFIC SYSTEMIC IMMUNE RESPONSE IN MICE

  大本 知佳, 北川 孝一, 竹井 咲希, 森下 直矢, 片山 高嶺, Hotta Hak, Kawabata Masato, Shirakawa Toshiro

  19th Annual Meeting of Japan Society of Gene Therapy, Jul. 2013, Japanese, Japan Society of Gene Therapy, 岡山, Domestic conference

  Oral presentation


• DEVELOPMENT OF THE ORAL UNIVERSAL TYPE A INFLUENZA VACCINE USING BIFIDOBACTERIUM DISPLAYING INFLUENZA-M2e PROTEIN

  尾崎 鈴佳, 北川 孝一, 代崎 千尋, 森下 直矢, 片山 高嶺, Kawabata Masato, Shirakawa Toshiro

  19th Annual Meeting of Japan Society of Gene Therapy, Jul. 2013, Japanese, Japan Society of Gene Therapy, 岡山, Domestic conference

  Oral presentation


• 尿路感染症患者より分離したPseudomonas aeruginosa 薬剤耐性株におけるefflux pump遺伝子の発現についての検討

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第87回日本感染症学会学術講演会, Jun. 2013, Japanese, 横浜, Domestic conference

  Poster presentation


• 尿路感染症患者より分離したPseudomonas aeruginosa 薬剤耐性株におけるefflux pump遺伝子の発現についての検討

  加藤 綾香, Osawa Kayo, Shigemura Katsumi, Tanaka Kazushi, Arakawa Soichi, Fujisawa Masato, Shirakawa Toshiro

  第87回日本感染症学会学術講演会, Jun. 2013, Japanese, 日本感染症学会, 横浜, Domestic conference

  Poster presentation


• Candida urinary tract isolation and Candida species susceptibilities to anti-fungus medication in Kobe University Hospital

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  28th International Congress of Chemotherapy and Infection, Jun. 2013, English, 横浜, International conference

  Poster presentation


• Candida urinary tract isolation and Candida species susceptibilities to anti-fungus medication in Kobe University Hospital

  Shigemura Katsumi, Osawa Kayo, Tanaka Kazushi, Hiroyuki Yoshida, Shirakawa Toshiro, Fujisawa Masato, Arakawa Soichi

  28th International Congress of Chemotherapy and Infection, Jun. 2013, English, 日本感染症学会他, 横浜, International conference

  Poster presentation


• Does mutation in gyrA or parC or efflux pump expression play the main role in fluoroquinolone-resistant Escherichia coli causing urinary tract infections?

  Shigemura Katsumi, Tanaka Kiwamu, Shirakawa Toshiro, Arakawa Soichi, Miyake Hideaki, Fujisawa Masato

  108thAUA(American Urological Association)annual meeting, May 2013, English, AUA(American Urological Association)annual meeting, サンディエゴ, アメリカ, International conference

  Poster presentation


• Development of the Oral Universal Type A Influenza Vaccine Using Bifidobacterium Displaying Influenza-M2e Protein

  尾崎 鈴佳, 森下 直矢, 北川 孝一, 代崎 千尋, 斉藤 大樹, Shigemura Katsumi, Fujisawa Masato, Kawabata Masato, Shirakawa Toshiro

  American Society of Gene & Cell Therapy 16th Annual Meeting, May 2013, English, American Society of Gene & Cell Therapy, Salt Lake City, America, International conference

  Poster presentation


• Combination of CD3+CD56+ (NKT) Cells Immunotherapy and Adenovirus-p53 Therapy for Head and Neck Squamous Cell Carcinoma

  斉藤 大樹, 森下 直矢, Kyung-Mi Lee, Dante Dator, Kawabata Masato, Fujisawa Masato, Shirakawa Toshiro

  American Society of Gene & Cell Therapy 16th Annual Meeting, May 2013, English, American Society of Gene & Cell Therapy, Salt Lake City, America, International conference

  Poster presentation


• Sonic hedgehog signaling and Androgens are linked in tumor-stromal interaction through Epithelial-Mesenchymal transition (EMT) in prostate cancer progression

  Shigemura Katsumi, Shirakawa Toshiro, Yamamichi F, Matsumoto M, Behnsawy HM, Meligy FY, Miyake Hideaki, Tanaka Kiwamu, Fujisawa Masato

  28thEAU(European Association of Urology), Mar. 2013, English, EAU(European Association of Urology), ミラノ, イタリア, International conference

  Poster presentation


• Frequency of Diarrheagenic Escherichia coli among Children in Surabaya, Indoneshia

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  Asian-African Research Forum on Emerginf and Reemerging Infections, Jan. 2013, English, International conference

  Oral presentation


• Development of a Multiplex PCR for the Rapid Identification of Salmonella Serotypes.

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  Asian-African Research Forum on Emerginf and Reemerging Infections, Jan. 2013, English, International conference

  Poster presentation


• tmRNAマーカーを用いたPCRによる細菌同定法の検討

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第65回日本細菌学会関西支部総会, Nov. 2012, Japanese, Domestic conference

  Oral presentation


• Multiplex PCRによるSalmonella 血清型の迅速スクリーニング法の開発

  OSAWA KAYO, SHIRAKAWA TOSHIRO

  第65回日本細菌学会関西支部総会, Nov. 2012, Japanese, Domestic conference

  Oral presentation


• 阪神地区における91 淋菌臨床株のgyrA, parC のアミノ酸変異とキノロン系

  Shigemura Katsumi, Tanaka Kazushi, Shirakawa Toshiro, Miyake Hideaki, Arakawa Soichi, Fujisawa Masato

  第41回 薬剤耐性菌研究会, Oct. 2012, Japanese, 薬剤耐性菌研究会, 岐阜県, Domestic conference

  Poster presentation


• Sonic hedgehog signaling and Androgens are linked in tumor-stromal interaction through Epithelial-Mesenchymal transition (EMT) in prostate cancer progression

  Shigemura Katsumi, Fatma Y. Meligy, Hosny M. Behnsawy, Fukashi Yamamichi, Wen-Chin Haung, Xiangyan Li, Kunito Yamanaka, Keisuke Hanioka, Miyake Hideaki, Kawabata Masato, Shirakawa Toshiro, Fujisawa Masato

  107th AUA(American Urological Association)annual meeting, May 2012, English, AUA(American Urological Association)annual meeting, アトランタ, International conference

  Poster presentation


• Significant biomarker for lower urinary tract symptoms in chronic prostatitis

  Shigemura Katsumi, Matsumoto M, Shirakawa Toshiro, Yamamichi F, Arakawa Soichi, Tanaka Kiwamu, Miyake Hideaki, Fujisawa Masato

  107th AUA(American Urological Association)annual meeting, May 2012, English, AUA(American Urological Association)annual meeting, アトランタ, International conference

  Poster presentation


• Possible role of sonic hedgehog signaling and the link with Epithelial-Mesenchymal transition (EMT) in renal cancer progression

  Shigemura Katsumi, Fatma Y. Meligy, Hosny M. Behnsawy, Fukashi Yamamichi, Wen-Chin Haung, Xiangyan Li, Lela, d Chung, Masuo Yamashita, Kawabata Masato, Shirakawa Toshiro, Fujisawa Masato

  107th AUA(American Urological Association)annual meeting, May 2012, English, AUA(American Urological Association)annual meeting, アトランタ, International conference

  Poster presentation


• Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections.

  Shigemura Katsumi, Yasufuku T, Shirakawa Toshiro, Matsumoto M, Nakano Y, Tanaka Kiwamu, Arakawa Soichi, Kawabata Masato, Fujisawa Masato

  107th AUA(American Urological Association)annual meeting, May 2012, English, AUA(American Urological Association)annual meeting, アトランタ, International conference

  Poster presentation


• Antimicrobial resistance in Salmonella strains clinically isolated in Hyogo, Japan (2009-2011)

  大澤 佳代, SHIRAKAWA TOSHIRO

  第86回日本感染症学会総会, Apr. 2012, Japanese, 長崎, Domestic conference

  Poster presentation


• Antimicrobial resistance in Salmonella strains clinically isolated in Hyogo, Japan (2009-2011)

  大澤 佳代, SHIRAKAWA TOSHIRO

  Asian-African Research Forum n Emerging and Reemerging, Jan. 2012, English, 神戸, International conference

  Poster presentation


• Characterization of wzz genes in Escherichia coli O157

  大澤 佳代, SHIRAKAWA TOSHIRO

  International Union of Microbiological Societies 2011 Congress, Sep. 2011, English, Sapporo, International conference

  Poster presentation


• 尿路感染症由来緑膿菌臨床株における高速液体クロマトグラフィー法によるフルオロキノロン系抗菌薬耐性の迅速診断法確立への検討

  松本穣, Shigemura Katsumi, Shirakawa Toshiro, 安福富彦, 中野雄造, Tanaka Kazushi, 木下承皓, Kawabata Masato, Arakawa Soichi, Fujisawa Masato

  第99回日本泌尿器科学会総会, Apr. 2011, Japanese, 日本泌尿器科学会総会, 名古屋, Domestic conference

  Poster presentation


• 尿路感染症由来緑膿菌株における高速液体クロマトグラフィー法によるフルオロキノロン系抗菌薬耐性の迅速診断法に関する検討

  松本穣, Shigemura Katsumi, Shirakawa Toshiro, 安福富彦, 中野雄造, Tanaka Kazushi, 木下承晧, Kawabata Masato, Arakawa Soichi, Fujisawa Masato

  第85回日本感染症学会総会・学術講演会, Apr. 2011, Japanese, 日本感染症学会総会・学術講演会, 東京, Domestic conference

  Poster presentation


• 帳球菌の尿路感染症臨床株におけるgyrA,parC遺伝子変異とフルオロキノロン系抗菌薬耐性の相関についての検討

  安福富彦, Shigemura Katsumi, Shirakawa Toshiro, 松本穣, 中野雄造, Tanaka Kazushi, 木下承皓, Kawabata Masato, Arakawa Soichi, Fujisawa Masato

  第99回日本泌尿器科学会総会, Apr. 2011, Japanese, 日本泌尿器科学会総会, 名古屋, Domestic conference

  Oral presentation


• 泌尿器科領域悪性腫瘍に対する抗癌化学療法中に生じた発熱性好中球減少症（ＦＮ)の検討

  安福富彦, Shigemura Katsumi, 松本穣, 中野雄造, Shirakawa Toshiro, Tanaka Kazushi, Arakawa Soichi, Fujisawa Masato

  第58回日本化学療法学会西日本支部総会, Nov. 2010, Japanese, 日本化学療法学会総会, 大分, Domestic conference

  Oral presentation


• 尿路感染症由来大腸菌の臨床株における薬剤排出ポンプ遺伝子の発現と各種抗菌薬耐性との関連の解析

  Shigemura Katsumi, 安福富彦, Shirakawa Toshiro, 木下承晧, 松本穣, 中野雄造, Tanaka Kazushi, Kawabata Masato, Arakawa Soichi, Fujisawa Masato

  第62回日本泌尿器科学会西日本総会, Nov. 2010, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference

  Oral presentation


• 前立腺癌患者末梢血中circulating tumor cells(CTCs)の検出法の開発

  山道深, 松岡孝幸, Kawabata Masato, 森下真一, Shirakawa Toshiro, Fujisawa Masato

  第60回日本泌尿器科学会中部総会, Nov. 2010, Japanese, 日本泌尿器科学会, 名古屋, Domestic conference

  Oral presentation


• 尿路感染症由来緑膿菌臨床株におけるgyrA,parC遺伝子変異とキノロン系抗菌薬耐性についての検討

  松本穣, Shigemura Katsumi, Shirakawa Toshiro, 安福富彦, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承皓, Kawabata Masato, Fujisawa Masato

  第19回日本腎泌尿器疾患予防医学研究会, Jul. 2010, Japanese, 日本腎泌尿器疾患医学研究会, 千葉, Domestic conference

  Oral presentation


• 尿路感染症由来緑膿菌臨床株におけるgyrA、parC遺伝子変異とキノロン系抗菌薬耐性の関連についての検討

  松本穣, Shigemura Katsumi, Shirakawa Toshiro, 安福富彦, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承皓, Kawabata Masato, Fujisawa Masato

  第58回日本化学療法学会総会, Jun. 2010, Japanese, 日本化学療法学会総会, 長崎, Domestic conference

  Oral presentation


• 尿路感染症由来緑膿菌臨床株におけるgyrA、parC遺伝子変異とキノロン系抗菌薬耐性の関連についての検討

  松本穣, Shigemura Katsumi, Shirakawa Toshiro, 安福富彦, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承晧, Kawabata Masato, Fujisawa Masato

  第98回日本泌尿器科学会総会, Apr. 2010, Japanese, 日本泌尿器科学会, 盛岡, Domestic conference

  Oral presentation


• 尿路感染症由来大腸菌の臨床株における薬剤排出ポンプ遺伝子の発現と各種抗菌薬耐性との関連の解析

  安福富彦, Shigemura Katsumi, Shirakawa Toshiro, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承晧, Kawabata Masato, Fujisawa Masato

  第98回日本泌尿器科学会総会, Apr. 2010, Japanese, 日本泌尿器科学会, 盛岡, Domestic conference

  Poster presentation


• 「薬剤耐性（1）」尿路感染症由来大腸菌の臨床株における薬剤排出ポンプ遺伝子の発現と各種抗菌薬耐性との関連の解析

  安福富彦, Shigemura Katsumi, Shirakawa Toshiro, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承皓, Kawabata Masato, Fujisawa Masato

  第84回日本感染症学会総会・学術講演会, Apr. 2010, Japanese, 日本感染症学会, 京都, Domestic conference

  Others


• ヒト膀胱癌細胞におけるCox-2阻害剤、3剤の攻腫瘍効果の比較検討

  Shirakawa Toshiro, ザイナル アドヒム, 松岡孝幸, Shigemura Katsumi, Nibu Ken-ichi, Kawabata Masato, Fujisawa Masato

  第98回日本泌尿器科学会総会, Apr. 2010, Japanese, 日本泌尿器科学会, 盛岡, Domestic conference

  Oral presentation


• 尿路感染症起因大腸菌の臨床株におけるｇｙｒA、parC遺伝子変異とフルオロキノン系抗菌薬耐性の相関についての検討

  安福富彦, Shigemura Katsumi, Shirakawa Toshiro, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承晧, 原田益善, Kawabata Masato, Fujisawa Masato

  第52回日本感染症学会中日本地方会学術集会, Nov. 2009, Japanese, 日本感染症学会, 名古屋, Domestic conference

  Oral presentation


• A case of intrauterine fetal death assosiated with multiple anomalry

  Shirakawa Toshiro, Makihara Natsuko, Amano Mariko, Morimoto Noriyuki, Morizane Mayumi, Yamasaki Mineo, Yamada Hideto, Kitazawa Riko

  第121回近畿産婦人科学会学術集会, Nov. 2009, Japanese, 近畿産婦人科学会, 神戸, Domestic conference

  Oral presentation


• Risk factors and the mechanisms for fluoroquinolone resistance in the 156 clinically isolated Escherrichia colistrains of urinary tract infections

  Tomihiko Yasufuku, Shigemura Katsumi, Shirakawa Toshiro, Yuzo Nakano, Tanaka Kazushi, Arakawa Soichi, Shouhiro Kinoshita, Kawabata Masato, Fujisawa Masato

  第25回腎移植・血管外科研究会, Nov. 2009, English, 尿路感染症研究会, 東京, Domestic conference

  Others


• EMERGENCE OF FLUOROQUINOLONE-RESISTANT E. COLI STRAIN AND THEIR RELATED MUTATIONS OF THE GYRA AND PARC GENES IN UTI PATIENTS IN JAPAN

  Tomihiko Yasufuku, Shigemura Katsumi, Shirakawa Toshiro, Yuzo Nakano, Tanaka Kazushi, Arakawa Soichi, Shouhiro Kinoshita, Kawabata Masato, Fujisawa Masato

  UTI研究会, Nov. 2009, English, UTI研究会, 東京, International conference

  Oral presentation


• 大腸菌の臨床株におけるgyrA, parC遺伝子変異とフルオロキノロン系抗菌薬耐性の相関についての検討

  安福富彦, Shigemura Katsumi, Shirakawa Toshiro, 中野雄造, Tanaka Kazushi, 武中篤, Arakawa Soichi, 木下承皓, Kawabata Masato, Fujisawa Masato

  第97回日本泌尿器科学会総会, Apr. 2009, Japanese, 日本泌尿器科学会, 岡山, Domestic conference

  Oral presentation


• 前立腺肥大症患者におけるシロドシンおよびナフトピジルの臨床効果に関する比較検討

  Shirakawa Toshiro, Haraguchi Takahiro, 松本穣, 竹田雅, 森下真一, 山道深, 源吉顕治, Harada Kenichi, Tanaka Kazushi, 武中篤, Fujisawa Masato

  第97回日本泌尿器科学会総会, Apr. 2009, Japanese, 日本泌尿器科学会, 岡山, Domestic conference

  Oral presentation


• EMERGENCE OF FLUOROQUINOLONE-RESISTANT E. COLI STRAIN AND THEIR RELATED MUTATIONS OF THE GYRA AND PARC GENES IN UTI PATIENTS IN JAPAN

  Tomihiko Yasufuku, Shigemura Katsumi, Shirakawa Toshiro, Yuzo Nakano, Tanaka Kazushi, Arakawa Soichi, Shouhiro Kinoshita, Kawabata Masato, Fujisawa Masato

  第104回ＡＵＡ（Amerigcan Urological Association）, Apr. 2009, English, 米国泌尿器科学会, シカゴ, アメリカ, International conference

  Poster presentation


• 腎臓がん患者におけるsorcinの発現低下

  Nakamura Tsutomu, Okamura Noboru, Gotoh Akinobu, Shirakawa Toshiro, Fujisawa Masato, Sakaeda Toshiyuki

  第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference

  Oral presentation


• ヒト膀胱癌細胞に対するミドカインプロモーターを組み込んだ増殖制限型アデノウイルスベクター（ADMKE1a）の有用性の検討

  Shirakawa Toshiro, Nomi Masashi, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato, Gotoh Akinobu

  第46回日本癌治療学会, Oct. 2008, Japanese, 日本癌治療学会, 名古屋, Domestic conference

  Oral presentation


• Suppression of sorcin mRNA in patients with renal cell carcinoma

  川上 恵, Nakamura Tsutomu, Okamura Noboru, 寺尾 秀治, Gotoh Akinobu, Shirakawa Toshiro, Fujisawa Masato, 山森 元博, Sakaeda Toshiyuki

  第67回日本癌学会学術総会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference

  Poster presentation


• Current status of gene therapy for prostate cancer

  Shirakawa Toshiro

  9th International Congress on Cell Biology, Oct. 2008, English, Korean Society for Molecular and Cellular Biology, Seoul, Korea, International conference

  [Invited]

  Invited oral presentation


• Pre-clinical studies of GMJ2.1: carrier cell-based adenoviral oncolytic virotherapy for head and neck aquamous cell carcinoma

  Shirakawa Toshiro

  2008 International Society for Cell and Gene Therapy of Cancer, China Conference, Sep. 2008, English, International Society for Cell and Gene Therapy of Cancer, Shijiazhuang, China, International conference

  Oral presentation


• Therapeutic efficacy of midkine promoter-based conditionally replicative adenovirus vector for targetting the midkine-expressing human bladder cancer cells

  Shirakawa Toshiro, Tanaka Keiko, Takenaka Atsushi, Kamidono Sadao, Fujisawa Masato, Gotoh Akinobu

  第103回ＡＵＡ（American Urological Association）ａｎｎｕａｌ ｍｅｅｔｉｎｇ, May 2008, English, 米国泌尿器科学会, オーランド, アメリカ, International conference

  Poster presentation


• 腎癌におけるSorcin発現の検討とVEGF発現に及ぼす影響

  Okamura Noboru, Shirakawa Toshiro, Nakamura Tsutomu, Sakaeda Toshiyuki, Okumura Katsuhiko, Takenaka Atsushi, Fujisawa Masato, Gotoh Akinobu

  第96回日本泌尿器科学会, Apr. 2008, Japanese, 日本泌尿器科学会, 横浜, Domestic conference

  Poster presentation


• 感染症分野における分子疫学および分子診断の進歩について

  Shirakawa Toshiro

  第30回日本臨床検査専門医会総会, Nov. 2007, Japanese, 日本臨床検査専門医会, 大阪, Domestic conference

  Invited oral presentation


• Effect of sorcin on VEGF expression in renal cell carcinoma

  Okamura Noboru, Shirakawa Toshiro, Nakamura Tsutomu, Sakaeda Toshiyuki, Takenaka Atsushi, Fujisawa Masato, Gotoh Akinobu

  第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference

  Oral presentation


• Clinical Studies of New Anticancer Drugs Results of clinical study of Ad-OC-TK gene therapy for the patients with hormone refractory metastatic prostate cancer

  Shirakawa Toshiro, Gotoh Akinobu, Tanaka Kazushi, Takenaka Atsushi, Hara Isao

  第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference

  Oral presentation


• 骨転移を有するホルモン不応性前立腺癌に対する遺伝子治療臨床研究の長期成績

  Shirakawa Toshiro, Gotoh Akinobu, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Kamidono Sadao, Fujisawa Masato

  第45回日本癌治療学会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference

  Public symposium


• ホルモン不応性再燃前立腺癌の治療 骨転移を有するホルモン不応性前立腺癌に対する遺伝子治療臨床研究の長期成績

  Shirakawa Toshiro, Gotoh Akinobu, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Kamidono Sadao, Fujisawa Masato

  第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference

  Oral presentation


• The impact and perspective on chronic kidney disease in Vietnam

  Ito Jun, Kawabata Masato, Shirakawa Toshiro

  第22回日本国際保健医療学会総会, Oct. 2007, Japanese, 日本国際保健医療学会, 大阪, Domestic conference

  Oral presentation


• Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer

  Shirakawa Toshiro, Gotoh Akinobu, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Kamidono Sadao, Fujisawa Masato

  第66回日本ガン学会学術総会, Oct. 2007, English, 日本癌学会, 横浜, Domestic conference

  [Invited]

  Invited oral presentation


• ホルミウムレーザー前立腺核出術(HoLEP)22例の臨床的検討

  Ooba Takeshi, Soga Hideo, Shirakawa Toshiro, Fujisawa Masato

  第28回日本レーザー医学会, Sep. 2007, Japanese, 日本レーザー医学会, 北海道, Domestic conference

  Oral presentation


• Evaluation of protein expression in human renal cell carcinoma by proteome analysis using the NBS method

  Nakamura Tsutomu, Okamura Noboru, Gotoh Akinobu, Shirakawa Toshiro, Fujisawa Masato, Sakaeda Toshiyuki, Okumura Katsuhiko

  日本薬物動態学会ビジョン・シンポジウム, Jul. 2007, English, 日本薬物動態学会, 東京, Domestic conference

  Poster presentation


• Results of a phase I/II study of Ad-OC-TK/VAL gene therapy for the patients with metastatic or local recurrent prostate cancer

  Shirakawa Toshiro, Gotoh Akinobu, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Kamidono Sadao, Fujisawa Masato

  第13回日本遺伝子治療学会, Jun. 2007, Japanese, 日本遺伝子治療学会, 名古屋, Domestic conference

  Public symposium


• Long-term results of a phase I/II study of Ad-OC-TK/VAL gene therapy for the patients with metastatic or local recurrent prostate cancer

  Shirakawa Toshiro, Gotoh Akinobu, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Kamidono Sadao, Fujisawa Masato

  第10回米国遺伝子治療学会, Jun. 2007, English, 米国遺伝子治療学会, シアトル, アメリカ, International conference

  Oral presentation


• The impact and perspective on chronic kidney disease in Vietnam

  Ito Jun, Fujisawa Masato, Kawabata Masato, Shirakawa Toshiro

  第50回日本腎臓学会総会（第１回アジアフォーラムCKDイニシアチブ）, May 2007, English, 日本腎臓学会、アジア太平洋腎臓学会、国際腎臓学会, 浜松, International conference

  Oral presentation


• 選択的cyclooxygenase-II(COX-2)阻害剤etodolacのヒト前立腺がん細胞株における抗腫瘍効果の検討

  Shigemura Katsumi, Shirakawa Toshiro, Gotoh Akinobu, Fujisawa Masato

  第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference

  Oral presentation


• マウス前立腺癌モデルに対するPETを用いたAd-OC-TK/VAL遺伝子治療効果および遺伝子導入効率の評価に関する有用性の検討

  Shirakawa Toshiro, Takenaka Atsushi, Fujisawa Masato, Gotoh Akinobu

  第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference

  Oral presentation


• ヒト膀胱癌細胞における選択的Cox-2阻害剤、EtodolacのE-cadherin発現増強および抗腫瘍効果の検討

  Shirakawa Toshiro, Shigemura Katsumi, Gotoh Akinobu, Kawabata Masato, Fujisawa Masato

  第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会, 神戸, Domestic conference

  Oral presentation


• 内分泌療法抵抗性前立腺癌に対するAd-OC-TK plus Valacyclovir遺伝子治療臨床研究におけるquality of lifeの評価

  SHIRAKAWA TOSHIRO, TANAKA KAZUSHI, TAKENAKA ATSUSHI, ARAKAWA SOICHI, Hara Isao, FUJISAWA MASATO

  第58回日本泌尿器科学会西日本大会, Nov. 2006, Japanese, 日本泌尿器科学会, 長崎, Domestic conference

  Oral presentation


• Phase I/II clinical trial of Ad-OC-TK plus VAL for the patients with metastatic or local recurrent prostate cancer: Kobe University Experience

  SHIRAKAWA TOSHIRO

  2006 International Society for Cell and Gene Therapy of Cancer, Japan Conference, Oct. 2006, English, International Society for Cell and Gene Therapy of Cancer, 千葉, International conference

  Oral presentation


• Ad-OC-TK/VAL遺伝子治療臨床試験における肝機能障害に対する検討

  SHIRAKAWA TOSHIRO, TAKENAKA ATSUSHI, Hara Isao, ARAKAWA SOICHI, FUJISAWA MASATO

  第４４回日本癌治療学会総会, Oct. 2006, Japanese, 日本癌治療学会, 東京, Domestic conference

  Oral presentation


• 【18F】FDGを用いたPETによるAd-OC-TK/VAL遺伝子治療評価方法の有用性の検討

  SHIRAKAWA TOSHIRO, FUJISAWA MASATO

  第６５回日本癌学会学術総会, Sep. 2006, Japanese, 日本癌学会, 横浜, Domestic conference

  Oral presentation


• Improvement of Quality of life of patients with metastatic or local recurrent prostate cancer after Phase Ⅰ/Ⅱ clinical trial of Ad-OC-TK plus Valacyclovir.

  SHIRAKAWA TOSHIRO, FUJISAWA MASATO

  第１２回日本遺伝子治療学会, Aug. 2006, English, 日本遺伝子治療学会, 東京, Domestic conference

  Oral presentation


• ホルミウムレーザー前立腺核手術(HoLEP)２２例の臨床的検討

  Ooba Takeshi, SOGA HIDEO, SHIRAKAWA TOSHIRO, FUJISAWA MASATO

  日本レーザー医学会関西地方会, Jul. 2006, Japanese, 日本レーザー医学会, 神戸, Domestic conference

  Oral presentation


• Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model

  SHIRAKAWA TOSHIRO, KAWABATA MASATO

  American Society of Gene Therapy 9th annual meeting, May 2006, English, 米国遺伝子治療学会, バルチモア, International conference

  Oral presentation


• 視床下部下垂体精巣軸におけるNeuropeptide YおよびPancreatic polypeptideの役割

  Gotoh Akinobu, SHIRAKAWA TOSHIRO, FUJISAWA MASATO

  第94回日本泌尿器科学会, Apr. 2006, Japanese, 日本泌尿器科学会, 福岡, Domestic conference

  Oral presentation


• α１遮断薬による前立腺肥大症の薬物療法についての排尿症状（ＩＰＳＳ）を中心とした長期薬効の検討

  SHIRAKAWA TOSHIRO

  第９４回日本泌尿器科学会総会, Apr. 2006, Japanese, 日本泌尿器科学会, 福岡, Domestic conference

  Poster presentation


• α1受容体遮断薬による前立腺肥大症の薬物療法についての排尿症状(IPSS)を中心とした長期薬効の検討

  SHIRAKAWA TOSHIRO, Ooba Takeshi, Yamada Yuji, FUJISAWA MASATO

  第94回日本泌尿器科学会, Apr. 2006, Japanese, 日本泌尿器科学会, 福岡, Domestic conference

  Oral presentation


• ヒト膀胱癌細胞に対するミドカインプロモーターを組み込んだ増殖制限型アデノウイルスベクター(AD-MK-E1a)の有用性の検討

  SHIRAKAWA TOSHIRO, Gotoh Akinobu, FUJISAWA MASATO

  第94回日本泌尿器科学会, Apr. 2006, Japanese, 日本泌尿器科学会, 福岡, Domestic conference

  Oral presentation


• No association of VEGF genotype with mRNA expression in renal cell carcinoma

  田中 久登, OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 山森 元博, 瀬戸 亮太, 中村 任, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  第26回日本臨床薬理学会年会, Dec. 2005, Japanese, 日本臨床薬理学会, 別府, Domestic conference

  Poster presentation


• 腎臓癌におけるVEGF発現量と遺伝子型

  田中 久登, OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 山森 元博, 瀬戸 亮太, 中村 任, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  第26回日本臨床薬理学会, Dec. 2005, Japanese, 日本臨床薬理学会, 別府, Domestic conference

  Poster presentation


• Correlation of expression levels of various genes with EGFR in renal cell carcinoma

  徳井 健次, OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 中村 任, 田中 久登, YAGI, Mariko, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  第55回日本薬学会近畿支部, Nov. 2005, Japanese, 日本薬学会, 西宮, Domestic conference

  Oral presentation


• Intra-muscular infjection of rb-IL-2 enhanced the antitumor effect of Ad-OC-TK plus ACV Suicide-gene therapy on murine prostate concer model

  SHIRAKAWA, Toshiro, 張 竹君, 寺尾 秀治, WADA,Yoshitaka, FUJISAWA, Masato, GOTOH,Akinobu

  第７回泌尿器遺伝子・細胞治療研究会, Nov. 2005, Japanese, 泌尿器遺伝子・細胞治療研究会, 岡山, Domestic conference

  Oral presentation


• 前立腺肥大症に対するα１受容体遮断薬長期投与症例における排尿症状動態に関する検討

  SHIRAKAWA, Toshiro, 寺尾 秀治, 日向 信之, 合田 上政, OOBA, Takeshi, WADA,Yoshitaka, YAMADA,Yuji, GOTOH,Akinobu, OKADA,Hiroshi, FUJISAWA, Masato

  第１２回日本排尿機能学会, Oct. 2005, Japanese, 日本排尿機能学会, 松本, Domestic conference

  Oral presentation


• 腎臓癌におけるEGFR発現量と各種遺伝子の発現相関

  徳井 健次, OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 中村 任, 田中 久登, YAGI, Mariko, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  第55回日本薬学会近畿支部総会・大会, Oct. 2005, Japanese, 日本薬学会, 西宮, Domestic conference

  Poster presentation


• 腎臓癌におけるEGFR発現量およびゲフィチニブ感受性関連体細胞変異

  大松 秀明, OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 中村 任, 徳井 健次, 田中 久登, YAGI, Mariko, 大石 美惠, 西口 工司, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  第15回医療薬学会年会, Oct. 2005, Japanese, 日本医療薬学会, 岡山, Domestic conference

  Poster presentation


• Multi-Functional GMP Facility for Cell and Gene Therapy, in Kobe City, Japan

  SHIRAKAWA, Toshiro

  The Williamsburg BioProcessing Conference Asia-Pacific 2nd Annual Meeting, Sep. 2005, English, The Williamsburg BioProcessing, シンガポール, International conference

  [Invited]

  Invited oral presentation


• Real-Time PCR法を用いた腸チフスの血中細菌定量法の開発

  SHIRAKAWA, Toshiro, 松本 安代, 高田 哲男, GOTOH,Akinobu, KAWABATA, Masato, 木下 承晧, KUMAGAI, Syunichi, ARAKAWA, Souichi

  第７９回日本感染症学会, Apr. 2005, Japanese, 日本感染症学会, 名古屋, Domestic conference

  Poster presentation


• 2003年臨床分離MRSAにおけるバンコマイシン耐性関連遺伝子保有状況

  高田 哲男, SHIRAKAWA, Toshiro, 松本 安代, 木下 承晧, KUMAGAI, Syunichi, GOTOH,Akinobu, KAWABATA, Masato

  第７９回日本感染症学会, Apr. 2005, Japanese, 日本感染症学会, 名古屋, Domestic conference

  Oral presentation


• 腎癌における各種遺伝子のmRNA発現変動及び遺伝子型

  OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 中村 任, 盛岡 正志, 徳井 健次, 田中 久登, YAGI, Mariko, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  日本薬剤学会第20年会, Mar. 2005, Japanese, 日本薬剤学会, 東京, Domestic conference

  Poster presentation


• Change of mRNA levels of several genes in renal cell carcinoma

  OKAMURA, Noboru, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 寺尾 秀治, 中村 任, 盛岡 正志, 徳井 健次, 田中 久登, YAGI, Mariko, SAKAEDA, Toshiyuki, OKUMURA, Katsuhiko

  日本薬剤学会第20回記念大会, Mar. 2005, Japanese, 日本薬剤学会, 東京, Domestic conference

  Oral presentation


• 前立腺癌骨転移巣に対する遺伝子治療

  SHIRAKAWA, Toshiro

  第２１回神戸UGカンファレンス, 2005, Japanese, 神戸UGカンファレンス, 神戸, Domestic conference

  [Invited]

  Invited oral presentation


• 泌尿器科病棟における血液培養陽性例の検討

  合田 上政, FUJISAWA, Masato, SHIRAKAWA, Toshiro, 土橋 正樹, 近藤 有, OKADA,Hiroshi, KAMIDONO,Sadao

  第54回日本泌尿器科学会中部総会, Nov. 2004, Japanese, 第54回日本泌尿器科学会中部総会, 泉佐野, Domestic conference

  Oral presentation


• 前立腺癌骨転移巣に対する遺伝子治療臨床研究

  SHIRAKAWA, Toshiro

  第６９回日本泌尿器科学会東部総会, Sep. 2004, Japanese, 日本泌尿器科学会東部総会, 東京, Domestic conference

  [Invited]

  Invited oral presentation


• 間歇的アンドロゲン除去療法の休薬中に性交渉が可能となった前立腺癌の一例

  GOTOH,Akinobu, SHIRAKAWA, Toshiro, HARA, Isao, KAMIDONO,Sadao

  第15回日本性機能学会学術総会・西部総会, Sep. 2004, Japanese, 第15回日本性機能学会学術総会・西部総会, 徳島, Domestic conference

  Oral presentation


• 原発巣の診断に苦慮した甲状腺癌陰嚢皮下転移の1例

  合田 上政, SHIRAKAWA, Toshiro, GOTOH,Akinobu, OKADA,Hiroshi, HARA, Isao, KAMIDONO,Sadao, FUJISAWA, Masato

  第187回日本泌尿器科学会関西地方会, Jun. 2004, Japanese, 第187回日本泌尿器科学会関西地方会, 神戸, Domestic conference

  Oral presentation


• 経直腸的前立腺針生検後の感染阻止化学療法に関する検討

  寺尾 秀治, KAMIDONO,Sadao, GOTOH,Akinobu, SHIRAKAWA, Toshiro, 日向 信之, 合田 上政

  第52回日本化学療法学会総会, Jun. 2004, Japanese, 第52回日本化学療法学会総会, 沖縄, Domestic conference

  Oral presentation


• 院内感染制御における泌尿器科医の役割

  SHIRAKAWA, Toshiro, GOTOH,Akinobu, 寺尾 秀治, 日向 信之, 重村 克巳, 合田 上政, WADA,Yoshitaka, MURAMAKI,Mototsugu, TANAKA, Kazushi, YAMADA,Yuji, HARA, Isao, KAMIDONO,Sadao

  第92回日本泌尿器科学会総会, Apr. 2004, Japanese, 第92回日本泌尿器科学会総会, 大阪, Domestic conference

  Oral presentation


• ヒト精巣組織におけるTRAILおよびDR4、DR5、DcR1、DcR2の発現に関する免疫組織学的検討

  合田 上政, FUJISAWA, Masato, SHIRAKAWA, Toshiro, 寺尾 秀治, 山口 耕平, 近藤 有, 土橋 正樹, OKADA,Hiroshi, GOTOH,Akinobu, KAMIDONO,Sadao

  第92回日本泌尿器科学会総会, Apr. 2004, Japanese, 第92回日本泌尿器科学会総会, 大阪, Domestic conference

  Oral presentation


• 前立腺癌の遺伝子治療

  SHIRAKAWA, Toshiro

  ＣＯＥシンポジウム 千葉大学大学院「消化器扁平上皮癌に対する最先端多戦略治療拠点形成」Cancer Gene Therapy Symposium, Feb. 2004, Japanese, ＣＯＥシンポジウム, 千葉, Domestic conference

  [Invited]

  Invited oral presentation


• Process development of gene therapies in Japan

  SHIRAKAWA, Toshiro

  The williamsburg BioProcessing Conference Asia-Pacific 1st annual meeting, Sydney, Australia, 2004, English, The williamsburg BioProcessing Conference Asia-Pacific 1st annual meeting, Sydney, Australia, シドニー, International conference

  [Invited]

  Invited oral presentation


• 薬剤耐性淋菌性尿道炎の分子生物学的検討およびDHPLCを用いた迅速遺伝子診断法の開発

  重村 克己, SHIRAKAWA, Toshiro, OKADA,Hiroshi, TANAKA, Kazushi, ARAKAWA, Souichi, 木下 承酷, GOTOH,Akinobu, KAMIDONO,Sadao

  ・第５３回日本泌尿器科学会中部総会, Nov. 2003, Japanese, 日本泌尿器科学会中部総会, 金沢, Domestic conference

  [Invited]

  Invited oral presentation


• 放射線併用抗癌化学療法が有用であった女性尿道癌の2例

  日向 信之, SHIRAKAWA, Toshiro, WADA,Yoshitaka, 重村 克巳, OKADA,Hiroshi, GOTOH,Akinobu, KAMIDONO,Sadao

  第53回日本泌尿器科学会中部総会, Oct. 2003, Japanese, 第53回日本泌尿器科学会中部総会, 金沢, Domestic conference

  Oral presentation


• 当科における最近の腹腔鏡下手術

  重村 克巳, SHIRAKAWA, Toshiro, OKADA,Hiroshi, TANAKA, Kazushi, ARAKAWA, Souichi, 木下 承晧, GOTOH,Akinobu, KAMIDONO,Sadao

  第53回日本泌尿器科学会中部総会, Oct. 2003, Japanese, 第53回日本泌尿器科学会中部総会, 金沢, Domestic conference

  Oral presentation


• 前立腺癌骨転移巣に対する遺伝子治療臨床研究の現況

  合田 上政, FUJISAWA, Masato, 土橋 正樹, 山崎 隆文, 張 竹君, SHIRAKAWA, Toshiro, GOTOH,Akinobu, OKADA,Hiroshi, ARAKAWA, Souichi, KAMIDONO,Sadao

  第41回日本癌治療学会総会, Oct. 2003, Japanese, 日本癌治療学会, 札幌, Domestic conference

  [Invited]

  Invited oral presentation


• 精巣腫瘍晩期再発症例の臨床的検討

  GOTOH,Akinobu, SHIRAKAWA, Toshiro, KAMIDONO,Sadao

  第53回日本泌尿器科学会中部総会, Oct. 2003, Japanese, 第53回日本泌尿器科学会中部総会, 金沢, Domestic conference

  Oral presentation


• 後腹膜鏡下右腎尿管全摘除術および腹腔鏡下膀胱全摘除術を併施した1症例

  SHIRAKAWA, Toshiro, OKADA,Hiroshi, GOTOH,Akinobu, 日向 信之, WADA,Yoshitaka, KAMIDONO,Sadao, 宇治 達哉, 山本 明良

  第53回日本泌尿器科学会中部総会, Oct. 2003, Japanese, 第53回日本泌尿器科学会中部総会, 金沢, Domestic conference

  Oral presentation


• CD44v8-10分子遺伝子導入は膀胱癌細胞株の生物学的悪性度を亢進させる

  重村 克巳, OKADA,Hiroshi, TANAKA, Kazushi, ARAKAWA, Souichi, KAMIDONO,Sadao, SHIRAKAWA, Toshiro, GOTOH,Akinobu, 木下 承晧

  第62回日本癌学会学術総会, Sep. 2003, Japanese, 第62回日本癌学会学術総会, 名古屋, Domestic conference

  Oral presentation


• 放射光による微量元素分析と生命科学・医学への応用 前立腺癌細胞内の亜鉛分布状態の変化―ホルモンと亜鉛の関係

  SHIRAKAWA, Toshiro, SUGIMURA, Kazuro, 北村 ゆり, 敷根 俊輔, 川上 拓男, 井手 亜里, GOTOH,Akinobu

  第１４回日本微量元素学会, Jul. 2003, Japanese, 日本微量元素学会, 大阪, Domestic conference

  [Invited]

  Invited oral presentation


• 新しい迅速直接抗菌剤感受性測定装置の開発とそのUTIにおける有用性

  OKADA,Hiroshi, 重村 克巳, SHIRAKAWA, Toshiro, TANAKA, Kazushi, GOTOH,Akinobu, KAWABATA,Gaku, ARAKAWA, Souichi, 浜口行雄, KAMIDONO,Sadao

  第51回日本化学療法学会総会, May 2003, Japanese, 第51回日本化学療法学会総会, 横浜, Domestic conference

  Oral presentation


• 前立腺癌に対する腹腔鏡下前立腺全摘除術の治療成績とQOL

  SHIRAKAWA, Toshiro, GOTOH,Akinobu, 日向 信之, WADA,Yoshitaka, HARA, Isao, OKADA,Hiroshi, KAMIDONO,Sadao

  第91回日本泌尿器科学会総会, Apr. 2003, Japanese, 第91回日本泌尿器科学会総会, 徳島, Domestic conference

  Oral presentation


• CD44R1分子遺伝子導入は膀胱癌細胞株の生物学的悪性度を亢進させる

  熊野 晶文, SHIRAKAWA, Toshiro, TANAKA, Kazushi, HARA, Isao, KAWABATA,Gaku, OKADA,Hiroshi, KAMIDONO,Sadao, 生田 繁, FUJISAWA, Masato

  第91回日本泌尿器科学会総会, Apr. 2003, Japanese, 第91回日本泌尿器科学会総会, 徳島, Domestic conference

  Oral presentation

• アメリカ遺伝子治療学会


• 日本癌治療学会


• 日本癌学会


• 日本感染症学会


• 日本遺伝子治療学会


• 日本泌尿器科学会

• 腸管細胞の獲得免疫における動態評価

  橋井 佳子, 戸村 道夫, 香山 尚子, 白川 利朗, 片山 高嶺, 皆川 光

  日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 地方独立行政法人大阪府立病院機構大阪国際がんセンター(研究所), 01 Apr. 2021 - 31 Mar. 2024


• 尿路感染症における網羅的薬剤耐性機構の研究

  重村 克巳, 大澤 佳代, 宮良 高維, 白川 利朗

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2019 - 31 Mar. 2022


• Development of a mucosal long peptide cancer vaccine using a membrane transport polymer as a carrier.

  白川 利朗, 佐久間 信至

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2019 - 31 Mar. 2022


• Development of a novel oral vaccine against COVID-19

  Toshiro Shirakawa

  AMED, ワクチン開発推進事業, 新型コロナウイルス感染症（COVID-19）に対するワクチン開発（アカデミア主導）, Kobe Univeristy, Oct. 2020 - Mar. 2022, Principal investigator


• 【AMED】腸管免疫を利用した新規経口がんワクチンの開発

  白川 利朗

  国立研究開発法人日本医療研究開発機構, 橋渡し研究戦略的推進プログラム, Apr. 2019 - Mar. 2022, Principal investigator

  Competitive research funding


• Clarification of the mechanism of effectiveness of the oral cancer vaccine a platform expressing a cancer antigen

  橋井 佳子, 白川 利朗, 片山 高嶺

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Osaka University, 01 Apr. 2017 - 31 Mar. 2020


• Midkine-Promoter based Conditionally Replicative Adenovirus expressing siRNA against EGFR for Head and Neck Cancer

  Nibu Ken-ichi, SHIRAKAWA toshiro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Kobe University, 01 Apr. 2016 - 31 Mar. 2019

  Background: Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinomas (HNSCCs). Midkine expression is restricted in adult tissues, but is increased in several malignant tumors, including HNSCCs. Here we evaluated the antitumor effect of Midkine-promoter based conditionally replicative adenovirus expressing siRNA against EGFR for targeting HNSCCs expressing Midkine. Methods: A conditionally replicative adenovirus vector controlled by the Midkine promoter, Ad-MK-siEGFR, was generated by integrating gene-expressing siRNA against EGFR. Antitumor effect of Ad-MK-siEGFR was tested in vitro using established HNSCC cell line, T891 with strong Midkine expression. Results: Expression of EGFR in T891 infected with Ad-MKsiEGFR was significantly lower than that of T891 infected with control. Cytotoxicity assays showed significant growth suppression of Ad-MK-siEGFR in T891 cells.


• Gene therapy for head and neck cancer by introducing suppressor of cytokine signaling (SOCS)

  Otsuki Naoki, Shirakawa Toshiro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2016 - 31 Mar. 2019

  The JAK / STAT signaling pathway, which is one of the cytokine signaling pathways activated in head and neck cancer, is suppressed by suppressor of cytokine signaling (SOCS). By overexpression of SOCS3 mediated by adenovirus vector in a head and neck cancer cell line, it was shown that the growth of tumor cells is suppressed.


• 尿路感染症における多剤耐性菌の迅速診断・迅速疫学診断法の確立

  重村 克巳

  学術研究助成基金助成金／基盤研究(C), Apr. 2016 - Mar. 2019

  Competitive research funding


• 腸管免疫を利用した新規経口がんワクチンの開発

  白川 利朗

  AMED, 橋渡し研究戦略的推進プログラム：シーズB, Apr. 2017 - Mar. 2018, Principal investigator

  Competitive research funding


• ステルス型カルバペネム耐性菌の分子疫学的解析及び効果的検出法の確立

  大澤 佳代

  学術研究助成基金助成金／基盤研究(C), Apr. 2015 - Mar. 2018

  Competitive research funding


• Development of novel HCV treatment using oral vaccine

  SHIRAKAWA TOSHIRO, KATAYAMA Takane

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, Apr. 2014 - Mar. 2017, Principal investigator

  Currently, there are about 170 million HCV (hepatitis C virus) carriers worldwide. Although the treatment outcomes for chronic HCV infection have been improved with interferon and antiviral drugs, the curative rate is still not satisfactory. Recently, we have generated a novel oral HCV vaccine displaying HCV-NS3 protein on the cell surface of bifidobacteria and confirmed that it could induce the HCV-specific cellular immunity in a mouse experimental model. In this study, we have developed novel combinational oral vaccine therapy for HCV infection and confirmed its synergistic effect with interferon using a mouse syngeneic tumor model expressing NS3 protein.

  Competitive research funding


• 【AMED】染色体性薬剤耐性遺伝子を保持する薬剤耐性菌の分子疫学的解析

  白川 利朗

  国立研究開発法人日本医療研究開発機構, 医療分野国際科学技術共同研究開発推進事業 戦略的国際共同研究プログラム（ベトナム・インドネシア）, 2017, Principal investigator

  Competitive research funding


• 頭頸部癌に対するヒト乳頭腫ウイルス遺伝子を標的とした集学的治療の開発

  大月 直樹

  学術研究助成基金助成金／基盤研究(C), Apr. 2013 - Mar. 2016

  Competitive research funding


• 悪性胸膜中皮腫に対する新規治療法の開発及び実用化に関する研究

  白川 利朗

  革新的がん医療実用化研究事業, 2016, Principal investigator

  Competitive research funding


• メタロβラクタマーゼ産生腸内細菌の分布調査及び早期診断法の検討

  大澤 佳代

  科学研究費補助金／基盤研究(C), Apr. 2012 - Mar. 2015

  Competitive research funding


• Development of a novel oral therapeutic HCV vaccine using bifidobacterium displaying antigen

  SHIRAKAWA Toshiro, HOTTA Haku, KATAYAMA Takane

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 2011 - 2013, Principal investigator

  More than 170 million people worldwide are chronic HCV (Hepatitis C virus) carriers. A combination of pegylated interferon-alpha with ribavirin, the standard treatment for HCV infection, has been effective in fewer than 50 percent of patients infected with HCV genotype 1. A strong T cell response against the nonstructural protein 3 (NS3) is important for recovery from acute HCV infection, and an early multi-specific CD4 helper and CD8 cytotoxic T cell response is critical for HCV clearance. In the present study, we successfully constructed a genetically modified Bifidobacterium longum displaying recombinant HCV-NS3 peptides containing some CD4 and CD8 epitopes located in the HCV-NS3 region as an oral vaccine against chronic HCV infection. The oral administration of this vaccine could induce NS3-specific immune responses in mice through intestinal mucosal immunity.

  Competitive research funding


• Genetherapy for Head and Neck Cancer using carrier cell-based delivery of replication-selective adenoviral vector

  NIBU Ken-ichi, OTSUKI Naoki, SHIRAKAWA Toshiro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Kobe University, 2009 - 2011

  While multimodal treatments have been performed for the treatment of head and neck cancers, the prognoses of the patients with advanced head and neck cancer are still poor. The estimated survival rates of those patients are around 30%. New strategies for the treatment for head and neck cancer are desirable. To address this issue, we developed the midkine promoter-driven replication-selective adenoviral vector containing siRNA for EGFR or VEGF. With this adenoviral vector, synergistic effect of oncolytic adenovirus and inhibition of oncogene via RNA interference is effect.


• Novel oral vaccine using genetically engineering bifidobacterium displaying antigen on its cell-surface

  SHIRAKAWA Toshiro, KATAYAMA Tkakane

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 2008 - 2010

  Genetically modified probiotic bacteria show promise as an antigen delivery vehicle for mucosal immunization. We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. We confirmed the efficacy of this oral vaccine in a murine typhoid fever model.


• 癌細胞ワクチンによるオンコリティック・アデノウイルスの新規ドラッグデリバリー

  白川 利朗

  2010, Principal investigator

  Competitive research funding


• ヒト乳頭腫ウイルス遺伝子を標的とした頭頸部癌に対する遺伝子治療

  大月 直樹

  科学研究費補助金／基盤研究(C), 2008

  Competitive research funding


• Discovery of targets for treatment with renal cell carcinoma by gene and protein expression profile analysis

  OKUMURA Katsuhiko, SAKAEDA Toshiyuki, GOTOH Akinobu, SHIRAKAWA Toshiro, OKAMURA Noboru, NAKAMURA Tsutomu

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Kobe University, 2004 - 2005

  Renal cell carcinoma (RCC) is one of the most chemotherapy or radiotherapy-resistant malignant tumors, and therefore, the standard therapy is surgical treatment. Also, there is no efficient biomarker for diagnosis. To elucidate resistant mechanisms and discovery novel targets for treatment and biomarker for diagnosis, transcriptome and proteome analysis were carried out using RCC and adjacent normal tissues. Since lower expression of sorcin in RCC was found, we investigated its role in cancer proliferation by RNA interference. Up-regulation of vascular endothelial growth factor (VEGF), a potent angiogenesis factor contributing to cancer proliferation, was found by knock-down of sorcin using siRNA in renal cell carcinoma cells, Caki-1. This suggested that lower expression of sorcin caused up-regulation of VEGF, thereby lead cancer proliferation. To comprehensive analysis of protein expressions in RCC and adjacent normal tissues, samples were labeled with 2-nitrobeazenesulfonyl chloride with six ^<12>C or ^<13>C atoms. Then, they were applied MALDI-TOF/Ms and pair peak of 6 Da difference were analyzed and identified. Unknown proteins were identified in addition to known proteins, which have been reported to be up-regulated in RCC.


• 増殖型アデノウイルスベクターおよびキャリアー細胞を用いた膀胱癌に対する遺伝子治療

  白川 利朗

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B), Grant-in-Aid for Young Scientists (B), Kobe University, 2004 - 2005

  膀胱壁筋層に浸潤する膀胱癌の約50%は、すでに癌の微小転移を有しており、1年以内に臨床上、明らかな転移巣を呈するといわれている。近年の医学の進歩、特に多剤併用抗癌化学療法の確立にも関わらず、それらの患者のほとんどは2年以内に死亡する。現在、遺伝子治療を代表とする分子標的療法が大きな注目を集めているが、膀胱癌を対象としたそれらの新しい治療法の開発も切望されるところである。 従来の非増殖型ウイルスベクターについては、その遺伝子導入効率において限界が指摘されており、癌細胞においてのみ複製される腫瘍特異的な増殖型ウイルスベクターが盛んに研究されている。本研究で用いる増殖型ウイルスベクターはウイルスの複製に必要な遺伝子、E1aを腫瘍特異的プロモーターにより制御し、腫瘍内でのみ増殖可能としたアデノウイルスベクターである。 Cox-2はサイトカインや発癌プロモーターなどの刺激により、マクロファージ、血管内皮細胞、癌細胞などにおいて誘導され、炎症反応、血管新生、発癌などに関与すると言われ、膀胱癌や大腸癌など多くのヒト癌細胞での発現増強が確認されている。我々はCox-2プロモーターを組み込んだ増殖型アデノウイルスベクター、AdE3-cox-2-327を既に作製した。本ベクターはCox-2を強発現する膀胱癌などの癌細胞においてのみ増殖可能であり、癌細胞内で複製を繰り返すことにより細胞融解を引き起こし癌細胞を特異的に殺傷する。 平成16年度、われわれはAdE3-cox-2-327の膀胱癌に対する抗癌作用をIn vitro, In vivo双方で確認した。また平成17年度、AdE2-cox-2-327をキャリアー細胞、A549細胞に感染させヒト膀胱癌細胞KK47を接種して作成したマウスの皮下腫瘍に直接、投与することにより抗腫瘍効果が高まることを確認した。


• Clinical research of gene therapy using tissue-specific promoter for the treatment of metastatic prostate cancer.

  KAMIDONO Sadao, GOTOH Akinobu, MAEDA Sakan, SUGIMURA Kazuro, MATSUO Masafumi, SHIRAKAWA Toshiro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A), Grant-in-Aid for Scientific Research (A), Kobe University, 2002 - 2005

  Background : The absence of effective therapies for hormone refractory prostate cancer establishes the need to develop novel therapeutic modality, such as a gene therapy, that can be applied either separately or in conjunction with current treatment modalities for the treatment of advanced prostate cancer. The phase I/II clinical trial of the Ad-OC-TK (recombinant adenoviral vector containing osteocalcin promoter driven herpes-simplex-virus thymidine kinase gene) plus VAL (Valacyclovior) for the treatment of hormone-refractory prostate cancer was performed at the Kobe University Hospital, Japan.. Method : To date, six patients with localized recurrence or bone metastasis of hormone refractory prostate cancer were enrolled. The doses of a Ad-OC-TK injected directly to localized recurrent tumor or bone metastatic lesion was 2.5 x 10^9 or 10^<10> plaque-forming unit (PFU) / Day 1 and Day 8. Patient was given one gram of VAL twice daily for 21 days. Results : The initial patients tolerated this therapy without serious adverse events. Despite intralesional injections, both the hsvTK and adenoviral genes were able to detect in peripheral blood samples. Biopsies of each lesion demonstrated hsvTK, CAR and OC proteins after treatment demonstrating transcriptional expression in these specimens and increased apoptosis post-treatment observed by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay. Initially, serum PSA levels declined in 4 out of 6 patients coincident with valacyclovir pro-drug activation of hsv-TK. The quantitative analysis of bone scintigraphy showed the decreased RI accumulation only in injected lesion. Conclusions : The Ad-OC-TK plus VAL therapy as a tissue-specific OC promoter-based toxic gene therapy has demonstrated the localized anti-tumor effect without any serious adverse events in the initial Japanese patients with hormone-refractory prostate cancer.


• 前立腺癌転移巣に対する臓器特異性プロモーターを用いた遺伝子治療臨床研究

  守殿 貞夫

  科学研究費補助金／基盤研究(A), 2005

  Competitive research funding


• 前立腺癌骨転移巣に対する遺伝子治療における、ＰＥＴを用いた評価法の確立

  後藤 章暢

  科学研究費補助金／基盤研究(B), 2005

  Competitive research funding


• 骨肉腫再発巣および骨転移に対する臓器特異性プロモーターを用いた遺伝子治療臨床研究

  秋末 敏宏

  科学研究費補助金／基盤研究(B), 2005

  Competitive research funding


• 遺伝子治療用アデノウイルスベクターの高生産バイオリアクタープロセスの開発

  福田 秀樹

  科学研究費補助金／萌芽研究, 2005

  Competitive research funding


• 遺伝子治療による、膀胱癌の放射線および抗癌剤の感受性増強効果の研究

  白川 利朗

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B), Grant-in-Aid for Young Scientists (B), Kobe University, 2002 - 2003

  膀胱壁筋層に浸潤した膀胱癌に対する治療法の、現在における第一選択は膀胱全摘出術である。尿路変更術の進歩などにより、膀胱全摘出術を受ける患者さんの術後のQOL(Quality of Life)は著しく改善されたが、膀胱機能の温存やさらなるQOLの向上を目指して、現在、様々な膀胱温存療法が検討されている。アメリカにおいて行われた大規模な臨床試験では、著しい局所浸潤、または全身状態の不良などで手術不可能な症例、あるいは患者さん自身が膀胱を摘出することを拒否した症例に対して、経尿道的膀胱腫瘍切除術、放射線療法、および抗癌化学療法の三者併用による膀胱温存療法が施行され、病期によっては膀胱全摘出術と同等の治療成績が確認された。本研究では、これらの三者併用療法に加えて、p53遺伝子や自殺遺伝子の導入による遺伝子治療をさらに併用し、膀胱癌の放射線や抗癌剤に対する感受性を増強することによる、進行性膀胱癌に対する膀胱温存根治療法の実現の可能性を検討した。 最初に種々のP53遺伝子の変異を持つ膀胱癌細胞と持たない膀胱癌細胞での放射線感受性を検討した。結果、正常のP53遺伝子を持つ膀胱癌細胞では、放射線照射によりP53依存性の細胞死を顕著に認めたが、P53遺伝子に変異を持つ膀胱癌細胞では認められず放射線感受性も比較的低かった。以上の結果よりP53遺伝子治療と放射線療法の併用療法の可能性が示唆された。 次にアデノウイルスベクターを用いたCD/5-FC遺伝子治療と放射線療法の併用療法の膀胱癌に対する有用性をヒト膀胱癌細胞株、KK47細胞を用いて検討した。結果、本併用療法は細胞培養系、および動物実験双方において相乗的な抗癌作用を示した。本研究により膀胱癌に対する遺伝子治療と放射線療法の併用療法の可能性が示唆された。


• Efficacy of Combination Therapy of Ionizing Radiation and Gene Therapy in Prostate Cancer in vitro

  SOEJIMA Toshinori, SHIRAKAWA Toshiro, GOTOH Akinobu, SUGIMURA Kazuro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University Graduate School of Medicine, 2000 - 2002

  Several studies have demonstrated that the function of the p53 gene is one of the major determinants of intrinsic cellular sensitivity to the cytotoxic effects of ionizing radiation (IR). Moreover, a strategy to combine adenovirus-mediated wild-type p53 gene transfer with DNA-damaging treatments, such as IR and chemotherapeutic agents, has also been studied in glioblastoma, lung, colorectal, ovarian, and head-and-neck cancers, and additional cytotoxicity or tumor-suppressing activity has been consistently observed. In prostate cancer cells, the significant cytotoxicity has been previously reported with the induction of recombinant wild-type p53 adenovirus (Ad5CMV-p53). In this study, the interactions between IR and Ad5CMV-p53 gene therapy in two androgen-independent prostate cancer cell lines (DU145 and PC-3) were evaluated. We demonstrated that this combination therapy resulted in remarkable synergistic effects and also assessed its molecular mechanisms. The cell growth inhibition in DU145 (p53-mutated) cells by IR was strongly enhanced by additional Ad5CMV-p53 infection in a viral dose-dependent manner. In DU145 cells, IR alone induced minimal p53 mRNA expression. However, IR combined with Ad5CMV-p53 infection stimulated significant increase in p53 mRNA expression supplemented with Bax and p21 mRNA expressions. In PC-3 (p53-null), IR induced Bax and p21 mRNA expression, while the combination effects were observed in p53, Bax, and p21 mRNA expression. Apoptotic cell deaths were rarely observed after IR alone (DU145: 3%, PC-3: 5%). However, after combination therapy, the proportion of apoptotic cells greatly increased (sevenfold in DU145 cells, and twice in PC-3 cells). G1 cell cycle arrest was observed after Ad5CMV-p53 infection and the combination in both cell lines. In conclusion, Ad5CMV-p53 infection enhances the effect of radiation therapy by efficient induction of apoptosis and cell cycle arrest. This combination therapy could be one of the optimal treatment strategies for radioresistant prostate cancer.


• Development of testicular tumor gene therapy using human testicular tumor cell-specific promoters

  GOTOH Akinobu, KAMIDONO Sadao, SHIRAKAWA Toshiro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University School of Medicine, 2000 - 2002

  One of the most basic issues in gene therapy for cancer is how to express the relevant genes efficiency and specifically in cancer cells. In recent years, there has been an upsurge in basic research into gene therapy for cancer using organ-specific promoters specifically activated in cancer cells and in related clinical trials, with particular attention focused on therapy involving a combination of organ-specific promoters and suicide genes. Motivated by the finding that serum β-HCG (human chorionic gonadotropin) is elevated in over 70% of patients with advanced testicular tumor resistant to chemotherapy, the present study was designed to develop a gene therapy based on the application of a β-HCG promoter as an organ-specific promoter and to investigate its usefulness. It is intended to select a β-HCG promoter with DNA size of 729 base pairs, but we also cloned the DNA of β-HCG promoters of various other sizes, and measured the activity of each promoter in testicular tumor cells in order to determine the optimal size of a β-HCG promoter for gene therapy. It was found that the cloned β-HCG promoter DNA with 729 base pairs had the best specificity, and this was inserted into a plasmid vector integrated into a luciferase gene. This vector was introduced genetically into a variety of cells-choriocarcinoma cells (JAR), embryonal cancer cells (NEC8, NEC14), prostate cancer cells (PC-3, DU145), and bladder cancer cells (WH), and luciferase activity measured to confirm cell-specific activity in the β-HCG promoter. High levels of promoter activity were observed only in the β-HCG producing choriocarcinoma cells (JAR) and embryonal cancer cells (NEC8, NEC14). Based on these findings, we created an Ad-β-HCG -TK and undertook a similar experiment, in which specific anti-tumor activity was found only in the choriocarcinoma cells (JAR) and the embryonal cancer cells (NEC8, NEC14). No cell-damaging action was observed in normal tissue. Next, in order to explore the development of gene therapy using replication-competent adenovirus vectors, we created one integrating an E1A gene controlled by a ? -HCG promoter. At present, we are engaged in in vivo and in vitro therapy studies using this vector to investigate the optimal gene therapy for human testicular tumors, with the eventual aim of conducting a comparison with gene therapy using suicide genes.

• 免疫原性ポリペプチド表層発現ビフィズス菌（米国）

  SHIRAKAWA TOSHIRO, 堀田 博, 片山 高嶺

  14/768508, 18 Aug. 2015, 大学長, 9925259, 27 Mar. 2018

  Patent right


• 免疫原性ポリペプチド表層発現ビフィズス菌

  SHIRAKAWA TOSHIRO, HOTTA HAK, 片山 高嶺

  特願2015-501435, 14 Feb. 2014, 大学長, 特許6213969, 29 Sep. 2017

  Patent right


• 腫瘍免疫誘導剤

  SHIRAKAWA TOSHIRO, 斎藤 彩, 松岡 孝幸

  特願2011-508225, 29 Mar. 2010, 大学長, 特許5582542, 25 Jul. 2014

  Patent right


• ビフィズス菌表層提示融合タンパク質発現遺伝子

  SHIRAKAWA TOSHIRO, 山本 さくら

  特願2011-531985, 17 Sep. 2010, 大学長, 特許5561681, 20 Jun. 2014

  Patent right


• 経口ワクチン

  SHIRAKAWA TOSHIRO, KAWABATA MASATO, 高田 哲男, 谷口 道子, 岡本 明子

  特願2009-505269, 19 Mar. 2008, 大学長, 特許5187642, 01 Feb. 2013

  Patent right